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A B S T R A C T
Background
Tramadol is often prescribed to treat pain and is associated physical disability in osteoarthritis (OA). Due to the pharmacologic
mechanism of tramadol, it may lead to fewer associated adverse effects (i.e. gastrointestinal bleeding or renal problems) compared to
non-steroidal anti-inflammatory drugs (NSAIDs). This is an update of a Cochrane Review originally published in 2006.
Objectives
To determine the benefits and harms of oral tramadol or tramadol combined with acetaminophen or NSAIDs in people with os-
teoarthritis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase databases, as well as the US
National Institutes of Health and World Health Organization trial registries up to February 2018. We searched the LILACS database
up to August 2015.
Selection criteria
We included randomized controlled trials (RCTs) that evaluated the effect of tramadol, or tramadol in combination with acetaminophen
(paracetamol) or NSAIDs versus placebo or any comparator in people with osteoarthritis.
Data collection and analysis
We used standard methodologic procedures expected by Cochrane.
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Main results
We included 22 RCTs (11 more than the previous review) of which 21 RCTs were included in meta-analyses for 3871 participants
randomized to tramadol alone or tramadol in combination with another analgesic and 2625 participants randomized to placebo or
active control. Seventeen studies evaluated tramadol alone and five evaluated tramadol plus acetaminophen. Thirteen studies used
placebo controls and eleven studies used active controls (two trials had both placebo and active arms). The dose of tramadol ranged
from 37.5 mg to 400 mg daily; all doses were pooled. Most trials were multicenter with a mean duration of two months. Participants
were predominantly women with hip or knee osteoarthritis, with a mean age of 63 years and moderate to severe pain. There was a high
risk of selection bias as only four trials reported both adequate sequence generation and allocation concealment. There was a low risk
for performance bias as most studies blinded participants. There was a high risk of attrition bias as 10/22 trials showed incomplete
outcome data. Most of the trials were funded by the pharmaceutical industry.
Moderate quality evidence (downgraded due to risk of bias) indicated that tramadol alone and in combination with acetaminophen
had no important benefit on pain reduction compared to placebo control (tramadol alone: 4% absolute improvement, 95% confidence
interval (CI) 3% to 5%; 8 studies, 3972 participants; tramadol in combination with acetaminophen: 4% absolute improvement, 95%
CI 2% to 6%; 2 studies, 614 participants).
Fifteen out of 100 people in the tramadol group improved by 20% (which corresponded to a clinically important difference in pain)
compared to 10/100 in the placebo group (5% absolute improvement). Twelve out of 100 people improved by 20% in the tramadol
in combination with acetaminophen group compared to 7/100 in the placebo group (5% absolute improvement).
Moderate quality evidence (downgraded due to risk of bias) indicated that tramadol alone and in combination with acetaminophen
led to no important benefit in physical function compared to placebo (tramadol alone: 4% absolute improvement, 95% CI 2% to 6%;
5 studies, 2550 participants; tramadol in combination with acetaminophen: 4% absolute improvement, 95% CI 2% to 7%; 2 studies,
614 participants).
Twenty-one out of 100 people in the tramadol group improved by 20% (which corresponded to a clinically important difference in
physical function) compared to 16/100 in the placebo group (5% absolute improvement). Fifteen out of 100 people improved by 20%
in the tramadol in combination with acetaminophen group compared to 10/100 in the placebo group (5% absolute improvement).
Moderate quality evidence (downgraded due to risk of bias) indicated that, compared to placebo, there was a greater risk of developing
adverse events with tramadol alone (risk ratio (RR) 1.34, 95% CI 1.24 to 1.46; 4 studies, 2039 participants) and tramadol in combination
with acetaminophen compared to placebo (RR 1.91, 95% CI 1.32 to 2.76; 1 study, 308 participants). This corresponded to a 17%
increase (95% CI 12% to 23%) with tramadol alone and 22% increase (95% CI 8% to 41%) with tramadol in combination with
acetaminophen.
The three most frequent adverse events were nausea, dizziness and tiredness. Moderate quality evidence (downgraded due to risk of
bias) indicated that there was a greater risk of withdrawing from the study because of adverse events with tramadol alone compared to
placebo (RR 2.64, 95% CI 2.17 to 3.20; 9 studies, 4533 participants), which corresponded to a 12% increase (95% CI 9% to 16%).
Low quality evidence (downgraded due to risk of bias and inconsistency) indicated that there was a greater risk of withdrawing from
the study because of adverse events with tramadol in combination with acetaminophen compared to placebo (RR 2.78, 95% CI 1.50
to 5.16; 2 studies, 614 participants), which corresponded to a 8% absolute improvement (95% CI 2% to 19%).
Low quality evidence (downgraded due to risk of bias and imprecision) indicated that there was a greater risk of developing serious
adverse events with tramadol alone compared to placebo (110/2459 participants with tramadol compared to 22/1153 participants
with placebo; RR 1.78, 95% CI 1.11 to 2.84; 7 studies, 3612 participants), which corresponded to a 1% increase (95% CI 0% to
4%). There were no serious adverse events reported in one small study (15 participants) of tramadol with acetaminophen compared to
placebo.
Authors’ conclusions
Moderate quality evidence indicates that compared to placebo, tramadol alone or in combination with acetaminophen probably has no
important benefit on mean pain or function in people with osteoarthritis, although slightly more people in the tramadol group report
an important improvement (defined as 20% or more). Moderate quality evidence shows that adverse events probably cause substantially
more participants to stop taking tramadol. The increase in serious adverse events with tramadol is less certain, due to the small number
of events.
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P L A I N L A N G U A G E S U M M A R Y
Tramadol for osteoarthritis
This summary of a Cochrane Review presents what we know from research about the benefits and harms of tramadol (a pain reliever) for
treating osteoarthritis (OA). We examined the published research up to 1 February 2018 and found 22 studies involving 3871 people
taking tramadol and 2625 people in a comparator group. Compared with placebo (dummy treatment), moderate quality evidence
showed that taking tramadol for up to three months had no important benefit on mean pain or function, although slightly more people
in the tramadol group reported an important improvement (defined as 20% or more). Also, people may have had more side effects
that them to stop taking it, such as nausea, vomiting, dizziness, constipation, tiredness and headache. We were less certain of the risk
of serious effects due to the small number of events. Most of the trials were funded by the pharmaceutical industry.
What is osteoarthritis and what is tramadol?
OA is a disease of the joints, such as the knee or hip. When the joint loses cartilage, the bone grows to try and repair the damage.
Instead of making things better, the bone grows abnormally and makes things worse. For example, the bone can make the joint painful
and unstable. This can affect physical function or ability to use the knee.
Tramadol is an opioid used to treat OA. Unlike other pain relievers such as non-steroidal anti-inflammatory drugs (NSAIDs), it does
not cause bleeding in the stomach and intestines, or kidney problems. It also does not affect the cartilage at the end of the bones.
However, tramadol may not decrease swelling.
What are the results of this review?
People in the 22 included trials took various daily doses of tramadol or a placebo, an NSAID or a different pain reliever. Most of them
were women, with an average age of 63 years, and with moderate to severe pain. The length of the studies ranged from one week to
three months. The results below are for tramadol alone compared to placebo. There were similar results for tramadol in combination
with acetaminophen.
Pain (0 to 100 visual analog scale (VAS); lower scores mean less pain)
People who took tramadol alone rated their pain to be four points lower than placebo (4% absolute improvement). People who took
tramadol alone rated their pain to be 50.3; people who took a placebo rated their pain to be 54.3.
Ten percent of people who took placebo had a clinically important improvement (at least 20%) in pain and 15% who took tramadol
group had a clinically important improvement (5% more people).
Physical function (Western Ontario and McMaster Universities Arthritis Index (WOMAC) 0 to 1700 scale; lower scores mean better
physical function)
People who took tramadol alone rated their physical function to be 68 points lower than placebo (4% absolute improvement). People
who took tramadol alone rated their physical function to be 991; people who took placebo rated their physical function to be 1059.
Twenty-one percent of people who took tramadol had a clinically important improvement in physical function and 16% of people
who took placebo had a clinically important improvement (5% more people).
Total side effects
Sixty-six out of 100 people may have had side effects when taking tramadol alone compared to 49 out of 100 people when taking a
placebo (17% more people).
Withdrawals from study due to side effects
Nineteen out of 100 people withdrew from the study because of side effects when taking tramadol alone compared to seven out of 100
people when taking a placebo (12% more people).
Serious side effects
Three out of 100 people had serious side effects when taking tramadol alone compared to two out of 100 people when taking a placebo
(1% more people).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tramadol alone compared with placebo for osteoarthritis
Patient or population: osteoarthrit is of the hip or knee, or both
Settings: outpat ient clinics
Intervention: t ramadol alone
Comparison: placebo
Outcomesa Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* * Corresponding risk* *
Placebo Tramadol alone
Pain assessed with: 0-
100-mm VASpain inten-
sity where 0 = no pain
Follow-up: range 1
week to 3 months
The mean pain was 54.
3 points
The mean pain in the
intervent ion group was
4 points lower (3 lower
to 5 lower)b
- 3972 (8 RCTs) ⊕⊕⊕©
Moderatee
Mean pain: 4% abso-
lute improvement (95%
CI 3% to 5% improve-
ment),b 7% relat ive im-
provement (6% to 9%
improvement),
SMD -0.25 (95% CI -0.
32 to -0.18)f
NNTB 13 (95% CI 10 to
18)g
A cross-over study
(Thorne 2008), which
was not included in the
meta-analyses, showed
improvement in pain
in the intervent ion
group compared to the
placebo group (mean ±
SD: 189.0 ± 105.0 ver-
sus 230.0 ± 115.4; P =
0.00)
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10 out of 100 improved
by 20%c
5 more out of 100 (3
more to 6 more) in the
intervent ion group im-
proved by 20%c
RR 1.50 (95%CI 1.30 to
1.60)d
Physical function as-
sessed with:
WOMAC Physical Func-
t ion (scale 0 to 1700)
Follow-up: range 1
week to 3 months
The mean physical
funct ion was 1059
The mean physical
funct ion in the inter-
vent ion group was 68
points lower (41 lower
to 99 lower)b
- 2550 (5 RCTs) ⊕⊕⊕©
Moderatee
Mean funct ion: 4%
absolute improvement
(95% CI 2% to 6% im-
provement),b 6% rela-
t ive improvement (95%
CI 4% to 9% improve-
ment),f
SMD -0.20 (95% CI -0.
29 to -0.12),
NNTB 13 (95% CI 9 to
21)g
A cross-over study
(Thorne 2008), which
was not included in the
meta-analyses, showed
improvement in physi-
cal funct ion in the in-
tervent ion group com-
pared to the placebo
group (mean ± SD: 632.
4 ± 361.3 vs 727.4 ±
383.4; P = 0.02)
16 out of 100 improved
by 20%c
5 more out of 100 (3
more to 8 more) in the
intervent ion group im-
proved by 20%c
RR 1.31 (95%CI 1.19 to
1.50)d
Number of participants
experiencing any ad-
verse events
Follow-up: range 1
week to 3 months
492 per 1000 659 per 1000
(610 to 718)
RR 1.34
(95%CI 1.24 to 1.46)
2039 (4 RCTs) ⊕⊕⊕©
Moderatee
17% absolute worsen-
ing (95% CI 12% more
to 23%more),
34% relat ive worsening
(95% CI 24% more to
46%more),
NNTH 6 (95% CI 5 to 9)
A cross-over study
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(Thorne 2008), which
was not included in the
meta-analyses, showed
that there was lit t le or
no dif ference in the to-
tal number of adverse
events between the in-
tervent ion group (79.
8%) and placebo group
(65.9%) (P = 0.08)
Number of participants
who withdrew due to
adverse events
Follow-up: range 1
week to 3 months
73 per 1000 194 per 1000
(159 to 235)
RR 2.64
(95%CI 2.17 to 3.20)
4533 (9 RCTs) ⊕⊕⊕©
Moderatee
12% absolute worsen-
ing (95% CI 9% more to
16%more),
164% relat ive worsen-
ing (95% CI 117% more
to 220%more),
NNTH 9 (95%CI 7 to 12)
In a cross-over study
(Thorne 2008), which
was not included in the
meta-analyses, 15 par-
t icipants withdrew af -
ter randomizat ion due
to adverse events, 12
of which were in the in-
tervent ion group at the
t ime of withdrawal
Number of participants
experiencing any seri-
ous adverse events
Follow-up: range 1
week to 3 months
19 per 1000 34 per 1000
(21 to 54)
RR 1.78
(95%CI 1.11 to 2.84)
3612 (7 RCTs) ⊕⊕©©
Lowe,h
1% absolute worsening
(95% CI 0% more to 4%
more),
78% relat ive worsening
(95% CI 11% more to
184%more),
NNTH 68 (95% CI 29 to
477)
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In a cross-over study
(Thorne 2008), which
was not included in
the meta-analyses, 1
serious adverse event
occurred in a part ici-
pant in the intervent ion
group
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
* * The assumed and the corresponded risk was calculated f rom the SMD and SE.
CI: conf idence interval; MCID: minimal clinically important dif f erence; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat
for an addit ional harmful outcome;RCT: randomized controlled trial;RR: risk rat io;SD: standard deviat ion; SE: standard error; SMD: standardized mean dif ference; WOMAC:
Western Ontario and McMaster Universit ies Arthrit is Index.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aContinuous outcomes summarized using SMDs and SEs, and binary outcomes expressed as RRs. We used standard inverse-
variance f ixed-ef fect meta-analysis to combine the trials in Review Manager 5 (Review Manager 2014).
bAbsolute improvement on a common scale (e.g. 100 mm, 1700-point scale) calculated by mult iplying the SMD by the SD of
the scale (in the control group at baseline) as suggested by the Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
cAssumed and corresponding risks calculated f rom the SMD and SE, with improvement based on an MCID of 20%of the given
scale using the Wells calculator (f rom the Cochrane Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ).
dRR and its 95%CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The
corresponding risk was divided by the assumed risk.
eDowngraded one level due to unclear risk of bias (all t rials had high or unclear risk of at least one type of bias).
fRelat ive improvement percentage def ined as relat ive to the control group risk at baseline.
gNNTB corresponded to the number of part icipants that needed to be treated to see one part icipant improve. Improvement
def ined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (f rom the CMSG Editorial
of f ice; musculoskeletal.cochrane.org/ ne.org/ ).
hDowngraded one level due to imprecision.
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B A C K G R O U N D
Description of the condition
Osteoarthritis (OA) is a disease characterized by joint pain, stiff-
ness, distortion of joint architecture and functional limitations
(Zhang 2008). It accounts for a substantial number of healthcare
visits and costs across the world (Murray 2012).
OA, also known as degenerative arthritis, is one of the most fre-
quent disorders and is the most common cause of disability in
older adults (Lesnoff-Caravaglia 2007). It frequently affects the
hands, feet, and large weight-bearing joints such as the hips and
the knees (Buckwalter 2004). The prevalence of OA increases with
age, since the ability of the articular cartilage to heal decreases, es-
pecially in people aged 50 years and older (Cross 2014; Lawrence
2008).
The enzymatic and mechanical breakdown of the matrix of the
joint cartilage, and the cartilage’s decreased capacity for regenera-
tion are key features of the pathophysiology of OA. In OA, an ex-
cessive amount of proteases such as nitric oxide and other inflam-
matory cytokines are produced by chondrocytes (Lammert 2014).
These mediators cause cellular injury, inhibit cartilage synthesis
and render the chondrocytes susceptible to apoptosis. These in-
flammatory phenomena, in addition to promoting cartilage dam-
age, stimulate A delta and C fibers in the synovium and surround-
ing tissues. This neural stimulation leads to peripheral and central
sensitization, and chronic pain (Kean 2004).
Pain is the most common symptom of OA, and as pain levels
rise, people experience a reduced range of motion and increasing
disability (Bjordal 2004; Dieppe 2005). The pain and function
limitations substantially reduce the quality of life of people with
OA (Kean 2004). People with OA have a lower quality of life than
people with gastrointestinal, cardiovascular or chronic respiratory
illnesses (Reginster 2002).
Description of the intervention
The treatment goals for OA are to reduce pain and to main-
tain or improve (or both) functional status and quality of life
(ACR 2000; Pendleton 2000; Tannenbaum 2000). Several clini-
cal practice guidelines recommend non-pharmacologic and phar-
macologic therapies for the management of OA (Hochberg 2012;
Jevsevar 2013; Richmond 2010; Zhang 2008).
Non-pharmacologic therapies include weight reduction in obese
people, physical therapy (for muscle strengthening), exercise and
occupational therapy (e.g. training in the use of devices to assist
ambulation) (Hochberg 2012; Jevsevar 2013; NCCCC 2008;
Richmond 2010; Zhang 2008).
A wide variety of pharmacologic therapies are recommended by
the American College of Rheumatology (ACR), the American
Academy of Orthopaedic Surgeons (AAOS) and the Osteoarthri-
tis Research Society International (OARSI) (Hochberg 2012;
Richmond 2010; Zhang 2008), and are used to treat OA including
analgesics such as tramadol (Hochberg 2012; Zhang 2008), non-
steroidal anti-inflammatory drugs (NSAIDs) (Hochberg 2012;
Jevsevar 2013; Richmond 2010), and acetaminophen (paraceta-
mol; NCCCC 2008; Zhang 2008). Acetaminophen, although not
associated with an increased risk of gastrointestinal events, is less
effective than NSAIDs in reducing pain (NCCCC 2008; Towheed
2006).
NSAIDs are the cornerstone of pharmacologic therapy for the
management of OA, relieving symptoms such as pain (Towheed
2006). However, their use is associated with gastrointestinal
(Towheed 2006), cardiac (Zhang 2008), and renal problems
(NCCCC 2008), especially in elderly people (Pelletier 2016).
There has been ongoing debate that cyclo-oxygenase-2 (COX-
2)-selective NSAIDs have increased cardiac adverse events com-
pared to traditional NSAIDs. However, one non-inferiority trial
published in the New England Journal of Medicine demonstrated
that the COX-2-selective NSAID, celecoxib, was not inferior to
naproxen or ibuprofen in terms of cardiac adverse events (Nissen
2016).
Tramadol has been increasingly used for pain relief in people
with OA due to having potentially fewer adverse events than with
NSAIDs (Cepeda 2006). The ACR and the OARSI recommend
tramadol in managing OA pain (Hochberg 2012; Zhang 2008),
because in contrast to NSAIDs, it does not produce gastroin-
testinal bleeding, renal (Zhang 2004) or cardiovascular problems
(Pelletier 2016). Tramadol is an opioid that acts on the neuro-
transmission of norepinephrine and serotonin and modifies the
transmission of pain impulses (Pelletier 2016). This dual action
makes tramadol an attractive option, although dependency is a
concern, as with all opiates.
Although the analgesic effect of tramadol for acute and neuro-
pathic pain has been established, there are few systematic reviews
that evaluate the benefits of tramadol for OA. One systematic
review included 11 trials comparing tramadol to placebo and
other active controls (Cepeda 2006). Another systematic review in-
cluded 18 trials comparing opioids including tramadol to placebo
(Avouac 2007). These systematic reviews demonstrated a signifi-
cant decrease in pain as well as benefits on physical function.
How the intervention might work
The mechanism for benefits of tramadol in OA is unclear: tramadol
lacks peripheral action (i.e. it has no local effects on the joints)
and its benefits may decline with chronic use (i.e. development of
tolerance), as part of its action is opioid-related. Nonetheless, the
central action of tramadol could be of great benefit as this action
could decrease the central neuronal sensitization produced by the
persistent nociceptive peripheral input (Jett 1997). In addition,
tolerance may not be a problem in this people with OA, since
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systematic reviews have shown that 44% of participants prescribed
opioids for chronic non-cancer pain continued to take opioids for
up to 24 months (Kalso 2004).
Why it is important to do this review
Clinical studies are the best way to determine whether people with
OA benefit from using tramadol. This review examined the clinical
benefit and harms of tramadol for people with OA.
O B J E C T I V E S
To determine the benefits and harms of oral tramadol or tramadol
combined with acetaminophen or NSAIDs in people with os-
teoarthritis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs). Published stud-
ies, as well as unpublished studies were eligible.
Types of participants
We included studies in adults (i.e.18 years and older) with OA
affecting any joints. We included studies that evaluated partici-
pants who met one of the following: 1. the ACR clinical criteria
for OA; and 2. radiographic evidence of OA. We excluded studies
that evaluated other types of arthritis (e.g. rheumatoid arthritis,
non-osteoarthritic joint pain or back pain) or that did not provide
data specific to participants with OA. We also excluded studies of
tramadol for postoperative pain.
Types of interventions
We included studies that compared tramadol (with or without
acetaminophen or NSAIDs) with either a placebo or an active
treatment.
Types of outcome measures
We included studies that reported the effect of tramadol on pain
intensity, physical function and adverse events of tramadol. If a
trial reported many time points, we recorded the last time point.
Major outcomes
The major outcomes of interest were based on the recommenda-
tions for outcomes in OA trials (Altman 1996; Bellamy 1997).
1. Pain.
2. Physical function.
3. Number of participants experiencing any adverse event.
4. Number of participants who withdrew due to adverse
events.
5. Number of participants experiencing any serious adverse
events.
For trials which assessed results using more than one pain scale,
we used the hierarchy of pain-related outcomes described by Jüni
2006 by extracting data on the pain scale that was highest on this
list:
1. global pain;
2. pain on walking;
3. WOMAC Osteoarthritis Index pain subscore;
4. composite pain scores other than WOMAC;
5. pain on activities other than walking;
6. rest pain or pain during the night;
7. WOMAC Global Algofunctional score;
8. Lequesne Osteoarthritis Index global score;
9. other algofunctional scale;
10. participant’s global assessment;
11. physician’s global assessment.
For trials which assessed results from more than one physical func-
tion scale, we used the same approach as noted above, using the
following hierarchy:
1. global disability score;
2. walking disability;
3. WOMAC Disability subscore;
4. composite disability scores other than WOMAC;
5. disability other than walking;
6. WOMAC Global Scale;
7. Lequesne Osteoarthritis Index global score;
8. other algofunctional scale;
9. participant’s global assessment;
10. physician’s global assessment.
If a study reported pain or function outcomes at several time
points, we extracted the measure at the end of the treatment pe-
riod.
Minor outcomes
1. Symptoms of opioid dependence, such as craving or
physical withdrawal symptoms.
Search methods for identification of studies
Electronic searches
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Electronic databases
We searched the following databases:
1. the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library; 2018, Issue 1;
2. Ovid MEDLINE 1966 to 1 February 2018;
3. Ovid Embase 1980 to 1 February 2018;
4. LILACS 1982 to 13 August 2015.
Trial registries
1. US National Institutes of Health trial registry up to
February 2018 (ClinicalTrials.gov).
2. World Health Organization trial registry up to February
2018 ( apps.who.int/trialsearch).
Search terms
For the identification of the studies in MEDLINE, we used the
MeSH/EMTREE terms: Appendix 1.
There were no language restrictions. We translated non-English
language articles and assessed them. Where applicable, we com-
municated with the authors to obtain information not presented
or that was unclear in the manuscripts.
For each of the other databases, we based search strategies on the
search strategy developed for MEDLINE, but revised appropri-
ately. We searched bibliographies from all retrieved articles for ad-
ditional studies.
Data collection and analysis
Selection of studies
Two review authors (KTA and either CC or JV) independently
screened titles and abstracts for inclusion of all potentially relevant
studies identified by the search. We retrieved the full text of all
articles in which the record or abstract referred to a trial of tramadol
and OA.
Two review authors ( KTA and either CC or JV) independently
screened the full text and identified studies for inclusion, and iden-
tified and recorded reasons for exclusion of the ineligible studies.
We resolved disagreements through discussion, and, if required,
by a third review author ( VW, PT). We identified and excluded
duplicates and collated multiple reports of the same study so that
each study, rather than each report, was the unit of interest in
the review. We recorded the selection process in sufficient de-
tail to complete a PRISMA flow diagram ( prisma-statement.org/
PRISMAStatement/Default.aspx).
Data extraction and management
Two review authors (KTA and either CC or JV) independently
extracted information from each study using a standardized, pi-
loted extraction form accompanied by a codebook. We resolved
disagreements by discussion, and, if necessary, consulted a third
review author (VW).
We extracted the following study characteristics.
1. Methods: study design, total duration of study, study
setting and withdrawals.
2. Participants: number, mean age, age range, sex, disease
duration, types of joints affected, inclusion criteria and exclusion
criteria.
3. Interventions: generic and trade name of the intervention,
type of control used, dosage, frequency, route of administration
and duration of treatment.
4. Outcomes: major and minor outcomes specified and
collected, and time points reported.
5. Characteristics of the design of the trial as outlined in the
Assessment of risk of bias in included studies section.
6. Notes: type and source of financial support for trial, and
notable declarations of interest of trial authors.
When necessary, we approximated means and measures of dis-
persion from figures in the reports. For cross-over trials, we ex-
tracted data from the first period only to include in the meta-
analyses. Whenever possible, we used results from an intention-to-
treat (ITT) analysis. If effect sizes could not be calculated, we con-
tacted the authors for additional data. One review author (TEH)
transferred data into Review Manager 5 (Review Manager 2014).
We double-checked that data were entered correctly by comparing
the data presented in the systematic review with the study reports.
Assessment of risk of bias in included studies
The articles that fulfilled the inclusion criteria underwent quality
appraisal. Two review authors (two of the following authors: JB,
JV, NA, CC, TEH, LM) independently assessed risk of bias for
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We resolved
disagreements through discussion, and by a third review author if
a consensus could not be reached (KTA, JP, VW, AWSR).
We assessed the following risk of bias domains for RCTs:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We graded each potential source of bias as high, low or unclear
risk, and provided a quote from the study report together with
a justification for our judgment in the ’Risk of bias’ table (see
Characteristics of included studies table). Randomization was ad-
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equate if it resulted in an unpredictable allocation schedule. Au-
thors had to note that they used a random component (e.g. ran-
dom assignments generated by a computer).
Allocation concealment was adequate if participants and investi-
gators responsible for participant selection were unable to suspect
before allocation which treatment was used. Authors had to indi-
cate that they employed central randomization by a third party or
used sequentially numbered, opaque, sealed envelopes.
Blinding of participants was adequate if experimental and control
preparations were explicitly described as indistinguishable or if a
study used a double-dummy technique. Blinding of study person-
nel was adequate if authors explicitly stated that investigators were
blinded. Blinding of outcome assessors was adequate if blinding
of participants was considered adequate for self-reported outcome
measures. Blinding of outcome assessors was considered unclear
if authors only explicitly stated that participants were blinded for
outcome measures that were not self-reported, as personnel inter-
acting with participants may not have been blinded and may have
influenced outcome assessment.
Outcome data were considered complete if reasons for any losses
to follow-up, treatment withdrawals or trial group changes were
explained by the authors and the reasons for those occurrences
were unlikely to be connected with their subsequent outcome.
In addition, the occurrence of missing data had to be balanced
between intervention and control groups.
Outcome reporting was considered complete if the outcomes listed
in the protocol matched those reported in the article. Risk of bias
for outcome reporting was considered unclear if the protocol was
not available.
An article was deemed to have demonstrated a low risk of bias for
’other biases’ if no other internal biases were identified. Analyses
were considered adequate if all randomized participants were in-
cluded in the analysis according to the ITT principle.
For the cross-over RCTs, we answered the following questions to
assess the risk of bias (see other bias section in the Assessment of
risk of bias in included studies).
1. Was use of a cross-over design appropriate?
2. Was it clear that the order of receiving treatments was
randomized?
3. Could it be assumed that the trial was not biased from
carry-over effects?
4. Were unbiased data available?
Measures of treatment effect
Major outcomes
1. Pain
We extracted the mean and standard deviation (SD) of pain in each
study group after treatment, and calculated the mean differences
(MD). In cases where the studies reported the difference in pain
with no measure of dispersion, we estimated the standard error
(SE) of the difference from the P value and the number of partici-
pants in each group, as described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). To pool the data,
we chose generic inverse variance fixed-effect models a priori. We
also used random-effects models to verify if the two models gave
consistent results. We then transformed the MD between groups
and the SE into a standardized mean difference (SMD) and the SE
of that SMD. We calculated the corresponding number needed to
treat for an additional beneficial outcome (NNTB) and the mean
percentage of participants who acquired a minimally clinically im-
portant difference (MCID) using the Wells calculator (available at
the CMSG Editorial office musculoskeletal.cochrane.org/). The
Wells calculator obtains the NNTB by taking the reciprocal of
the net proportion of the population benefiting from an inter-
vention (1/P(b)). The net proportion benefiting is dependent on
the proportions benefiting in control and treatment groups and
the proportion worsening in control and treatment groups which
are in turn derived from the normal distribution of the difference
between the minimally important difference and the effect size of
a trial (SMD) (Norman 2001).
We also calculated the risk ratio (RR) by dividing the percentage
of participants who improved in the treatment group by the mean
percentage of participants who improved in the control group
(corresponding risk/assumed risk) and 95% confidence intervals
(CI). We added information on the NNTB, the mean percentage
of participants who acquire an MCID and the RR in the footnotes
of the ’Summary of findings’ tables. The MCID was 20% of a
pain scale (Pham 2003; Tubach 2005). It is important to note that
when results are not statistically significant but CIs are wide, results
may be explained by uncertainty. Thus, it does not preclude the
intervention from having an effect if more research was conducted.
2. Physical function
We extracted the mean and SD in each study arm after treatment
and calculated the MDs and 95% CI. If studies reported the MD
in physical function between treatments without a measure of dis-
persion, we estimated the SE of the difference from the P value
and the number of participants in each group, as described in the
Chapter 7 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). To pool the data, we chose generic in-
verse variance fixed-effect models a priori. We also used random-
effects models to verify if the two models gave consistent results.
We then transformed the MD between groups and the SE into a
SMD and the SE of that SMD. We calculated the corresponding
NNTB and the mean percentage of participants who acquired an
MCID using the Wells calculator (available at the CMSG Edito-
rial office musculoskeletal.cochrane.org/). We also calculated the
RR by dividing the percentage of participants who improved in
the treatment group by the mean percentage of participants who
improved in the control group (corresponding risk/assumed risk).
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We added information on the NNTB, the mean percentage of
participants who acquired an MCID and the RR in the footnotes
of the ’Summary of findings’ tables. The MCID was 20% for
physical function (Pham 2003; Tubach 2005).
3. Harms of tramadol
To evaluate the harms of tramadol, we extracted the proportion of
participants who developed any adverse events, withdrawals due
to adverse events and serious adverse events. We relied upon the
definitions used by authors of the trials. We calculated the RR and
corresponding number needed to treat for an additional harmful
effect (NNTH), with 95% CIs.
Minor outcomes
1. Withdrawal symptoms and propensity for abuse
To evaluate the data pertaining to withdrawal symptoms, we ex-
tracted the proportion of participants who developed these symp-
toms and the proportion of participants who developed a propen-
sity for abuse. We calculated the RR and corresponding NNTH,
with 95% CIs.
Unit of analysis issues
Where multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms.
Dealing with missing data
We contacted investigators or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data
where possible (e.g. when a study was identified as an abstract only
or when data were not available for all participants).
For dichotomous outcomes, we calculated the withdrawal rate
using the number of participants randomized in the group as the
denominator.
For continuous outcomes, we calculated the MD or SMD based
on the number of participants analyzed at that time point. If the
number of participants analyzed was not presented for each time
point, we used the number of randomized participants in each
group at baseline.
Where possible, we computed missing SDs from other statistics
such as SEs, CIs or P values, according to the methods recom-
mended in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Chapter 7; Higgins 2011).
Assessment of heterogeneity
To evaluate statistical heterogeneity, we performed a visual in-
spection of the forest plot to assess differences in results between
the studies when there was a sufficient number of trials. We also
used the I² and Chi² statistical tests (Higgins 2003). We assessed
clinical heterogeneity in terms of participants, interventions, out-
comes, study characteristics and setting of the included trials. As
recommended in theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), the interpretation of an I² value of
0% to 40% might not be important; 30% to 60% may represent
moderate heterogeneity; 50% to 90% may represent substantial
heterogeneity and 75% to 100% represents considerable hetero-
geneity. The Chi² test was interpreted where a P ≤ 0.05 indicated
evidence of statistical heterogeneity.
Assessment of reporting biases
We created and examined funnel plots to explore possible small-
study biases when there was a sufficient number of trials. To assess
outcome reporting bias, we verified trial protocols against pub-
lished reports.
Data synthesis
We summarized continuous outcomes using SMDs and expressed
dichotomous outcomes as RRs. We used standard inverse-variance
fixed-effect meta-analyses to combine the trials (DerSimonian
1986). We also used random-effects models to verify if the two
models gave consistent results.SMD were also translated into MDs
on commonly used scales.
GRADE and ’Summary of findings’ tables
We created ’Summary of findings’ tables for the major outcomes.
We added the absolute and relative percent change in the ’Sum-
mary of findings’ tables.
Two review authors (of: JB, JV, NA, CC, TEH) independently as-
sessed the quality of the evidence. We used the five GRADE con-
siderations (unclear risk of bias, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of a body
of evidence as it related to the studies which contributed data to
the meta-analyses for the prespecified outcomes. We reported the
quality of evidence as high, moderate, low or very low. Low quality
means our confidence in the effect estimate was limited, whereas
the moderate quality means we were moderately confident in the
effect estimate. We considered the following criteria for upgrad-
ing the quality of evidence, if appropriate: large effect, dose-re-
sponse gradient and plausible confounding effect. We used meth-
ods and recommendations described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011; Schünemann
2011). We used GRADEpro software to prepare the ’Summary of
findings’ tables (GRADEpro GDT). We justified all decisions to
downgrade or upgrade the quality of studies using footnotes and
made comments to aid the reader’s understanding of the review
where necessary. We resolved disagreements by consensus, and by
a third review author if a consensus could not be reached (KTA,
JP, VW, AWSR).
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Subgroup analysis and investigation of heterogeneity
We analyzed placebo-controlled studies and active-controlled
studies separately. We analyzed studies that evaluated tramadol
alone or tramadol plus acetaminophen or NSAIDs together, as the
results of these trials were similar.
Interpreting results and reaching conclusions
We followed the guidelines in the Cochrane Handbook for Sys-
tematic Reviews of Interventions for interpreting results and dis-
tinguished a lack of evidence of effect from a lack of effect
(Schünemann 2011).
R E S U L T S
Description of studies
Results of the search
In the updated search conducted in February 2018, we iden-
tified 347 records through database searching and 37 records
through other sources. After eliminating duplicates, we screened
372 records. We excluded 332 records after reviewing their titles
and abstracts, leaving 40 full-text articles which were assessed for
eligibility. Eighteen articles were then excluded after reviewing the
full text of these articles: three articles were not relevant to chronic
management of knee or hip OA, or OA was not evaluated sepa-
rately in these articles; two articles did not evaluate tramadol and
13 were not RCTs. We included 22 articles in this review and we
excluded 11 of these from the meta-analyses due to missing data.
Three of these articles were secondary publications of another trial
(Gana 2006), with no new outcomes of interest (Florete 2008;
Vorsanger 2007), and eight which were reports of protocols for
which the full data could not be accessed (see Appendix 2). Thus,
we included 11 articles in this review, which represented 11 RCTs
in this updated search. When combined with the RCTs from the
search of the earlier version of this systematic review (11 RCTs),
it amounted to 22 RCTs (see PRISMA flow diagram in Figure 1).
However, one of these could not be included in the meta-analyses
because it was a cross-over trial in which results were presented
for all treatment periods combined for all outcomes of interest
(Thorne 2008). These data were presented separately in the re-
sults.
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Figure 1. Study flow diagram. OA: osteoarthritis; RCT: randomized controlled trial.
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Included studies
We included 22 RCTs in the present update (11 more than the
previous review) of which 21 RCTs were included in meta-analy-
ses for 3871 participants who were randomized to tramadol alone
or tramadol in combination with another analgesic and 2625 par-
ticipants who were randomized to placebo or active-control (see
Characteristics of included studies table for further details). All
studies were funded by the pharmaceutical industry with the ex-
ception of two (Bianchi 2003; Fujii 2014). All RCTs were parallel
in design, with the exceptions of four studies, which used a cross-
over design (Bird 1995; Pavelka 1998; Peeva 2010; Thorne 2008).
One study provided no data on the benefits of tramadol, as the
aim of the study was to evaluate the tramadol-sparing effect of
naproxen (Schnitzer 1999). One cross-over study provided data on
benefits but this evidence could not be pooled with other studies
as results were presented for all treatment periods combined (Peeva
2010). These two studies were included since they provided some
data for the evaluation of harms. Only two trials were registered in
the ClinicalTrials.gov register (Park 2012; Peeva 2010), although
10 trials included in the meta-analyses were published after 2005.
Thirteen RCTs used placebo controls (Babul 2004; Burch 2007;
DeLemos 2011; Emkey 2004; Fishman 2007; Fleischmann 2001;
Gana 2006; Kean 2009; Malonne 2004; Peeva 2010; Schnitzer
1999; Silverfield 2002; Thorne 2008). In 11 studies, the ac-
tive control was either acetaminophen 1500 mg/day (Bianchi
2003); NSAIDs (i.e. diclofenac 86.9 mg/day (Pavelka 1998), di-
clofenac 75 mg/day to 100 mg/day (Beaulieu 2008), celecoxib
200 mg/day (DeLemos 2011), loxoprofen 180 mg/day (Fujii
2014), meloxicam 7.5 mg or 15 mg or aceclofenac 100 mg (Park
2012), acetaminophen, indomethacin, brufen, diclofenac, feldene
or mefenamate (Wilder-Smith 2001) (since this group was not
randomized, it was excluded from the analyses) and naproxen
500 mg/day (Peeva 2010)); or other opioids (i.e. transdermal fen-
tanyl 25 µg/day to 50 µg/day (Fujii 2014), dihydrocodeine 120
mg/day (Wilder-Smith 2001), dextropropoxyphene 300 mg/day
(Jensen 1994), transdermal buprenorphine 5 µg/day to 20 µg/day
(Karlsson 2009), and pentazocine 150 mg/day (Bird 1995)). Two
studies used both placebo and active controls (DeLemos 2011;
Peeva 2010). Seventeen studies evaluated tramadol alone (Babul
2004; Beaulieu 2008; Bianchi 2003; Bird 1995; Burch 2007;
DeLemos 2011; Fishman 2007; Fleischmann 2001; Gana 2006;
Jensen 1994; Karlsson 2009; Kean 2009; Malonne 2004; Pavelka
1998; Schnitzer 1999; Thorne 2008; Wilder-Smith 2001), and
five evaluated tramadol plus acetaminophen (Emkey 2004; Fujii
2014; Park 2012; Peeva 2010; Silverfield 2002).
The doses of tramadol used in the studies were variable, ranging
from 37.5 mg to 400 mg daily. We assessed whether there were
differences in the results depending on dose. Since the results were
similar, we decided to pool the doses. All studies evaluated people
with symptomatic OA of the hip or knee (or both) with 13 studies
including participants with knee or hip OA and nine studies with
knee OA. All studies included people aged 18 years or older, and
12 studies included people aged 35 years or older. Participants were
predominantly women, with a mean age of 63 years. Most studies
included participants with moderate to severe pain, with several
studies defining this as a visual analog scale (VAS) score of at least
40 mm on a 100 mm scale. The mean number of participants in
the tramadol group was 176 (range 10 to 815) and in the control
groups was 119 (range 10 to 405). The mean length of the studies
was 54 days (range 3 days to 91 days). Nine studies were 12 weeks
long and four studies were eight weeks long; the remainder of the
studies varied in duration.
Assessed primary and secondary outcomes
Major outcomes: pain and physical function
A total of 19 RCTs reported major outcomes, such as pain or
physical function (or both) outcome of interest (i.e. RCTs with
outcomes rated the highest on the hierarchy of outcomes described
in the methods) (Babul 2004; Beaulieu 2008; Bianchi 2003; Bird
1995; Burch 2007; DeLemos 2011; Emkey 2004; Fishman 2007;
Fleischmann 2001; Fujii 2014; Gana 2006; Jensen 1994; Karlsson
2009; Kean 2009; Malonne 2004; Park 2012; Pavelka 1998;
Silverfield 2002; Wilder-Smith 2001). All these RCTs reported
the effect of tramadol on pain. Eleven RCTs reported the effect
of tramadol on physical function (Babul 2004; Beaulieu 2008;
DeLemos 2011; Emkey 2004; Fleischmann 2001; Gana 2006;
Jensen 1994; Kean 2009; Park 2012; Pavelka 1998; Silverfield
2002).
Six RCTs evaluated pain using the WOMAC Pain subscale
(Beaulieu 2008; DeLemos 2011; Fishman 2007; Kean 2009;
Pavelka 1998; Silverfield 2002). Eight RCTs evaluated pain inten-
sity using a VAS (Babul 2004; Bianchi 2003; Burch 2007; Emkey
2004; Fujii 2014; Gana 2006; Jensen 1994; Malonne 2004). One
trial evaluated pain intensity during movement using a 4-point
Likert scale (Wilder-Smith 2001), and the other trials evaluated
pain intensity using a 4-point Likert scale (Bird 1995; Fleischmann
2001), a numerical rating scale (Park 2012), and the Box scale 11
(Karlsson 2009).
Ten RCTs evaluated physical function using the WOMAC Phys-
ical Function subscale (Babul 2004; Beaulieu 2008; DeLemos
2011; Emkey 2004; Fleischmann 2001; Gana 2006; Kean 2009;
Park 2012; Silverfield 2002; Thorne 2008). One trial used the
WOMAC Total score (Pavelka 1998). One trial used an overall
assessment of the therapy scored on a 5-point Likert scale that
15Tramadol for osteoarthritis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
was then transformed into a dichotomous scale (Jensen 1994). We
used this overall assessment as a proxy for physical function.
Major outcomes: harms
All RCTs assessed harms outcomes, such as any adverse events,
withdrawal due to adverse events, and serious adverse events. These
included 10 trials assessing the number of participants with any
adverse events, 16 trials assessing the number of participants who
withdrew because of adverse events and 14 trials assessing the
number of participants with serious adverse events.
Minor outcomes: withdrawal symptoms and propensity for
abuse
Three trials reported withdrawal symptoms or propensity for
abuse, or both (Beaulieu 2008; DeLemos 2011; Gana 2006). An-
other trial reported that there was no evidence of abuse but did
not mention if it was assessed (Emkey 2004).
Excluded studies
In the full-text screening, we excluded 18 full-text articles in this
update. Three articles did not present data for knee or hip OA, two
articles did not evaluate tramadol and 13 did not report RCTs. A
list of some of the excluded studies from both abstract/title and
full-text screening phases is shown in Characteristics of excluded
studies table.
Risk of bias in included studies
Figure 2 shows the assessment of risk of bias for each included
study and Figure 3 shows a summary of the risk of bias across the
different types of bias.
16Tramadol for osteoarthritis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgments about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgments about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
Thirteen trials reported adequate sequence generation, eight trials
reported unclear sequence generation (Bird 1995; DeLemos 2011;
Emkey 2004; Kean 2009; Malonne 2004; Park 2012; Schnitzer
1999; Thorne 2008), and one trial reported inadequate sequence
generation (Wilder-Smith 2001).
Four trials reported adequate allocation concealment (Burch 2007;
Fishman 2007; Gana 2006; Peeva 2010), while most others had
unclear allocation concealment, except for two trials that had inad-
equate allocation concealment (Park 2012; Wilder-Smith 2001).
Blinding
All but five trials were at low risk of bias for blinding of par-
ticipants and all but six had a low risk of bias for blinding of
outcome measures. However, most trials had unclear or high
risk of bias for blinding of personnel while seven trials showed
a low risk of bias. All but four trials were described as dou-
ble-blind (Fujii 2014; Karlsson 2009; Park 2012; Wilder-Smith
2001). Twelve trials reported the use of indistinguishable inter-
ventions to blind participants (Babul 2004; Bianchi 2003; Burch
2007; DeLemos 2011; Emkey 2004; Fleischmann 2001; Gana
2006; Jensen 1994; Malonne 2004; Pavelka 1998; Schnitzer 1999;
Silverfield 2002), whereas four trials used double-dummy tech-
niques (Beaulieu 2008; Fishman 2007; Kean 2009; Peeva 2010).
Though described as double-blind, the authors of two trials did
not describe blinding procedures (Bird 1995; Thorne 2008).
Incomplete outcome data
Ten trials were at a low risk of bias for incomplete outcome data
for pain and physical function (Beaulieu 2008; Bianchi 2003;
Burch 2007; Jensen 1994; Malonne 2004; Pavelka 1998; Peeva
2010; Schnitzer 1999; Thorne 2008; Wilder-Smith 2001), two
were unclear (Bird 1995; Fujii 2014), and the reminder showed
a high risk of bias. Twelve trials were at a low risk of bias for
incomplete outcome data for adverse events, three were unclear
(Bird 1995; Fujii 2014; Park 2012), and the reminder showed a
high risk of bias. Eleven trials described their benefits analysis to
be according to the ITT principle (Babul 2004; DeLemos 2011;
Emkey 2004; Fishman 2007; Fleischmann 2001; Gana 2006;
Karlsson 2009; Kean 2009; Park 2012; Silverfield 2002; Thorne
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2008), but some of these trials provided numbers for final analyses
that were different from the numbers of randomized participants
for pain and physical function outcomes. Among studies which
did not employ the ITT principle and for which benefits data
were usable for the purposes of this review update, exclusion of
participants from the analysis of benefits outcomes ranged from
10% to 45% in the experimental groups and from 6% to 60% in
the control groups.
Selective reporting
All outcomes mentioned in trials’ methods were reported in most
studies. However, we could only find the protocol of two trials
(Peeva 2010; Park 2012). Most studies reported adverse events
that were the most common.
Other potential sources of bias
Some of the cross-over trials did not appear to use adequate meth-
ods (Bird 1995; Pavelka 1998).
Effects of interventions
See: Summary of findings for the main comparison Tramadol
alone compared with placebo for osteoarthritis; Summary of
findings 2 Tramadol in combination with acetaminophen
compared with placebo for osteoarthritis; Summary of findings 3
Tramadol alone compared with acetaminophen for osteoarthritis;
Summary of findings 4 Tramadol alone compared with
NSAIDs for osteoarthritis; Summary of findings 5 Tramadol
alone compared with other opioids for osteoarthritis; Summary
of findings 6 Tramadol in combination with acetaminophen
compared with NSAIDs for osteoarthritis; Summary of findings
7 Tramadol in combination with acetaminophen compared with
other opioids for osteoarthritis
Major outcomes
Benefits
Pain
Placebo-controlled studies
Eight trials including 2647 participants in the tramadol alone
groups and 1325 participants in the placebo control groups con-
tributed to the analysis of knee or hip pain. Two trials includ-
ing 350 participants in the combined tramadol/acetaminophen
groups and 264 in the placebo control groups contributed to the
analysis of knee or hip pain.
We found moderate quality evidence that tramadol alone had a
small and probably not clinically important pain reduction com-
pared to placebo control interventions (SMD -0.25, 95% CI -
0.32 to -0.18; Summary of findings for the main comparison).
Fifteen out of 100 people in the tramadol group improved by
20% (which corresponded to a clinically important difference in
pain) compared to 10/100 in the placebo group (see Summary of
findings for the main comparison). On a scale of 0 to 100, people
in the tramadol group had a 4-point reduction in pain (95% CI 3
to 5; 8 studies, 3972 participants). This translated into an NNTB
of 13 (95% CI 10 to 18). There was no substantial clinical het-
erogeneity of the participants (i.e. there were no important dif-
ferences in sample, intervention or control group characteristics).
An I2 statistic of 0% indicated a low degree of statistical hetero-
geneity. A visual inspection of the funnel plot suggested symmetry
(see Figure 4). Applying the GRADE criteria to value the overall
quality of the evidence, we downgraded once due to unclear risk
of bias in the included trials (see Summary of findings for the main
comparison).
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Figure 4. Funnel plot of comparison: 1 Tramadol versus placebo, outcome: 1.1 Pain.
One cross-over study, which was not included in the meta-anal-
yses, showed that WOMAC Osteoarthritis Index subscale scores
for pain were statistically significantly better with tramadol com-
pared to placebo (189.0 (SD 105.0) with tramadol versus 230.0
(SD 115.4) with placebo; P = 0.0001), but these differences were
probably not clinically important (Thorne 2008). The study also
measured pain intensity using an ordinal scale (0 = none, 1 = mild,
2 = moderate, 3 = severe, 4 = excruciating) and a VAS scale (from
0 mm to 100 mm). Tramadol had statistically significantly lower
VAS pain intensity scores compared with placebo (37.4 (SD 23.9)
with tramadol versus 45.1 (SD 24.3) with placebo; P = 0.0009),
but these differences were probably not clinically important.
We found moderate quality evidence that tramadol in combina-
tion with acetaminophen had a small but probably not clinically
important pain reduction compared to placebo control interven-
tions (SMD -0.28, 95% CI -0.45 to -0.12; Summary of findings
2). Twelve out of 100 people improved in a clinically important
way in the tramadol in combination with acetaminophen group
compared to 7/100 in the placebo group (see Summary of findings
2). On a scale of 0 to 100, people in the tramadol in combination
with acetaminophen group had a 4-point reduction in pain (95%
CI 2 to 6; 2 studies, 614 participants). This translated into an
NNTB of 14 (95% CI 9 to 33). There was no substantial clinical
heterogeneity of the participants (i.e. there were no important dif-
ferences in sample, intervention or control group characteristics).
An I2 statistic of 0% indicated a low degree of heterogeneity. Ap-
plying the GRADE criteria to the overall quality of the evidence,
we downgraded once due to unclear risk of bias in the included
trials (see Summary of findings 2).
Active-controlled studies
Eleven trials including 1017 participants in experimental groups
and 668 participants in active control groups (which included ac-
etaminophen, NSAIDs and opioids as active controls) contributed
to the analyses of knee or hip pain.
Due to very low quality evidence, we were uncertain whether tra-
madol alone reduced pain compared to acetaminophen (SMD
0.13, 95% CI -0.80 to 1.06; Summary of findings 3; Bianchi
2003). Seven out of 100 people improved in a clinically impor-
tant way with tramadol compared to 9/100 people in the ac-
etaminophen group (see Summary of findings 3). Compared to
the acetaminophen group, people in the tramadol group had a 2-
point increase in pain (95% CI -12 to 16 on a scale of 0 to 100;
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1 study, 20 participants). Applying the GRADE criteria to the
overall quality of the evidence, we downgraded three times due
to unclear risk of bias and the serious imprecision in the included
trials (see Summary of findings 3).
We found moderate quality evidence that tramadol alone was less
effective in pain reduction compared to NSAIDs (SMD 0.21, 95%
CI 0.07 to 0.36; Summary of findings 4; Beaulieu 2008; DeLemos
2011; Pavelka 1998). Twelve out of 100 people improved in a clin-
ically important way in the tramadol group compared to 17/100
in the NSAID group (see Summary of findings 4). Compared to
NSAIDs, people in the tramadol group had a 4-point worsening
in pain on a scale of 0 to 100 (95% CI 1 to 7; 3 studies, 952 par-
ticipants). This translated into an NNTB of 12 (95% CI 7 to 35).
There was no substantial clinical heterogeneity of the participants
(i.e. there were no important differences in sample, intervention
or control group characteristics). An I2 statistic of 23% indicated
a low degree of statistical heterogeneity. Applying the GRADE
criteria to the overall quality of the evidence, we downgraded once
due to unclear risk of bias in the included trials (see Summary of
findings 4).
We found moderate quality evidence that tramadol alone did not
lead to pain reduction compared to other opioids (SMD -0.11,
95% CI -0.33 to 0.12; 4 studies, 411 participants; Summary
of findings 5; Bird 1995; Jensen 1994; Karlsson 2009; Wilder-
Smith 2001). Twenty-six out of 100 people improved in a clinically
important way in the tramadol group compared to 23/100 people
in the other opioid group (see Summary of findings 5). There was
no substantial clinical heterogeneity of the participants (i.e. there
were no important differences in sample, intervention or control
group characteristics). An I2 statistic of 0% indicated a low degree
of statistical heterogeneity. Applying the GRADE criteria to the
overall quality of the evidence, we downgraded once due to unclear
risk of bias in the included trials (see Summary of findings 5).
We found moderate quality evidence that tramadol in combina-
tion with acetaminophen did not lead to pain reduction com-
pared to NSAIDs (SMD 0.12 95% CI -0.16 to 0.39; Summary of
findings 6; Fujii 2014; Park 2012). Forty-two out of 100 people
improved in a clinically important way in the tramadol in com-
bination with acetaminophen group compared to 47/100 people
in the NSAIDs group (2 studies, 226 participants; Summary of
findings 6). There was no substantial clinical heterogeneity of the
participants (i.e. there were no important differences in sample,
intervention or control group characteristics). An I2 statistic of
35% indicated a low degree of statistical heterogeneity. Applying
the GRADE criteria to the overall quality of the evidence, we
downgraded once due to unclear risk of bias in the included trials
(see Summary of findings 6).
We found low quality evidence that tramadol in combination with
acetaminophen did not lead to pain reduction compared to other
opioids (SMD 0.06, 95% CI -0.31 to 0.43; 2 studies, 226 par-
ticipants; Summary of findings 7; Fujii 2014). Thirty out of 100
people improved in a clinically important way in the tramadol
in combination with acetaminophen group compared to 32/100
people in the other opioids group (1 study, 130 participants; see
Summary of findings 7). Applying the GRADE criteria to the
overall quality of the evidence, we downgraded twice due to un-
clear risk of bias in the included trials and the imprecision between
trials (see Summary of findings 7).
Physical function
Placebo-controlled trials
Five studies including 1789 participants in the tramadol alone
groups and 761 participants in the placebo control groups
contributed to the analysis of physical function (Babul 2004;
DeLemos 2011; Fleischmann 2001; Gana 2006; Kean 2009). Two
studies including 350 participants in the tramadol in combination
with acetaminophen groups and 264 participants in the placebo
control groups contributed to the analysis of physical function
(Emkey 2004; Silverfield 2002).
We found moderate quality evidence that tramadol alone had a
small but probably not clinically important benefit in physical
function compared to placebo (SMD -0.20, 95% CI -0.29 to -
0.12; Summary of findings for the main comparison). Twenty-
one percent of people in the tramadol group improved by 20%,
which corresponded to a clinically important difference in physi-
cal function, and 16% of people improved in a clinically impor-
tant way in the placebo group (see Summary of findings for the
main comparison). On a scale of 0 to 100, people in the tramadol
group had a 4-point improvement in physical function (95% CI 2
to 6; 5 studies, 2550 participants). This translated into an NNTB
of 13 (95% CI 9 to 21). There was no substantial clinical het-
erogeneity of the participants (i.e. there were no important dif-
ferences in sample, intervention or control group characteristics).
An I2 statistic of 54% indicated a moderate degree of statistical
heterogeneity. One trial was responsible for the statistical hetero-
geneity (DeLemos 2011). The trial had three intervention groups
with different doses of tramadol (100 mg, 200 mg and 300 mg)
and had both a placebo and active control group. The trial indi-
cated no statistically significant or clinically important difference
in physical function (SMD -0.02, 95% CI -0.18 to 0.14). Apply-
ing the GRADE criteria to the overall quality of the evidence, we
downgraded once due to unclear risk of bias in the included trials
(see Summary of findings for the main comparison).
One study, which was not included in the meta-analyses, found
that WOMAC Osteoarthritis Index subscale scores for physical
function were statistically significantly better with tramadol alone
compared to placebo, but these differences were probably not clin-
ically important (632.4 (SD 361.3) with tramadol alone versus
727.4 (SD 383.4) with placebo; P = 0.0205; Thorne 2008).
We found moderate quality evidence that tramadol in combina-
tion with acetaminophen had a small but probably not clinically
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important benefit in physical function compared to placebo (SMD
-0.27, 95% CI -0.43 to -0.11; Summary of findings 2). Fifteen
percent of people improved in a clinically important way in the
tramadol in combination with acetaminophen group compared to
10% in the placebo group (see Summary of findings 2 for the main
comparison). On a scale of 0 to 100, people in the tramadol in
combination with acetaminophen group had a 4-point improve-
ment in physical function (95% CI 2 to 7; 2 studies, 614 partic-
ipants). This translated into an NNTB of 12 (95% CI 8 to 30).
There was no substantial clinical heterogeneity of the participants
(i.e. there were no important differences in sample, intervention
or control group characteristics). An I2 statistic of 0% indicated
low degree of heterogeneity. Applying the GRADE criteria to the
overall quality of the evidence, we downgraded once due to un-
clear risk of bias in the included trials (see Summary of findings
2).
Active-controlled trials
Five studies including 769 participants in experimental groups and
410 participants in active control groups (which included NSAIDs
and other opioids) contributed to the analysis of physical function.
We found low quality evidence that tramadol alone had a small
but probably not clinically important worsening in physical func-
tion compared to NSAIDs (SMD 0.23, 95% CI 0.09 to 0.37;
Summary of findings 4; Beaulieu 2008; DeLemos 2011; Pavelka
1998). Twelve out of 100 people improved in a clinically impor-
tant way with tramadol alone compared to 17/100 people in the
NSAIDs group (see Summary of findings 4). On a scale of 0 to
100, people in the tramadol group had a 5-point worsening in
physical function compared to the NSAIDs group (95% CI 2 to 8;
3 studies, 952 participants). This translated into an NNTB of 11
(95% CI 7 to 27). There was no substantial clinical heterogene-
ity of the participants (i.e. there were no important differences in
sample, intervention or control group characteristics). However,
an I2 statistic of 70% indicated a high degree of statistical hetero-
geneity. One trial was responsible for most of the statistical het-
erogeneity (Pavelka 1998). This trial has a small sample size (54
participants) and included participants as young as 18 years old,
contrary to most studies. It employed a cross-over design and only
data obtained during the first four weeks of the trial were analyzed.
The SMD, though not statistically significant, indicated an im-
provement in physical function compared to NSAIDs, contrary
to the other trials comparing tramadol alone and NSAIDs (SMD
-0.38, 95% CI -0.92 to 0.16). Applying the GRADE criteria to
the overall quality of the evidence, we downgraded twice due to
unclear risk of bias and inconsistency (see Summary of findings
4).
We found moderate quality evidence that tramadol alone had a
small but probably not clinically important benefit in overall as-
sessment at end of therapy compared to other opioids (RR 1.32,
95% CI 1.04 to 1.68; 1 study, 190 participants; Summary of
findings 5; Jensen 1994). According to the only study in this anal-
ysis, 67/100 people defined their overall assessment at end of ther-
apy as good or better in the tramadol group compared to 51/100
people in the opioids group. This translated into an NNTB of 7
(95% CI 3 to 50). Applying the GRADE criteria to the overall
quality of the evidence, we downgraded once due to unclear risk
of bias (see Summary of findings 5).
We found low quality evidence that tramadol in combination with
acetaminophen did not improve physical function compared to
NSAIDs (SMD 0.20, 95% CI -0.21 to 0.61; 1 study, 91 partici-
pants; Summary of findings 6; Park 2012). Seventeen out of 100
people improved in a clinically important way in the tramadol
in combination with acetaminophen group compared to 22/100
people in the NSAIDs group (see Summary of findings 6). Apply-
ing the GRADE criteria to the overall quality of the evidence, we
downgraded twice due to unclear risk of bias and imprecision (see
Summary of findings 6).
Harms
Any adverse events
Placebo-controlled trials
Four trials including 1366 participants in the tramadol alone
groups and 673 participants in the placebo control groups re-
ported the number of participants presenting with any adverse
events (Babul 2004; Fishman 2007; Gana 2006; Malonne 2004).
One trial including 197 participants in the combined tramadol/
acetaminophen groups and 111 participants in the placebo control
group reported the number of participants presenting with any
adverse events (Silverfield 2002). There were 1424 people with
adverse events in these five trials. Tramadol may cause adverse ef-
fects such as nausea, vomiting, dizziness, constipation, tiredness,
headache, sweating and abdominal pain.
We found moderate quality evidence that there was a greater risk
of developing any adverse events with tramadol alone compared
to placebo (RR 1.34, 95% CI 1.24 to 1.46; 4 studies, 2039 par-
ticipants; Summary of findings for the main comparison). Sixty-
six out of 100 people may have developed adverse effects when
taking tramadol alone compared to 49/100 people when taking
placebo, which corresponded to 17 more people out of 100 who
develop adverse events. The NNTH to cause one additional par-
ticipant to experience an adverse event was 6 (95% CI 5 to 9).
An I2 statistic of 62% indicated a high degree of heterogeneity.
One trial was responsible for most of the statistical heterogeneity
(Malonne 2004). This could be explained by the duration of the
trial, which was two weeks as compared to the 12-week duration
for the other trials, as well as the population, which was exclusively
white as compared to the slightly more diverse population of the
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other studies. It had a higher RR than the other studies (RR 2.33,
95% CI 1.53 to 3.55). Applying the GRADE criteria to the overall
quality of the evidence, we downgraded once due to unclear risk
of bias (see Summary of findings for the main comparison).
In one study which was not included in the meta-analyses, 94
(79.8%) participants reported adverse events during tramadol
treatment while 88 (65.9%) participants reported adverse events
during placebo treatment (Thorne 2008). The difference in the
overall number of adverse events between treatment groups was
not clinically significant (P = 0.0833).
We found moderate quality evidence that there was a greater risk of
developing any adverse events with tramadol in combination with
acetaminophen compared to placebo (RR 1.91, 95% CI 1.32 to
2.76; 1 study, 308 participants; Summary of findings 2). Forty-five
out of 100 people may have developed adverse effects when taking
tramadol in combination with acetaminophen compared to 23/
100 people when taking a placebo, which corresponded to 22 more
people out of 100 who developed adverse events. The NNTH to
cause one additional participant to experience an adverse event was
5 (95% CI 3 to 14; Summary of findings 2). Applying the GRADE
criteria to the overall quality of the evidence, we downgraded once
due to unclear risk of bias (see Summary of findings 2).
Active-controlled trials
Five trials reported the number of participants presenting with
any adverse event including 326 participants in experimental
groups (tramadol alone and tramadol in combination with ac-
etaminophen) and 331 participants in active control groups (in-
cluding NSAIDs and opioids). There were 403 people with ad-
verse events in these five trials.
We found moderate quality evidence that there was a greater risk
of developing any adverse events with tramadol alone compared
to NSAIDs (RR 1.31, 95% CI 1.03 to 1.67; 1 study, 128 par-
ticipants; see Summary of findings 4; Beaulieu 2008). Seventy-
seven out of 100 people may have developed adverse effects when
taking tramadol alone compared to 59 out of 100 people when
taking NSAIDs, which corresponded to 18 more people out of
100 who develop adverse events. The NNTH to cause one addi-
tional participant to experience an adverse event was 6 (95% CI
3 to 57). Applying the GRADE criteria to the overall quality of
the evidence, we downgraded once due to unclear risk of bias (see
Summary of findings 4).
Due to very low quality evidence, we were uncertain whether tra-
madol alone had an increased risk of adverse events compared to
other opioids (RR 0.99, 95% CI 0.87 to 1.13; 3 studies, 438 partic-
ipants; Summary of findings 5; Bird 1995; Jensen 1994; Karlsson
2009). An I2 statistic of 90% indicated a high degree of hetero-
geneity for the trials comparing tramadol alone to other opioids.
One trial was responsible for some of the statistical heterogeneity
(Jensen 1994). This trial indicated that tramadol increased the risk
of overall adverse events compared to other opioids, contrary to
the findings of the other trials. This could be explained by the
high dose of tramadol given to the treatment group (tramadol
100 mg three times daily). Applying the GRADE criteria to the
overall quality of the evidence, we downgraded three times due to
unclear risk of bias, inconsistency and imprecision (see Summary
of findings 5).
We found low quality evidence that in one trial comparing tra-
madol in combination with acetaminophen to NSAIDs, there was
no increase in risk of developing any adverse events (RR 1.17 95%
CI 0.87 to 1.57; 1 study, 91 participants; Summary of findings 6;
Park 2012). Applying the GRADE criteria to the overall quality
of the evidence, we downgraded twice due to unclear risk of bias
and imprecision (see Summary of findings 6).
Withdrawals due to adverse events
Placebo-controlled trials
Nine trials with 2979 participants in the tramadol alone groups
and 1555 participants in the placebo control groups contributed
to the meta-analyses of participants withdrawn or dropped out
because of adverse events (Babul 2004; Burch 2007; DeLemos
2011; Fishman 2007; Fleischmann 2001; Gana 2006; Kean 2009;
Malonne 2004; Schnitzer 1999). Two trials with 350 participants
in the tramadol in combination with acetaminophen groups and
264 participants in the placebo control groups contributed to the
meta-analyses of participants withdrawn or dropped out because
of adverse events (Emkey 2004; Silverfield 2002). There were 796
people with adverse events that made them stop the treatment in
the 11 trials.
We found moderate quality evidence that participants who re-
ceived tramadol alone had a greater risk of withdrawing from the
study because of adverse events compared to participants who re-
ceived placebo (RR 2.64, 95% CI 2.17 to 3.20; 9 studies, 4533 par-
ticipants; Summary of findings for the main comparison). Nine-
teen out of 100 people withdrew due to adverse events when tak-
ing tramadol alone and 7/100 people withdrew due to adverse
events when taking a placebo, which corresponded to 12 more
people out of 100 people who withdrew due to adverse events.
The NNTH to cause one additional participant to withdraw due
to adverse events was 9 (95% CI 7 to 12; Summary of findings for
the main comparison). An I2 statistic of 55% indicated a mod-
erate degree of heterogeneity. Two trials were responsible for the
statistical heterogeneity (Kean 2009; Malonne 2004). This could
be explained by the duration of the Malonne 2004 trial, which was
two weeks as compared to the 12-week duration of the other trials,
and the population, which was exclusively white as compared to
the slightly more diverse population of the other studies. While
both trials indicated that participants who received tramadol alone
had a greater risk of withdrawing from the study because of ad-
verse events compared to participants who received placebo (Kean
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2009: RR 5.04, 95% CI 2.94 to 8.62; Malonne 2004: RR 25.73,
95% CI 3.54 to 187.02), they had higher RRs and wider CIs
than the other trials. Applying the GRADE criteria to the overall
quality of the evidence, we downgraded twice due to unclear risk
of bias and inconsistency (see Summary of findings for the main
comparison).
In one study which was not included in the meta-analyses, 15
participants withdrew after randomization due to adverse events,
12 of whom were receiving tramadol at the time of their withdrawal
(Thorne 2008).
We found low quality evidence that participants receiving tra-
madol in combination with acetaminophen had a greater risk of
withdrawing from the study due to adverse events compared to
participants who received placebo (RR 2.78, 95% CI 1.50 to 5.16;
2 studies, 614 participants; Summary of findings 2). Thirteen
out of 100 people withdrew due to adverse events when taking
tramadol in combination with acetaminophen and 5/100 people
withdrew due to adverse events when taking placebo, which corre-
sponded to 8 more people out of 100 people who withdrew due to
adverse events. The NNTH to cause one additional participant to
withdraw due to adverse events was 13 (95% CI 6 to 44; Summary
of findings 2). An I2 statistic of 0% indicated a low degree of het-
erogeneity. Applying the GRADE criteria to the overall quality of
the evidence, we downgraded twice due to unclear risk of bias and
imprecision (see Summary of findings 2).
Active-controlled trials
Six trials with 891 participants in the tramadol alone groups
and 496 participants in the active control groups (including ac-
etaminophen, NSAIDs and opioids) contributed to the meta-anal-
yses of participants withdrawn or dropped out because of adverse
events. There were 275 adverse events that made them stop the
treatment in the 11 trials.
Due to very low quality evidence, we were uncertain whether tra-
madol alone had a greater risk of withdrawing from the study be-
cause of adverse events compared to acetaminophen (RR 5.00,
95% CI 0.27 to 92.62; 1 study, 20 participants; Summary of
findings 3; Bianchi 2003). Applying the GRADE criteria to the
overall quality of the evidence, we downgraded three times due
to unclear risk of bias and serious imprecision (see Summary of
findings 3).
We found low quality evidence that participants receiving tra-
madol alone had a greater risk of withdrawing from the study be-
cause of adverse events compared to NSAIDs (RR 1.88, 95% CI
1.27 to 2.76; 2 studies, 929 participants; Summary of findings
4; Beaulieu 2008; DeLemos 2011). Twenty-one out of 100 peo-
ple withdrew due to adverse events when taking tramadol alone
and 11/100 people withdrew due to adverse events when taking
NSAIDs, corresponding to 10 more people out of 100 people who
withdrew due to adverse events. The NNTH to cause one addi-
tional participant to withdraw due to adverse events was 10 (95%
CI 5 to 33; see Summary of findings 4 for the main comparison).
An I2 statistic of 60% indicated a high degree of heterogeneity. Ap-
plying the GRADE criteria to the overall quality of the evidence,
we downgraded twice due to unclear risk of bias and inconsistency
(see Summary of findings 4).
We found low quality evidence that participants receiving tra-
madol alone had an increased risk of withdrawing due to adverse
events compared to other opioids (RR 2.26, 95% CI 1.52 to 3.37;
3 studies, 438 participants; Summary of findings 5; Bird 1995;
Jensen 1994; Karlsson 2009). Thirty-one out of 100 people with-
drew due to adverse events when taking tramadol alone and 14/
100 people withdrew due to adverse events when taking other
opioids, corresponding to 17 more people out of 100 people who
withdrew due to adverse events. The NNTH to cause one addi-
tional withdrawal due to adverse events was 6 (95% CI 3 to 14).
An I2 statistic of 70% indicated a high degree of heterogeneity
among studies comparing tramadol alone to other opioids. One
trial was responsible for most of the statistical heterogeneity (Bird
1995). This trial had a short duration of two weeks and a small
sample size of 30 participants. It indicated that participants receiv-
ing tramadol had a decreased risk of withdrawing due to adverse
events compared to other opioids (RR 0.67, 95% CI 0.22 to 2.01),
contrary to the findings of the other trials. Applying the GRADE
criteria to the overall quality of the evidence, we downgraded twice
due to the unclear risk of bias and inconsistency (see Summary of
findings 5).
Serious adverse events
Placebo-controlled trials
Seven trials with 2460 participants in the tramadol alone groups
and 1153 participants in the placebo control groups contributed
to the analysis of participants experiencing any serious adverse
event (Babul 2004; Burch 2007; DeLemos 2011; Fishman 2007;
Fleischmann 2001; Gana 2006; Malonne 2004). One trial with
eight participants in the tramadol in combination with ac-
etaminophen groups and seven participants in the placebo control
groups contributed to the analysis of participants experiencing any
serious adverse event (Peeva 2010). There were 132 people with
serious adverse events in these eight trials. Serious adverse events
reported in the tramadol groups included unstable angina, chest
pain, breast cancer, diverticulitis, grand mal convulsions, prostate
cancer, popliteal bursitis, small intestinal obstruction, cholelithia-
sis, pancreatitis and abdominal pain. However, authors of the trials
mentioned only a few serious adverse events that may have been
related to tramadol use. These were syncope, subendocardial my-
ocardial infraction, renal insufficiency combined with an elevation
of liver enzymes with inflammation of the liver, gastritis and drug
withdrawal syndrome.
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We found low quality evidence that participants receiving tra-
madol alone had a greater risk of developing serious adverse events
compared to participants who received placebo (RR 1.78, 95% CI
1.11 to 2.84; 7 studies, 3612 participants; Summary of findings
for the main comparison). Three out of 100 people developed se-
rious adverse events when taking tramadol alone and 2/100 peo-
ple developed serious adverse events when taking a placebo, cor-
responding to 1 more person out of 100 people who developed
serious adverse events. The NNTH to cause one additional par-
ticipant to experience a serious adverse event was 68 (95% CI 29
to 477; Summary of findings for the main comparison). An I2
statistic of 0% indicated low heterogeneity between trials. Apply-
ing the GRADE criteria to the overall quality of the evidence, we
downgraded twice due to unclear risk of bias and imprecision (see
Summary of findings for the main comparison).
In one study which was not included in the meta-analyses, one se-
rious adverse event occurred during the double-blind phase of the
study (atrial flutter in one participant with a history of supraven-
tricular tachycardia who received tramadol 150 mg) (Thorne
2008).
We found low quality evidence that no serious adverse events
were reported in a study of tramadol in combination with ac-
etaminophen compared to placebo (1 study, 15 participants;
Summary of findings 2; Peeva 2010). Applying the GRADE cri-
teria to the overall quality of the evidence, we downgraded twice
due to serious imprecision (see Summary of findings 2).
Active-controlled trials
Seven trials with 348 participants in the tramadol groups and 350
participants in the active control groups evaluated the number
of participants experiencing serious adverse events but only two
contributed to the meta-analyses since five trials did not report
any serious adverse events. There were five people with serious
adverse events in these seven trials. Some of the serious adverse
events were gastrointestinal bleeding and severe pancreatitis. Due
to very low quality evidence, we were uncertain whether tramadol
alone compared to NSAIDs had an increased risk of developing
serious adverse events (RR 0.21, 95% CI 0.01 to 4.34; 2 studies,
188 participants; Summary of findings 4; Beaulieu 2008; Pavelka
1998). Applying the GRADE criteria to the overall quality of the
evidence, we downgraded three times due to unclear risk of bias
and serious imprecision (see Summary of findings 4).
Similarly, due to very low quality evidence, we were uncertain
whether participants who received tramadol alone had an increased
risk of developing serious adverse events compared to participants
who received other opioids (RR 7.42, 95% CI 0.39 to 141.00;
4 studies, 495 participants; Summary of findings 5; Bird 1995;
Jensen 1994; Karlsson 2009; Wilder-Smith 2001). Applying the
GRADE criteria to the overall quality of the evidence, we down-
graded three times due to unclear risk of bias and serious impre-
cision (see Summary of findings 5).
We found low quality evidence that there was no risk of develop-
ing serious adverse events for both the participants who received
tramadol in combination with acetaminophen and those who re-
ceived NSAIDs (1 study, 15 participants; Summary of findings 6;
Peeva 2010). Applying the GRADE criteria to the overall quality
of the evidence, we downgraded twice due to serious imprecision
(see Summary of findings 6).
Minor outcomes
Symptoms of opioid dependence: withdrawal symptoms and
propensity for abuse
Four trials reported withdrawal symptoms or the propensity for
abuse, or both (Beaulieu 2008; DeLemos 2011; Emkey 2004;
Gana 2006). However, only one trial provided the data required
to contribute to the systematic review (Beaulieu 2008). This trial
assessed propensity for abuse using the Drug Liking Index, a 9-
point scale. There was no difference between treatment groups in
these scores. For the number of participants who liked the drug
effect, tramadol had similar harms compared to NSAIDs (RR
1.03, 95% CI 0.62 to 1.74). Another trial reported that there was
no evidence of abuse, but did not mention how it was assessed
(Emkey 2004).
The other trials assessed this variable in various ways. One trial as-
sessed the psychic dependence using the 49-item Short Form Ad-
diction Research Center Inventory questionnaire and the 16-item
Physical Dependence Questionnaire (PDQ) (DeLemos 2011).
The rates of 12 related symptoms were different among treatment
groups. About 5% to 10% more participants in the tramadol group
reported these symptoms compared to the placebo group. In one
of the studies, physical dependence was assessed using a 16-item
PDQ, where there was one serious adverse event related to study
treatment and three drug withdrawal syndromes (non-serious ad-
verse events) in the tramadol group (Gana 2006). Thus, 4/815
(0.5%) participants in the tramadol group reported this event.
There was a different frequency of physical dependence symptoms
between treatment groups one week after discontinuation.
Two trials excluded participants that had any history of substance
abuse (Beaulieu 2008; Emkey 2004), and two other trials excluded
participants who had had substance abuse in the past six months
(DeLemos 2011; Gana 2006).
25Tramadol for osteoarthritis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Tramadol in combination with acetaminophen compared with placebo for osteoarthritis
Patient or population: osteoarthrit is
Settings: outpat ient clinics
Intervention: t ramadol in combinat ion with acetaminophen
Comparison: placebo
Outcomesa Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* * Corresponding risk* *
Placebo Tramadol in com-
bination with ac-
etaminophen
Pain assessed with:
self -report VAS pain in-
tensity (scale 0 to 100
where 0 = no pain)
Follow-up: range 10
days to 13 weeks
The mean pain was 48.
3 points
The mean pain in the
intervent ion group was
4 points lower (2 lower
to 6 lower)b
- 614 (2 RCTs) ⊕⊕⊕©
Moderatee
Mean pain: 4% abso-
lute improvement (95%
CI 2% to 6% improve-
ment),b
8% relat ive improve-
ment (95%CI 4% to 12%
improvement),f
SMD -0.28 (95% CI -0.
45 to -0.12), NNTB 14
(95% CI 9 to 33)g
7 out of 100 improved
by 20%c
5 more out of 100 (2
more to 9 more) in the
intervent ion group im-
proved by 20%c
RR 1.71 (95%CI 1.29 to
2.29)d
Physical function as-
sessed with: self -
report quest ionnaire
WOMAC Physical Func-
t ion (scale 0 to 10,
where 0 = no lim itat ion)
Follow-up: range 10
days to 13 weeks
The mean physical
funct ion was
5.9 points
The mean physical
funct ion in the inter-
vent ion group was 0.4
points lower (0.2 lower
to 0.7 lower)b
- 614 (2 RCTs) ⊕⊕⊕©
Moderatee
Mean funct ion: 4%
absolute improvement
(95% CI 2% to 7% im-
provement),b
7% relat ive improve-
ment (95%CI 3% to 12%
improvement),f
SMD -0.27 (95% CI -0.
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43 to -0.11), NNTB 12
(95% CI 8 to 30)g
10 out of 100 improved
by 20%c
5 more out of 100 (2
more to 9 more) in the
intervent ion group im-
proved by 20%c
RR 1.50 (95%CI 1.20 to
1.90)d
Number of participants
experiencing any ad-
verse event
Follow-up: range 10
days to 13 weeks
234 per 1000 447 per 1000
(309 to 646)
RR 1.91 (95%CI 1.32 to
2.76)d
308 (1 RCT) ⊕⊕⊕©
Moderatee
22% absolute worsen-
ing (95% CI 8% more to
41%more),
91% relat ive worsening
(95% CI 32% more to
176%more),
NNTH 5 (95%CI 3 to 14)
Number of participants
who withdrew due to
adverse events
Follow-up: range 10
days to 13 weeks
45 per 1000 126 per 1000
(68 to 235)
RR 2.78
(95%CI 1.50 to 5.16)
614 (2 RCTs) ⊕⊕©©
Lowe,h
8% absolute worsening
(95%CI 2%more to 19%
more),
178% relat ive worsen-
ing (95% CI 50% more
to 416%more),
NNTH 13 (95% CI 6 to
44)
Number of participants
experiencing any seri-
ous adverse events
Follow-up: range 10
days to 13 weeks
0 per 1000 0 per 1000 Not est imable 15 (1 RCT) ⊕⊕©©
Lowi
No events reported: not
est imable, NNTH not
est imable
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
* * The assumed and the corresponded risk was calculated f rom the SMD and SE.
CI: conf idence interval; MCID: minimal clinically important dif f erence; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat
for an addit ional harmful outcome;RR: risk rat io;SD: standard deviat ion; SE: standard error; SMD: standardized mean dif ference; WOMAC: Western Ontario and McMaster
Universit ies Arthrit is Index.27
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GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aContinuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse-
variance f ixed-ef fect meta-analysis to combine the trials in Review Manager 5 (Review Manager 2014).
bAbsolute improvement on a common scale (e.g. 100-mm, 1700-point scale) calculated by mult iplying the SMD by the SD of
the scale (in the control group at baseline) as suggested by the Cochrane Handbook for Systematic Reviews of Interventions (Sect ion
12.6.4; Higgins 2011).
cAssumed and corresponding risks calculated f rom SMD and SE, with improvement based on an MCID of 20% of the given
scale using the Wells calculator (f rom the Cochrane Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ).
dRR and its 95%CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The
corresponding risk was divided by the assumed risk.
eDowngraded one level due to unclear risk of bias (all t rials had high or unclear risk of at least one type of bias).
f The relat ive improvement percentage was def ined as relat ive to the control group risk at baseline.
gNNTB corresponded to the number of part icipants that needed to be treated to see one part icipant improve. Improvement
def ined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (f rom the Cochrane
Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ne.org/ ).
hDowngraded one level for imprecision (wide CI).
iDowngraded two levels for serious for imprecision (no events).
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Tramadol alone compared with acetaminophen for osteoarthritis
Patient or population: osteoarthrit is
Settings: outpat ient clinics
Intervention: t ramadol alone
Comparison: acetaminophen
Outcomesa Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* * Corresponding risk* *
acetaminophen Tramadol alone
Pain assessed with:
self -report VAS pain in-
tensity (scale 0 to 100
where 0 = no pain)
Follow-up: 1 week
The mean pain was 38
points
The mean pain in the
intervent ion group was
2 higher (12 lower to 16
higher)b
- 20 (1 RCT) ⊕©©©
Very lowe,f
Mean pain: 2% abso-
lute worsening (95% CI
16% worsening to 12%
improvement),b 5% rel-
at ive worsening (95%CI
42% worsening to 32%
improvement),g
SMD 0.13 (-0.80 to 1.
06),
NNTB not applicableh
9 out of 100 improved
by 20%c
2 less out of 100 (8 less
to 20 more)in the inter-
vent ion group improved
by 20%c
RR 0.78 (95%CI 0.11 to
3.22)d
Physical function - - - - - Not reported
Number of participants
experiencing any ad-
verse event
- - - - - Not reported
Number of participants
who withdrew due to
adverse events
Follow-up: 1 week
0 per 1000 0 per 1000 RR 5.00
(95%CI 0.27 to 92.62)
20 (1 RCT) ⊕©©©
Very lowe,f
NNTH not est imable
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Number of participants
experiencing any seri-
ous adverse events
- - - - - Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
* * The assumed and the corresponded risk was calculated f rom the SMD and SE.
CI: conf idence interval; MCID: minimal clinically important dif f erence; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat for
an addit ional harmful outcome;RR: risk rat io;SD: standard deviat ion; SE: standard error; SMD: standardized mean dif ference.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aContinuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse-
variance f ixed-ef fect meta-analysis to combine the trials in Review Manager 5 (Review Manager 2014).
bAbsolute improvement on a common scale (e.g. 100-mm, 1700-point scale) calculated by mult iplying the SMD by the SD of
the scale (in the control group at baseline) as suggested by the Cochrane Handbook for Systematic Reviews of Interventions (Sect ion
12.6.4; Higgins 2011).
cAssumed and corresponding risks calculated f rom the SMD and SE, with improvement based on an MCID of 20%of the given
scale using the Wells calculator (f rom the Cochrane Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ).
dRR and its 95%CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The
corresponding risk was divided by the assumed risk.
eDowngraded one level for unclear risk of bias (all t rials had high or unclear risk of at least one type of bias).
fDowngraded two levels for serious imprecision (few events and wide CI).
gRelat ive improvement percentage def ined as relat ive to the control group risk at baseline.
hNNTB corresponded to the number of part icipants that needed to be treated to see one part icipant improve. Improvement
was def ined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (f rom the Cochrane
Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ne.org/ ). It was only calculated for stat ist ically
signif icant results.
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Tramadol alone compared with NSAIDs for osteoarthritis
Patient or population: osteoarthrit is
Settings: outpat ient clinics
Intervention: t ramadol alone
Comparison: NSAIDs
Outcomesa Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* * Corresponding risk* *
NSAIDs Tramadol alone
Pain assessed with:
self -report VAS pain in-
tensity (scale 0 to 500
where 0 = no pain)
Follow-up: range 4
weeks to 12 weeks
The mean pain was
300.8 points
The mean pain in the
intervent ion group was
22 points higher (7
higher to 37 higher)b
- 952 (3 RCTs) ⊕⊕⊕©
Moderatee
Mean pain: 4%absolute
worsening (95% CI 1%
to 7% worsening),b
7% relat ive worsening
(95%CI 2%to 12%wors-
ening),f
SMD 0.21 (95% CI 0.07
to 0.36),
NNTB 12 (95% CI 7 to
35)g
17 out of 100 improved
by 20%c
5 less out of 100 (8 less
to 2 more) in the inter-
vent ion group improved
by 20%c
RR 0.71 (95%CI 0.53 to
0.88)d
Physical function as-
sessed with: self -
report quest ionnaire
WOMAC Physical Func-
t ion (scale 0 to 1700,
where 0 = no lim itat ion)
Follow-up: range 4
weeks to 12 weeks
The mean physical
funct ion was 1019
points
The mean physical
funct ion in the interven-
t ion group was
82 higher (32 higher to
131 higher)b
- 952 (3 RCTs) ⊕⊕©©
Lowe,h
Mean physical func-
t ion: 5% absolute wors-
ening (95% CI 2% to 8%
worsening),b
8% relat ive worsening
(95%CI 3%to 13%wors-
ening),f
SMD 0.23 (95% CI 0.09
to 0.37),
NNTB 11 (95% CI 7 to
27)g
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17 out of 100 improved
by 20%c
5 less out of 100 (7 less
to 2 less) in the inter-
vent ion group improved
by 20%c
RR 0.71 (95%CI 0.59 to
0.88)d
Number of participants
experiencing any ad-
verse event
Follow-up: 8 weeks
591 per 1000 774 per 1000
(609 to 987)
RR 1.31
(95%CI 1.03 to 1.67)
128 (3 RCTs) ⊕⊕⊕©
Moderatee
18% absolute worsen-
ing (95% CI 2% more to
40%more),
31% relat ive worsening
(95%CI 3%more to 67%
more),
NNTH 6 (95%CI 3 to 57)
Number of participants
who withdrew due to
adverse events
Follow-up: range 8
weeks to 12 weeks
112 per 1000 210 per 1000
(142 to 309)
RR 1.88
(95%CI 1.27 to 2.76)
929 (2 RCTs) ⊕⊕©©
Lowe,h
10% absolute worsen-
ing (95% CI 3% more to
20%more),
88% relat ive worsening
(95% CI 27% more to
176% more), NNTH 10
(95% CI 5 to 33)
Number of participants
experiencing any seri-
ous adverse events
Follow-up: range 4
weeks to 8 weeks
21 per 1000 4 per 1000
(0 to 90)
RR 0.21
(95%CI 0.01 to 4.34)
188 (2 RCTs) ⊕©©©
Very lowe,i
NNTH not applicable
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
* * The assumed and the corresponded risk was calculated f rom the SMD and SE.
CI: conf idence interval; MCID: minimal clinically important dif f erence; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat
for an addit ional harmful outcome;RR: risk rat io;SD: standard deviat ion; SE: standard error; SMD: standardized mean dif ference WOMAC: Western Ontario and McMaster
Universit ies Arthrit is Index.
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GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aContinuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse-
variance f ixed-ef fect meta-analysis to combine the trials in Review Manager 5 (Review Manager 2014).
bAbsolute ef fect on a common scale (e.g. 100-mm, 1700-point scale) calculated by mult iplying the SMD by the SD of the scale
(in the control group at baseline) as suggested by the Cochrane Handbook for Systematic Reviews of Interventions (Sect ion 12.6.4;
Higgins 2011).
cAssumed and corresponding risks calculated f rom the SMD and SE, with improvement based on an MCID of 20%of the given
scale using the Wells calculator (f rom the Cochrane Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ).
dRR and its 95%CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The
corresponding risk was divided by the assumed risk.
eDowngraded one level for unclear risk of bias (all t rials had high or unclear risk of at least one type of bias).
fRelat ive improvement percentage def ined as relat ive to the control group risk at baseline.
gNNTB corresponded to the number of part icipants that needed to be treated to see one part icipant improve. Improvement
def ined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (f rom the Cochrane
Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ne.org/ ).
hDowngraded one level for inconsistency.
iDowngraded two levels for serious imprecision (few events and wide CI).
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Tramadol alone compared with other opioids for osteoarthritis
Patient or population: osteoarthrit is
Settings: outpat ient clinics
Intervention: t ramadol alone
Comparison: other opioids
Outcomesa Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* * Corresponding risk* *
Other opioids Tramadol alone
Pain assessed with:
self -report VAS pain in-
tensity (scale 0 to 100
mm where 0 = no pain)
Follow-up: range 2
weeks to 12 weeks
The mean pain was 36
points
The mean pain in the
intervent ion group was
3 points lower (9 lower
to 3 higher)b
- 411 (4 RCTs) ⊕⊕⊕©
Moderatee
Mean pain: 3% abso-
lute improvement (95%
CI 3% worsening to 9%
improvement),b
8% relat ive improve-
ment (95% CI 8% wors-
ening to 25% improve-
ment),f
SMD -0.11 (95% CI -0.
33 to 0.12)
NNTB not applicableg
23 out of 100 improved
by 20%c
3 more out of 100 (4
less to 11 more) in the
intervent ion group im-
proved by 20%c
RR 1.13 (95%CI 0.83 to
1.48)d
Physical function as-
sessed with part ici-
pants rat ing their over-
all assessment of the
therapy at end of study
as good or better
Follow-up: 2 weeks
505 per 1000 667 per 1000
(525 to 848)
RR 1.32 (95%CI 1.04 to
1.68)
190 (1 RCT) ⊕⊕⊕©
Moderatee
16% absolute improve-
ment (95% CI 2% more
to 34%more),b
32% relat ive improve-
ment (95% CI 4% more
to 68%more),f
NNTB: 7 (95% CI 3 to
50)g
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Number of participants
experiencing any ad-
verse event
Follow-up: range 2
weeks to 12 weeks
541 per 1000 536 per 1000
(471 to 612)
RR 0.99 (95%CI 0.87 to
1.13)
438 (3 RCTs) ⊕©©©
Very lowe,h,i
1% absolute worsening
(95% CI 7% fewer to 7%
more),
1% relat ive worsening
(95% CI 13% fewer to
13%more),
NNTH not applicable
Number of participants
who withdrew due to
adverse events
Follow-up: range 2
weeks to 12 weeks
138 per 1000 311 per 1000
(209 to 464)
RR 2.26
(95%CI 1.52 to 3.37)
438 (3 RCTs) ⊕⊕©©
Lowe,h
17% absolute worsen-
ing (95% CI 7% more to
33%more),
126% relat ive worsen-
ing (95% CI 52% more
to 237%more),
NNTH 6 (95%CI 3 to 14)
Number of participants
experiencing any seri-
ous adverse events
Follow-up: range 2
weeks to 12 weeks
0 per 1000 0 per 1000 RR 7.42
(95%CI 0.39 to 141.00)
495 (4 RCTs) ⊕©©©
Very lowe,j
0% absolute worsening
(95% CI 0% fewer to 0%
fewer),
642% relat ive worsen-
ing (95% CI 13% fewer
to 41%more),
NNTH not applicable
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
* * The assumed and the corresponded risk was calculated f rom the SMD and SE.
CI: conf idence interval; MCID: minimal clinically important dif f erence; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat for
an addit ional harmful outcome;RR: risk rat io;SD: standard deviat ion; SE: standard error; SMD: standardized mean dif ference.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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aContinuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse-
variance f ixed-ef fect meta-analysis to combine the trials in Review Manager 5 (Review Manager 2014).
bAbsolute ef fect on a common scale (e.g. 100-mm, 1700-point scale) calculated by mult iplying the SMD by the SD of the scale
(in the control group at baseline) as suggested by the Cochrane Handbook for Systematic Reviews of Interventions (Sect ion 12.6.4;
Higgins 2011).
cAssumed and corresponding risks calculated f rom the SMD and SE, with improvement based on an MCID of
20% of the given scale using the Wells calculator (f rom the Cochrane Musculoskeletal Group Editorial of f ice;
mumusculoskeletal.cochrane.org/ ).
dRR and its 95%CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The
corresponding risk was divided by the assumed risk.
eDowngraded one level for unclear risk of bias (all t rials had high or unclear risk of at least one type of bias).
fRelat ive improvement percentage def ined as relat ive to the control group risk at baseline.
gNNTB corresponded to the number of part icipants that needed to be treated to see one part icipant improve. Improvement
was def ined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (f rom the Cochrane
Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ne.org/ ). It was only calculated for stat ist ically
signif icant results.
hDowngraded one level for inconsistency.
iDowngraded one level for imprecision (wide CI).
jDowngraded two levels for serious imprecision (few events and wide CI).
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Tramadol in combination with acetaminophen compared with NSAIDs for osteoarthritis
Patient or population: osteoarthrit is
Settings: outpat ient clinics
Intervention: t ramadol in combinat ion with acetaminophen
Comparison: NSAIDs
Outcomesa Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* * Corresponding risk* *
NSAIDs Tramadol in com-
bination with ac-
etaminophen
Pain assessed with:
self -report VAS pain in-
tensity (scale 0 to 10
mm where 0 = no pain)
Follow-up: range 8
weeks to 12 weeks
The mean pain was 5.2
points
The mean pain in the
intervent ion group was
0.3 points higher (0.4
lower to 0.9 higher)b
- 226 (2 RCTs) ⊕⊕⊕©
Moderatee
Mean pain: 3% abso-
lute worsening (95% CI
9%worsening to 4% im-
provement),b
6% relat ive worsening
(95% CI 17% worsening
to 8% improvement),f
SMD 0.12 (-0.16 to 0.
39),
NNTB not applicableg
47 out of 100 improved
by 20%c
5 less out of 100 (15
less to 6 more) in the
intervent ion group im-
proved by 20%c
RR 0.89 (95%CI 0.68 to
1.13)d
Physical function as-
sessed with: WOMAC
Physical Funct ion on a
96-point scale
Follow-up: 8 weeks
The mean physical
funct ion was 21.40
The mean physical
funct ion in the interven-
t ion group was 2 points
higher (2 lower to 6
higher)
- 91 (1 RCT) ⊕⊕©©
Lowe,h
Mean physical func-
t ion: 2% absolute wors-
ening (95% CI 7% wors-
ening to 2% improve-
ment),b
9% relat ive worsening
(95% CI 28% worsening
to 9% improvement),f
SMD 0.20 (-0.21 to 0.
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61)
NNTB not applicableg
22 out of 100 improved
by 20%c
5 less out of 100 (13
less to 7 more) in the
intervent ion group im-
proved by 20%c
RR 0.77 (95%CI 0.41 to
1.32)d
Number of participants
experiencing any ad-
verse event
Follow-up: 8 weeks
600 per 1000 702 per 1000
(522 to 942)
RR 1.17
(95%CI 0.87 to 1.57)
97 (1 RCT) ⊕⊕©©
Lowe,h
10% absolute worsen-
ing (95%CI 8%improve-
ment to 34% worsen-
ing),
17% relat ive worsening
(95% CI 13% improve-
ment to 57% worsen-
ing),
NNTH not applicable
Number of participants
who withdrew due to
adverse events
- - - - - Not reported
Number of participants
experiencing any seri-
ous adverse events
Follow-up: 3 days
0 per 1000 0 per 1000
(0 to 0)
Not est imable 15 (1 RCT) ⊕⊕©©
Lowi
NNTH not est imable
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
* * The assumed and the corresponded risk was calculated f rom the SMD and SE.
CI: conf idence interval; MCID: minimal clinically important dif f erence; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat
for an addit ional harmful outcome;RR: risk rat io;SD: standard deviat ion; SE: standard error; SMD: standardized mean dif ference; WOMAC: Western Ontario and McMaster
Universit ies Arthrit is Index.
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GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aContinuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse-
variance f ixed-ef fect meta-analysis to combine the trials in Review Manager 5 (Review Manager 2014).
bAbsolute ef fect on a common scale (e.g. 100-mm, 1700-point scale) calculated by mult iplying the SMD by the SD of the scale
(in the control group at baseline) as suggested by the Cochrane Handbook for Systematic Reviews of Interventions (Sect ion 12.6.4;
Higgins 2011).
cAssumed and corresponding risks calculated f rom the SMD and SE, with improvement based on an MCID of 20%of the given
scale using the Wells calculator (f rom the Cochrane Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ).
dRR and its 95%CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The
corresponding risk was divided by the assumed risk.
eDowngraded one level for unclear risk of bias (all t rials had high or unclear risk of at least one type of bias).
fRelat ive improvement percentage def ined as relat ive to the control group risk at baseline.
gNNTB corresponded to the number of part icipants that needed to be treated to see one part icipant improve. Improvement
def ined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (f rom the Cochrane
Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ne.org/ ). It was only calculated for stat ist ically
signif icant results.
hDowngraded one level for imprecision (wide CI).
iDowngraded two levels for serious imprecision (no events).
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Tramadol in combination with acetaminophen compared with other opioids for osteoarthritis
Patient or population: osteoarthrit is
Settings: outpat ient clinics
Intervention: t ramadol in combinat ion with acetaminophen
Comparison: other opioids
Outcomesa Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* * Corresponding risk* *
Other opioids Tramadol in com-
bination with ac-
etaminophen
Pain assessed with:
self -report VAS pain in-
tensity (scale 0 to 10
mm where 0 = no pain)
Follow-up: 12 weeks
The mean pain was 6.4
points
The mean pain of the
intervent ion group was
0.3 points higher (1.8
higher to 1.3 lower)b
- 130 (1 RCT) ⊕⊕©©
Lowe,f
Mean pain: 3%absolute
worsening (95% CI 18%
worsening to 13% im-
provement),b
5% relat ive worsening
(95% CI 28% worsening
to 20% improvement),f
SMD 0.06 (95%CI -0.31,
0.43),
NNTB not applicableh
32 out of 100 improved
by 20%c
2 less out of 100 (16
less to 13 more) in the
intervent ion group im-
proved by 20%c
RR 0.96 (95%CI 0.67 to
1.27)d
Physical function - - - - - Not reported
Number of participants
experiencing any ad-
verse event
- - - - - Not reported
Number of participants
who withdrew due to
adverse events
- - - - - Not reported
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Number of participants
experiencing any seri-
ous adverse events
- - - - - Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
* * The assumed and the corresponded risk was calculated f rom the SMD and SE.
CI: conf idence interval;MCID: minimal clinically important dif f erence; NNTB: number needed to treat for an addit ional benef icial outcome; RR: risk rat io;SD: standard deviat ion;
SE: standard error; SMD: standardized mean dif ference.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aContinuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse-
variance f ixed-ef fect meta-analysis to combine the trials in Review Manager 5 (Review Manager 2014).
bAbsolute ef fect on a common scale (e.g. 100-mm, 1700-point scale) calculated by mult iplying the SMD by the SD of the scale
(in the control group at baseline) as suggested by the Cochrane Handbook for Systematic Reviews of Interventions (Sect ion 12.6.4;
Higgins 2011).
cAssumed and corresponding risks calculated f rom the SMD and SE, with improvement based on an MCID of 20%of the given
scale using the Wells calculator (f rom the Cochrane Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ).
dRR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group.
Corresponding risk was divided by the assumed risk.
eDowngraded one level for unclear risk of bias (all t rials had high or unclear risk of at least one type of bias).
fDowngraded one level for imprecision.
gRelat ive improvement percentage is def ined as relat ive to the control group risk at baseline.
hNNTB corresponded to the number of part icipants that needed to be treated to see one part icipant improve. Improvement
def ined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (f rom the Cochrane
Musculoskeletal Group Editorial of f ice; musculoskeletal.cochrane.org/ ne.org/ ). It was only calculated for stat ist ically
signif icant results.
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D I S C U S S I O N
Summary of main results
In our systematic review and meta-analyses, we found tramadol
alone or in combination with acetaminophen demonstrated no
clinically important difference compared to placebo in terms of
mean pain relief and improvement of physical function in people
with OA. The benefits were small, and may not have been clini-
cally important since the 4-point improvement in pain was lower
than the MCID that we defined as 20 points on a 100-point scale,
although there were slightly more people in the tramadol group
who were clinically important responders for both pain and physi-
cal function. Adverse events were also higher for participants using
tramadol compared to placebo, which may limit the usefulness of
tramadol. The quality of this evidence was moderate for benefit
outcomes and low to moderate for harm outcomes for placebo-
controlled trials, mostly because of unclear risk of bias, as well
as imprecision, especially for the harm outcomes. The quality of
the evidence was very low to moderate for active-controlled trials,
mostly because of unclear risk of bias, imprecision and inconsis-
tency.
Tramadol alone had similar benefits to other opioids in terms of
pain relief and showed a small benefit in terms of physical func-
tion compared to other opioids, although probably not clinically
important. The quality of this evidence was moderate, due to
the unclear risk of bias in included trials. Tramadol alone showed
lower benefits than NSAIDs for pain and physical function. How-
ever, these benefits were only small, and not clinically important.
The quality of this evidence was moderate for pain and low for
physical function, due to the risk of bias, as well as imprecision
in the physical function analyses. Tramadol in combination with
acetaminophen had similar benefits to NSAIDs and opioids for
pain and physical function. The quality of this evidence was low
to moderate, due to the unclear risk of bias and imprecision. Tra-
madol alone had similar harms to NSAIDs and opioids, except for
withdrawals due to adverse events which were higher for tramadol
compared to these controls, and overall adverse events which were
higher for tramadol compared to NSAIDs. Tramadol in combi-
nation with acetaminophen also had similar harms to NSAIDs.
Studies in which participants received tramadol alone had more
adverse events than studies in which participants received tramadol
in combination with acetaminophen, when compared to placebo.
This could be explained by the higher dose of tramadol in the
studies in which participants received tramadol alone, compared
to a lower dose in studies of tramadol in combination with ac-
etaminophen. The quality of the evidence was very low to moder-
ate because of unclear risk of bias, imprecision of estimates and in-
consistency between trials. Although a higher propensity for abuse
when using tramadol was not established, it was rarely studied,
which precluded any conclusions being made.
Overall completeness and applicability of
evidence
This review had several limitations. Most trials were short in dura-
tion, with no trials that were longer than 13 weeks. The trials also
varied in terms of duration (i.e. range of one week to three months)
with a mean duration of two months. Trials allowed participants
to take a wide range of dosages of tramadol (i.e. 37.5 mg/day to
400 mg/day) and rarely reported the mean dose of tramadol actu-
ally received by participants. Only four studies compared different
doses of tramadol (DeLemos 2011; Fishman 2007; Gana 2006;
Kean 2009), but doses were pooled in this review since they did
not show different results. Most studies permitted additional use
of analgesics, usually for pain other than due to OA. Some trials
also permitted the use of other cointerventions such as physical
therapy if its use was stable during the study. The inclusion of
these cointerventions could have influenced the results.
Participants were predominantly women, with a mean age of 63
years and with moderate to severe pain, which represents most
people with OA. Even though this review included trials for OA of
the knee or hip (or both), it is important to note that a significant
proportion of the trials were conducted with participants with
knee OA only (13 studies including participants with knee or hip
OA and nine studies with knee OA).
Most studies were conducted in high-income countries. Studies
were conducted in North America (13 studies) and Europe (seven
studies, with one of these in both North America and Europe), Asia
(two studies) and Africa (one study). Two studies were conducted
in low- and middle-income countries (i.e. Romania and South
Africa) (Burch 2007; Wilder-Smith 2001).
Thirteen studies included predominantly white participants while
one study included predominantly African participants (study in
South Africa) and eight studies did not mention it in their inclu-
sion criteria or results. Since there are complex pain disparities re-
lated to ethnicity (Green 2003), and there are ethnic differences in
the experience of chronic pain (Riley 2002), findings of included
studies may not be applicable to people with OA of all races and
ethnicities.
Three studies were conducted with participants who had previ-
ously failed other treatments or benefited from other treatments,
which may add to clinical heterogeneity between studies. All stud-
ies listed multiple morbidities as exclusion criteria. Therefore, re-
view findings may not be applicable to people with OA who have
multiple morbidities. It is known that RCTs regularly exclude par-
ticipants who have multiple morbidities, which is not representa-
tive of the general population that a physician would encounter
in clinical practice. Findings that are applied in clinical practice
should consider the complexity of effective treatment of these par-
ticipants (Fortin 2006).
The included studies did not permit analysis of specified outcomes
in this subset of the population. In the included studies, women
of childbearing age were regularly excluded if they were pregnant,
lactating or not using adequate contraception. The findings of this
42Tramadol for osteoarthritis (Review)
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review may not be applicable to these women.
Based on the analyzed evidence, further research about the benefits
and harms of tramadol for people with OA should include par-
ticipants from different ethnicities and with multiple morbidities.
Other desirable characteristics are: more head-to-head compar-
isons with active comparators, relevant outcomes recommended
for OA, and study designs to accomplish low levels of risk of bias,
and that are independently funded.
Quality of the evidence
Most of the trials were funded by the pharmaceutical industry and
it was not possible to explore the role of this factor in explaining
the estimated treatment effect due to the low number of trials
that were not funded by industry. Many trials also had an unclear
risk of bias for allocation concealment, blinding of personnel and
selective outcome reporting, and a few of the trials were at high
risk of bias for incomplete outcome data.
Some of the most important factors in determining the analgesic
benefits and harms of tramadol are the dose being tested and the
duration of the treatment. In this systematic review, the mean dose
of tramadol varied between trials (range 37.5 mg to 400 mg daily),
as well as the mean length of the trials of 57 days varied (3 to
91 days), which may explain some of the heterogeneity found in
some analyses.
There was no substantive clinical heterogeneity (i.e. there were
no important differences in sample, intervention or control group
characteristics) but some comparisons showed moderate to high
levels of heterogeneity between trials. However, given the accept-
able lack of clinical heterogeneity, all trials were kept in the anal-
yses.
Few studies assessed withdrawal symptoms or propensity for abuse
and in various ways which precluded pooling this data. Since
studies excluded participants with a history of substance abuse, it
could lead to under-reporting of the problem since participants
who may abuse tramadol are likely to have a history of substance
abuse. Studies should be conducted to address this potential ad-
verse event in a more standardized manner. Studies addressing this
issue should also be conducted for longer duration than 91 days
(13 weeks), which was the longest duration in the trials assessed
in this systematic review.
Potential biases in the review process
We performed a systematic literature search, which included both
published (i.e. from various electronic databases) and unpublished
trials (i.e. from protocol registries). This approach helped to en-
sure that all publications were identified and thus reduced poten-
tial publication bias. However, there are eight protocols of com-
pleted trials for which we could not obtain data, which remains a
limitation (Studies awaiting classification). We contacted authors
of each trial and protocol at least twice to obtain any missing in-
formation. In the cases of these protocols, we could not obtain
more data. The funnel plot for trials contributing data for the pain
relief effect of tramadol compared to placebo showed no publica-
tion bias, but there is still potentially a publication bias since we
could not include any data from the protocols for which data was
not published (see Appendix 2 with list of studies and authors/
companies that were reached).
Two review authors independently performed selection of trials,
risk of bias assessment and data extraction, and consulted a third
review author if an agreement could not be reached. This process
helped to ensure the accuracy of data and to reduce the risk of bias
(Egger 2001; Gøtzsche 2007).
Agreements and disagreements with other
studies or reviews
The previously published Cochrane systematic review on tramadol
for OA included 11 trials that compared tramadol to placebo and
other active controls (Cepeda 2006). We included data from 10 of
these in our meta-analyses and included data from 10 additional
trials. Compared to this earlier published review, results showed
slightly less pain relief (4 more points on a 100-mm VAS for tra-
madol alone and tramadol in combination with acetaminophen
versus 8.5 more points on a 100-mm VAS for trials of tramadol
alone and tramadol in combination with acetaminophen) and
slightly higher physical function compared to placebo (4 out of 100
on a WOMAC Function scale for tramadol alone and tramadol in
combination with acetaminophen versus 3 out of 100 points on
a VAS for trials of tramadol alone and tramadol in combination
with acetaminophen). We included 11 more trials compared to
two other systematic reviews (Avouac 2007; Cepeda 2006), which
may be the reason that we found smaller effects when estimating
pain relief.
The current review also showed that tramadol was somewhat less
effective in reducing pain and improving physical function com-
pared to NSAIDs, which is a new finding compared to older sys-
tematic reviews of tramadol and other opioids, which could not
reach conclusions on this comparison because of the small number
of trials (Avouac 2007; Cepeda 2006).
The current review showed that the same types of adverse effects
were reported for tramadol compared to placebo in the last pub-
lished Cochrane Review of tramadol for OA (Cepeda 2006) and
others (Avouac 2007).
As with the previous Cochrane Review, it was difficult to provide
a robust estimate of adverse events when tramadol was compared
to other drugs as there were few trials (Cepeda 2006). However,
this review found an increased risk of withdrawals due to adverse
events in the tramadol group compared to other NSAIDs and opi-
oids. Similar to other systematic reviews of tramadol, there was
not enough controlled trial evidence to make conclusions about
withdrawal symptoms and propensity for abuse, so although ob-
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servational evidence suggested that tramadol may have been well
tolerated compared to other opioids, the same precautions against
addiction and abuse should be taken as with other opioids. Long
term RCTs of high quality are needed to investigate further po-
tential harms for people with OA compared to placebo and other
active treatments, such as acetaminophen, NSAIDs and other opi-
oids.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on moderate quality evidence, tramadol alone or in combi-
nation with acetaminophen probably has no important benefit on
mean pain intensity or physical function over placebo in people
with osteoarthritis. However, there were slightly more people in
the tramadol group who achieved a clinically important response.
Moderate quality evidence shows that adverse events probably
cause substantially more participants to stop taking tramadol. The
increase in serious adverse events with tramadol is less certain, due
to the small number of events. Use of tramadol for osteoarthritis
needs to consider the limited benefits with the likelihood of in-
creasing the adverse effects.
Implications for research
There is a need to study propensity for abuse in a more systematic
method since it is rarely reported in trials.
A C K N O W L E D G E M E N T S
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erature search. Jordi Pardo Pardo participated in the appraisal of
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appraisal of the methodologic quality of studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Babul 2004
Methods 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group
study
Setting: clinic
Participants Inclusion criteria: > 50 years of age, < 30 minutes of morning stiffness with OA of knee
or crepitus (or both); Participants met the ACR diagnostic criteria
Number of participants: 246; tramadol ER group: 124; control group: 122
Mean age: 61 years
% women: tramadol ER group: 66.1% women; control group: 56.6% women
Interventions Active group: tramadol ER 100 mg once/day, up to 400 mg/day in the morning
Control group: identical appearing placebo in the morning
2-7-day washout period during which all analgesics were discontinued
Tramadol ER initiated at 100 mg once/day and increased to 200 mg once/day by the
end of 1 week of treatment. After the first week, further increases to tramadol ER 300
mg or 400 mg once/day were allowed. Mean tramadol ER dose 276 mg once daily
Treatment continued for 12 weeks.
Outcomes Analgesia evaluated by Arthritis Pain Intensity VAS, and WOMAC Osteoarthritis Index
Pain VAS subscale (5 questions rating overall OA pain)
Physical function and stiffness evaluated using WOMAC Osteoarthritis Index and
WOMAC Osteoarthritis Index Physical Function subscale
Pain and physical function evaluated with VAS and WOMAC Osteoarthritis Index
Sleep evaluated using CPSI
Global Assessment of Therapy
Withdrawals due to adverse events
Adverse events; only number of adverse events reported
Extracted pain outcome: Arthritis Pain Intensity VAS (0-100 mm) at 12 weeks, with
lower values indicating benefit
Extracted physical function outcome: WOMAC Physical Function subscale (0-1700
mm) at 12 weeks, with lower values indicating benefit
Notes We contacted the author to clarify how the WOMAC Osteoarthritis Index was reported,
and the author provided all the information requested. For the pooling, we normalized
the WOMAC Total score
Study managed by SCIREX Corporation, Horsham (PA)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A list of randomization numbers
based on a computer-generated randomiza-
tion schedule was prepared.” (p.61)
49Tramadol for osteoarthritis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Babul 2004 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “Patients who fulfilled all study se-
lection criteria were assigned a random-
ization number sequentially with an equal
likelihood of being assigned to either treat-
ment group.” (p.61)
No mention of allocation concealment
Blinding of personnel Unclear risk Authors did not explicitly report blinding
of personnel.
Blinding of participants Low risk Quote: “…identical appearing placebo,
also given once a day.” (p.61)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Efficacy assessments were per-
formed throughout the course of the study
using a daily patient diary and clinic visit-
based assessments.” (p.61)
Since this was a participant-reported
outcome and participants were blinded,
the outcome assessment was considered
blinded
Incomplete outcome data for pain and
physical function
High risk Quote: “Efficacy analyses were conducted
on an intent-to-treat (ITT) population.”
(p.62)
Withdrawals due to adverse events were
27% (33/124) with tramadol vs 7% (9/
122) with placebo. The percentage of with-
drawals for reasons other than adverse
events (lack of efficacy and others) were 23.
4% (29/124) with tramadol vs 40.9% (50/
122) with placebo. There was a high num-
ber of withdrawals for reasons other than
adverse events so although benefits analyses
were done on ITT, the true outcome data
for half of the participants were unavailable
Incomplete outcome data for adverse ef-
fects
All outcomes
High risk Quote: “Safety analyses were conducted for
the safety population that included all ran-
domized patients who received at least one
dose of study medication.”
Withdrawals due to adverse events were
27% (33/124) with tramadol vs 7% (9/
122) with placebo. The percentage of with-
drawals for reasons other than adverse
events (lack of efficacy and other) were 23.
4% (29/124) with tramadol vs 40.9% (50/
122) with placebo. There was a high num-
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Babul 2004 (Continued)
ber of withdrawals for reasons other than
adverse events so although benefits analyses
were done on ITT, the true outcome data
for half of the participants were unavailable
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical
function and stiffness, and sleep quality)
appeared to have been reported in the re-
sults, but we did not have access to the pro-
tocol for verification
Other biases Low risk No other sources of bias detected.
Beaulieu 2008
Methods Randomized, double-blind, parallel-group comparison of the benefits, safety and clinical
benefits of CR tramadol vs SR diclofenac over a 6-week treatment period
Setting: clinic
Participants Number of participants: 129: CR tramadol: 62; SR diclofenac: 66
Men and non-pregnant women ages 35-75 years with chronic pain due to primary knee
or hip OA of at least moderate severity
Interventions Active group: CR tramadol titrated to optimal dose (200 mg/day, 300 mg/day or 400
mg/day)
Control group: SR diclofenac packaged and labeled in the same way as the treatment
and titrated to their optimal dose (75 mg or 100 mg once daily, or 75 mg twice a day)
, unless adequate pain control was achieved or adverse effects prevented the dose from
being titrated further
All participants were randomly assigned an initial dose of either active CR tramadol 200
mg and placebo SR diclofenac 75 mg each morning, or active SR diclofenac 75 mg and
placebo CR tramadol 200 mg each morning
Treatment lasted 6 weeks
Outcomes The overall PI over the preceding 2 weeks assessed with 100-mm VAS. The WOMAC
Physical Function subscale used to report physical function and pain
Impact of pain on quality and quantity of sleep using the Pain and Sleep Questionnaire
Withdrawals due to adverse events
Other outcomes included PI while walking on a flat surface, going up or down stairs,
at night while in bed, sitting or lying, standing upright, effect of pain on quality and
quantity of sleep, global assessment of clinical benefits (participant and investigator) and
Drug Liking Index. The effect sizes were assessed in terms of change over the study
period
Extracted pain outcome: WOMAC Pain subscale (0-100 mm) during the last 2 weeks
of treatment, with lower values indicating benefit
Extracted physical function outcome: WOMAC Physical Function subscale (0-1700
mm) at 8 weeks, with lower values indicating benefit
Notes Study funded by Purdue Pharma, Canada
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Study medication was prepack-
aged with an assigned randomization num-
ber, according to a computer-generated
code, in blocks of four.” (p.105)
Allocation concealment (selection bias) Unclear risk Quote: “Study medication was prepack-
aged with an assigned randomization num-
ber, according to a computer-generated
code, in blocks of four.” (p.105)
Not mentioned if packaging was opaque
and sealed. Techniques used to implement
the sequence not addressed
Blinding of personnel Unclear risk Authors did not explicitly report blinding
of personnel
Blinding of participants Low risk Quote: “Blinding was maintained using the
double-dummy technique.” (p.105)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients recorded their pain inten-
sity in a diary.” (p.105)
Quote: “At the completion of the study,
the patient and investigator each provided
a global assessment of clinical effectiveness.
” (p.105)
Since this was a participant-reported
outcome and participants were blinded,
the outcome assessment was considered
blinded
Incomplete outcome data for pain and
physical function
Low risk Quote: “Safety data are presented using the
ITT population and efficacy data are pre-
sented using the per protocol population.”
(p.106)
Quote: “All patients who completed the
study were included in the per protocol
population, with the exception of one pa-
tient with a protocol violation.” (p.106)
Quote: “one patient was excluded from all
analyses due to lack of evidence of OA.” (p.
106)
Quote: “Ninety-seven patients were eval-
uated for efficacy; 45 in the CR tramadol
group and 52 in the SR diclofenac group.”
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(p.106)
Only 97/129 (75%) participants were in-
cluded in the per-protocol population and
evaluated for benefits. The missing 31 peo-
ple withdrew from the study before com-
pletion due to reasons including adverse
events and inadequate pain control. With-
drawals due to adverse events were 16.1%
(10/62) with tramadol vs 15.2% (10/66)
with diclofenac. Percentage of withdrawals
for reasons other than adverse events (in-
adequate pain control, intermittent illness,
voluntary withdrawal, etc.) were 11.3% (7/
62) with tramadol vs 6.1% (4/66) with
diclofenac. Despite the overall withdrawal
rates being > 20%, most withdrawals were
due to reasons other than adverse events
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “Safety data are presented using the
ITT population and data are presented us-
ing the per protocol population.” (p.106)
Quote: “All randomly assigned patients
were included in the intent-to-treat (ITT)
population, with the exception of one pa-
tient who did not meet the eligibility crite-
ria.” (pp.105-106)
128/129 participants evaluated for safety
since they were included in ITT population
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical
function and stiffness, and sleep quality)
appeared to have been reported in results
but we did not have access to the protocol
for verification
Other biases Low risk No other sources of bias detected.
Bianchi 2003
Methods Prospective, randomized, double-blind, between-patient study
Setting: Rheumatology Unit of the Ospedale di Circolo e Fondazione Macchi, Varese
(Italy)
Participants 20 adults (2 men, 18 women), ages ≥ 38 years (mean age 67.5 years in tramadol group
and 71 years in control group) with OA of the knee and a minimum VAS score of 40
mm. Any treatments for pain were discontinued ≥ 24 hours before study. Intake of any
other analgesic medications suspended during study
Number of participants: tramadol group: 10; control group (acetaminophen): 10
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Interventions Active group: tramadol 50 mg 3 times/day for 7 days: n = 10
Control group: acetaminophen 500 mg 3 times/day for 7 days: n = 10
All treatments were masked by administration of identical capsules containing the drugs.
Any treatment for pain was discontinued ≥ 24 hours before study
Outcomes PI: recorded 120 minutes after taking drug on a 10-cm line VAS with endpoints ’no
pain’ and ’worst pain’
Synovial fluid and blood plasma: concentrations of tramadol, O-desmethyl-tramadol,
substance P and IL-6
Withdrawals due to adverse events: tramadol: 2/10 (due to nausea and vomiting); ac-
etaminophen: 0/10
Extracted pain outcome: PI (0-10 cm VAS) 2 hours after the medication administration,
with lower values indicating benefit
No physical function outcome reported
Notes We contacted the author to request the percentage of participants with pain relief. We
obtained no response
Funding source not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Enrolled patients were assigned
by computer-generated random numbers.
” (p.1902)
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Unclear risk Authors did not explicitly report blinding
of personnel.
Blinding of participants Low risk Quote: “All treatments were masked by ad-
ministration of identical capsules contain-
ing the drugs.” (p.1902)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Data regarding the efficacy of the
treatments were collected in the presence
of the investigator before the first drug ad-
ministration, and on the last day of each
drug treatment.” (p.1903)
Since this was a participant-reported
outcome and participants were blinded,
the outcome assessment was considered
blinded
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Incomplete outcome data for pain and
physical function
Low risk Data on participant baseline pain assess-
ment provided. However, 2/10 participants
withdrew from treatment due to adverse
events. It is not mentioned if the 2 dropouts
were included in the benefits assessment
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Data on participant baseline pain assess-
ment provided. However, 2/10 participants
withdrew from treatment due to adverse
events. It is not mentioned if the 2 dropouts
were included in the benefits assessment
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, synovial
fluid, plasma, IL-6 concentrations, O-
desmethyl-tramadol concentrations) ap-
peared to have been reported in the results
but no access to protocol for verification
Other biases Low risk No other sources of bias detected.
Bird 1995
Methods Cross-over, double-blind RCT
Setting: clinic
Participants 40 participants with radiologically confirmed diagnosis of OA of hip or knee within 12
months of starting the study; 19 participants completed both treatment periods
% women: active group: 65%; control group: 70%
Active group: 13 participants had moderate to severe OA; control group: 14 participants
had moderate to severe OA
Interventions Cross-over trial
Initial visit: active group received tramadol 50 mg 4 times/day; control group received
pentazocine 50 mg 4 times/day) for 2-week period
Second visit: participants crossed over to the other drug for another 2 weeks
No washout period
Outcomes Major:
Pain severity (4-point Likert scale: none, mild, moderate, severe) recorded on diary cards
completed daily
Duration of morning stiffness (minutes) and severity (same 4-point Likert scale)
Number of acetaminophen tablets consumed
Minor:
Duration of inactivity stiffness (minutes)
Pain during daily activities and walking (none, mild, moderate, severe)
Pain during sleep (normal sleep, some interruption of sleep, moderate interruption of
sleep, no sleep)
Functional impairment, e.g. climbing stairs, getting out of bed and rising from a chair
55Tramadol for osteoarthritis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bird 1995 (Continued)
(no difficulty, a little difficulty, moderate difficulty, great difficulty or impossible)
Participant’s assessment of treatment (very good, good, fair, poor or very poor)
Extracted pain outcome: severity of pain (4-point Likert scale) during the last 7 days of
treatment, with lower values indicating benefit
Extracted physical function outcome: no extractable data
Notes Grünenthal GmbH supplied the drugs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were then randomly allocated to
either tramadol 50 mg qds or pentazocine
50 mg qds.” (p.182)
No mention of how the allocation sequence
was randomly generated
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Unclear risk Authors did not explicitly report blinding
of personnel
Blinding of participants Unclear risk Authors did not explicitly report blinding
of participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Authors did not explicitly report blinding
of outcome assessors
Incomplete outcome data for pain and
physical function
Unclear risk Quote: “analyses of these total scores were
(…) carried out on two patient cohorts.
Cohort 1 comprised those patients who
took at least one dose of the study medica-
tion in each period and who had pain scores
for at least four days. Cohort 2 comprised
patients who took at least one dose of study
medication in each period and recorded
pain scores on less than four days unless
they withdrew due to lack of efficacy.” (p.
183)
Quote: “The single patient withdrawing for
treatment failure was taking pentazocine
and experienced a flare in OA.” (p.184)
Quote: “the study was somewhat compro-
mised by a high withdrawal rate due to ad-
verse events.” (p.187)
Only 19/40 (47.5%) participants com-
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pleted the study. Total withdrawals: 45%
with tramadol vs 60% with pentazocine.
Percentage for withdrawals due to adverse
events: 45% with tramadol vs 55% with
pentazocine. In cohort 2, unknown how
many people withdrew due to lack of bene-
fits so it is unknown how many participants
were excluded from the analyses. Unknown
how many people were in each cohort
Incomplete outcome data for adverse ef-
fects
All outcomes
Unclear risk Quote: “analyses of these total scores were
(…) carried out on two patient cohorts.
Cohort 1 comprised those patients who
took at least one dose of the study medica-
tion in each period and who had pain scores
for at least four days. Cohort 2 comprised
patients who took at least one dose of study
medication in each period and recorded
pain scores on less than four days unless
they withdrew due to lack of efficacy.” (p.
183)
Quote: “The single patient withdrawing for
treatment failure was taking pentazocine
and experienced a flare in OA.” (p.184)
Quote: “the study was somewhat compro-
mised by a high withdrawal rate due to ad-
verse events.” (p.187)
Only 19/40 (47.5%) participants com-
pleted the study. Total withdrawals: 45%
with tramadol vs 60% with pentazocine.
Percentage of withdrawals due to adverse
events: 45% with tramadol vs 55% with
pentazocine. In cohort 2, unknown how
many people withdrew due to lack of bene-
fits so it is unknown how many participants
were excluded from the analyses. Unknown
how many people were in each cohort
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, stiffness,
sleep quality, and physical function) ap-
peared to have been reported in the results
but we did not have access to the protocol
for verification
Other biases High risk 4/18 (22%) participants in the pentazocine
group used ≥ 80% of their medication but
13/19 (68.4%) participants in the tramadol
group used ≥ 80% of their medication. Re-
sults on treatment benefits may have been
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biased because participants in the penta-
zocine group were not as compliant with
taking their medication
Was use of a cross-over design appropriate?
Yes, OA was stable
Was it clear that the order of receiving treat-
ments was randomized? Unclear, random-
ized but no details on randomization pro-
cedure
Can it be assumed that the trial was not
biased from carry-over effects? No, no
washout period
Are unbiased data available? No, used a
Wilcoxon Rank Sum test which is used for
independent, not dependent samples
Burch 2007
Methods Multicenter, randomized, consisting of open-label and double-blind phase
Setting: clinic
Participants 1028 participants ages 40-80 years with pain due to OA (646 of whom were randomized
to double-blind treatment)
% women: active group: 62%; control group: 64%
Interventions 7-day washout period between the open-label and double-blind treatments included
During double-blind treatment, active group received tramadol titrated to final dose of
200 mg or 300 mg, which was maintained for 12 weeks. Control group received placebo
that was packaged and labeled in the same way as the treatment
Outcomes PI rated on an 11-point PI-NRS.
Assessments of the Patient and Physician Global Impressions of Change were both based
on the overall change in status from the beginning of the study using a 7-point categorical
scale ranging from 1 (very much improved) to 7 (very much worse). The Patient and
Physician Global Impressions of Change integrated the effect of treatment on pain,
adverse effects and the participant’s expectation of pain relief
Safety assessed by physical exam, clinical laboratory tests, vital signs, adverse events and
concomitant medication at all study visits
Withdrawals due to adverse effects reported. The effect sizes were assessed in terms of
change over the study period
Extracted pain outcome: PI-NRS (0-11 point) at 12 weeks, with lower values indicating
benefit
No physical function outcome reported
Notes Funding source not reported
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”At the beginning of the double-
blind phase, eligible patients were random-
ized (…) in blocks of six according to a pre-
viously established randomization schedule
computer-generated“ (p.330)
Quote: ”patients were assigned study med-
ication by means of a central interactive
voice-response system“ (p.330)
Allocation concealment (selection bias) Low risk Quote: ”…patients were assigned study
medication by means of a central interac-
tive voice-response system. (p.330)
Quote: “…inactive placebo tablets identi-
cal to the different dose forms of tramadol
Contramid OAD were packaged and la-
belled in the same way as the active treat-
ment” (p.330)
Blinding of personnel Low risk Quote: “Participants and site personnel
were blinded to treatment assignments” (p.
330)
Blinding of participants Low risk Quote: “Participants and site personnel
were blinded to treatment assignments” (p.
330)
Quote: “To maintain the double blind, in-
active placebo tablets identical to the dif-
ferent dose forms of Tramadol Contramid
OAD were packaged and labelled in the
same way as the active treatment.” (p.330)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Participants were asked to evaluate
the intensity of their pain.” (p.330)
Because participants and site personnel de-
scribed as blinded, risk of bias in outcome
assessment deemed low
Incomplete outcome data for pain and
physical function
Low risk Quote: “The efficacy analysis was con-
ducted on the full-analysis population, de-
fined as all patients who received at least
one dose of the randomized study medi-
cation regardless of the status of the post-
dosing assessment.” (p.331)
645/646 randomized participants were in-
cluded in the full analysis population.
Withdrawals due to adverse events were 10.
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2% (44/431) with tramadol vs 5.1% (11/
214) with placebo. Withdrawals due to rea-
sons other than adverse events were 14.4%
(62/431) with tramadol vs 17.8% (38/214)
with placebo
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “The safety population included all
patients who received at least one dose of
study medication.” (p.331)
All 646 randomized participants included
in safety population. Data from partici-
pants who did not discontinue due to lack
of benefits were censored at time of their
last dose of study medication. Withdrawals
due to adverse events: 10.2% (44/431) with
tramadol vs 5.1% (11/214) with placebo.
Withdrawals due to reasons other than
adverse events: 14.4% (62/431) with tra-
madol vs 17.8% (38/214) with placebo
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain and phys-
ical function) appeared to have been re-
ported in the results, but we did not have
access to the protocol for verification
Other biases Low risk No other sources of bias
DeLemos 2011
Methods Phase III, 12-week, multicenter, randomized, double-blind, placebo-controlled, dose-
ranging trial
Participants 1011 participants randomized, 1001 analyzed for safety/benefits; 555 completed study
treatment
Adults with knee or hip (or both) OA and baseline PI ≥ 40/100 on 100-mm VAS
Safety/ITT population for 5 groups (number of participants): tramadol 100 mg: 201;
200 mg: 199; 300 mg: 199; celecoxib: 202; placebo: 200
% women: tramadol 100 mg: 58.2%; tramadol 200 mg: 62.3%; tramadol 300 mg: 61.
8%; celecoxib: 64.9%; placebo: 68.5%
Interventions Eligible participants underwent a 2-7-day washout of prior analgesic therapy
Double-blind treatment period (12 weeks)
Active group 1: tramadol 100 mg
Active group 2; tramadol 200 mg
Active group 3: tramadol 300 mg
Active group 4: celecoxib
Control: placebo
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Outcomes Arthritis PI assessed over entire study using 100-mm VAS (0 = no pain, 100 = extreme
pain)
WOMAC Pain, Physical Functioning and Stiffness subscales
Participant and physician global assessment of disease activity on 100-mm VAS
Sleep assessed with the CPSI (which included 100-mm VAS)
At baseline and at weeks 6 and 12, participants completed the SF-36 Health Survey
Safety assessments included reports of adverse events, either spontaneously or in response
to non-directed
questioning, and results of physical exams, vital signs, clinical laboratory tests and elec-
trocardiograms at study visits. Participants completed 49-item Short Form ARCI ques-
tionnaire at baseline and week 12. Participants also completed 16-item PDQ at baseline,
week 12 (or early discontinuation), and week 13 (or 1 week after early discontinuation)
Extracted pain outcome: WOMAC Pain subscale (0-100 mm) at 12 weeks, with lower
values indicating benefit
Extracted physical function outcome: WOMAC Physical Function subscale (0-1700
mm) at 12 weeks, with lower values indicating benefit
Notes Supported by Biovail Corporation and Ortho-McNeil Janssen Scientific Affairs, LLC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized” (p.217)
Quote: “Patients (…) were randomly as-
signed to 12 weeks of study treatment in a
1:1:1:1:1 ratio.” (p.217)
No mention of how the randomization
process was carried out.
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment
Blinding of personnel Unclear risk Authors did not explicitly report blinding
of personnel
Blinding of participants Low risk Quote: “placebo tablets and capsules were
matched in size and color to the active tra-
madol ER tablets and the over encapsulated
celecoxib capsules, respectively.” (p.218)
Quote: “The double-blind was maintained
during the study by each patient taking 3
tablets and 1 capsule once daily.” (p.218)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Since this was a participant-reported
outcome and participants were blinded,
the outcome assessment was considered
blinded
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Incomplete outcome data for pain and
physical function
High risk Quote: “Patients who discontinued early
had their last observation carried forward
for efficacy analyses” (p.224)
10/1011 (9.9%) randomized participants
were not in the safety/ITT population
due to “no dose documented” (p.219). Al-
though only 555/1011 (54.9%) partici-
pants completed the study, 1001 partici-
pants were included in the safety/ITT anal-
ysis. Withdrawals due to adverse events: 18.
9% with tramadol vs 7.5% with placebo.
Withdrawals for reasons other than adverse
events (lack of efficacy, participant choice,
other): 24.6% with tramadol vs 41% with
placebo. The overall high withdrawal rate
due to reasons other than adverse events
was likely to lead to biased outcome data
despite ITT analysis
Incomplete outcome data for adverse ef-
fects
All outcomes
High risk 10/1011 (9.9%) randomized participants
were not in the safety/ITT population
due to “no dose documented” (p.219). Al-
though only 555/1011 (54.9%) partici-
pants completed the study, 1001 partici-
pants were included in the safety/ITT anal-
ysis. Withdrawals due to adverse events: 18.
9% with tramadol vs 7.5% with placebo.
Withdrawals for reasons other than adverse
events (lack of efficacy, participant choice,
other): 24.6% with tramadol vs 41% with
placebo. The overall high withdrawal rate
due to reasons other than adverse events
was likely to lead to biased outcome data
despite ITT analysis
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical
function and stiffness, and sleep quality)
appeared to have been reported in the re-
sults, but we did not have access to the pro-
tocol for verification
Other biases Low risk No other sources of bias.
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Methods Multicenter, randomized, double-blind, placebo-controlled trial
Participants Randomized 307 participants with ≥ 1 year of OA of hip or knee, experiencing at least
moderate OA pain. ITT population (number of participants): tramadol/acetaminophen:
153; control: 153
% women: active group: 65%; control group: 71.2%
Interventions Participants randomized after 3-week screening and washout period of all non-COX-2
analgesics
Active group: tramadol 37.5 mg/acetaminophen 325 mg combination pills for a total of
13 weeks. Medication titrated by 1 pill every 3 days to a total of 4 pills/day on day 10,
and thereafter as needed to a maximum of 8 pills/day
Control group: matching placebo for a total of 13 weeks
Outcomes Major benefits variable was VAS scores, which participants rated from ’no pain’ (0 mm)
to ’extreme pain’ (100 mm).
Minor outcomes included pain relief rating scores (scale of 4 to -1: 4 = complete, 3 =
a lot, 2 = moderate, 1 = slight, 0 = none, -1 = worse), overall medication assessment
by both physicians and participants at final visit, cumulative distribution of time to
discontinuation due to lack of benefits, proportion of participants discontinuing due to
lack of benefits, WOMAC Osteoarthritis Index questionnaire scores, and SF-36 Health
Survey scores
Extracted pain outcome: pain on VAS (0-100 mm) at 91 days, with lower values indi-
cating benefit
Extracted physical function outcome: WOMAC Physical Function subscale (0-10) at
91 days, with lower values indicating benefit
Notes Supported by Ortho-McNeil Pharmaceutical, Inc., Raritan (NJ)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized”
Quote: “Subjects were recruited from
within investigator’s medical practices and
through advertising.” (p.151)
No description of randomization process.
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Low risk Quote: “All subjects, investigators, and
clinical personnel were blinded to treat-
ment assignments until the trial was com-
plete and the database had been finalized.”
(p.151)
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Blinding of participants Low risk Quote: “Tramadol/APAP
[acetaminophen] or matching placebo was
titrated…” (p.150)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All subjects, investigators, and
clinical personnel were blinded to treat-
ment assignments until the trial was com-
plete and the database had been finalized.”
(p.151)
Incomplete outcome data for pain and
physical function
High risk Quote: “Efficacy analyses were performed
on the intent-to-treat population, defined
as all randomized subjects who took at
least one dose of study medication and for
whom a post-randomization efficacy mea-
surement was available.” (p.151)
306/307 randomized participants were in-
cluded in the ITT and evaluable-for-safety
populations. 227/307 randomized partic-
ipants completed treatment. Withdrawal
due to insufficient pain relief: 13/153 (8.
5%) with tramadol vs 26/154 (16.9%)
with placebo. Withdrawals due to adverse
events: 13.1% with tramadol vs 3.9% with
placebo. Withdrawals for reasons other
than adverse events (insufficient pain re-
lief, participant choice, intercurrent illness,
other): 21/153 (13.7%) with tramadol vs
54/153 (35.3%) with placebo. There was
an imbalance between the groups regarding
reasons for withdrawal and an important
(> 20%) overall withdrawal rate
Incomplete outcome data for adverse ef-
fects
All outcomes
High risk Quote: “Safety assessments were performed
on randomized subjects who took at least
one dose of study medication and had at
least one available post baseline safety mea-
surement.”
Withdrawals due to adverse events: 13.
1% with tramadol vs 3.9% with placebo.
Withdrawals for reasons other than ad-
verse events (insufficient pain relief, par-
ticipant choice, intercurrent illness, other):
21/153 (13.7%) with tramadol vs 54/153
(35.3%) with placebo. There was an imbal-
ance between the groups regarding reasons
for withdrawal and an important (> 20%)
overall withdrawal rate
64Tramadol for osteoarthritis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Emkey 2004 (Continued)
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, WOMAC
Osteoarthritis Index, SF-36 Health Survey)
appeared to have been reported in the re-
sults, but we did not have access to the pro-
tocol for verification
Other biases Low risk No other sources of bias.
Fishman 2007
Methods Randomized, multicenter, double-blind, parallel arm trial; 3 phases: baseline, run-in and
maintenance
Participants 552 participants ages 40-75 years with pain from OA of the knee, with WOMAC Pain
score > 150 mm at baseline
% women: tramadol 100 mg: 60.2%; tramadol 200 mg: 59.8%; tramadol 300 mg: 65.
7%; placebo: 61.6%
Interventions Baseline period included washout of prior analgesics.
Active group 1: tramadol 100 mg
Active group 2: tramadol 200 mg
Active group 3 tramadol 300 mg
Control group: placebo
Run-in: 6 days during which the dose was titrated by 100 mg increments every 2-3 days
until the randomized dose reached
Maintenance: benefits evaluations were performed at end of run-in and 3, 6 and 12
weeks of maintenance treatment at the randomized dose (of either tramadol or placebo)
Duration of treatment in all groups: 12 weeks
Outcomes WOMAC Pain score
Global rating of pain relief
Adverse events
Serious adverse events
Extracted pain outcome: WOMAC Pain subscale (0-500 mm) at 12 weeks, with lower
values indicating benefit
No physical function outcome was extracted as end-of-study data were not available
Notes Funded by Labopharm.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A centralized computer-generated
randomization list produce by Aptuit, Al-
lendale, NJ, assigned the three different
doses of study medication and placebo to
individual randomization numbers in a ra-
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tio of 1:1:1:2 and in blocks of five.” (p.275)
Allocation concealment (selection bias) Low risk Quote: “Patients at each center were as-
signed a sequential patient number that
corresponded to one of the random medi-
cation supplies in the block provided to the
center.” (p.275)
Used double-dummy technique
Blinding of personnel Low risk Quote: “A double-blind, double-dummy
technique was used to ensure that patients
and study personnel remained blinded to
both treatment assignment and dose. Treat-
ment assignments remained blinded until
the database was locked.” (p.275)
Blinding of participants Low risk Quote: “A double-blind, double-dummy
technique was used to ensure that patients
and study personnel remained blinded to
both treatment assignment and dose. Treat-
ment assignments remained blinded until
the database was locked.” (p.275)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A double-blind, double-dummy
technique was used to ensure that patients
and study personnel remained blinded to
both treatment assignment and dose. Treat-
ment assignments remained blinded until
the database were locked.” (p.275)
Incomplete outcome data for pain and
physical function
High risk Quote: “The efficacy analyses were con-
ducted on the full-analysis population: all
randomized patients who received at least
one dose of study medication and who had
at least one post baseline assessment of any
functional scale.” (p.275)
Quote: “Thirteen patients who were ran-
domized were not included in the full anal-
ysis population because they did not have a
post-baseline efficacy assessment.” (p.277)
Withdrawals due to adverse events: 20.
9% (68/325) in combined tramadol treat-
ment groups vs 7.5% (17/227) in placebo
group. Withdrawals for reasons other than
adverse events (treatment failure, partic-
ipant request, investigator initiated): 24.
6% (80/325) in the combined tramadol
treatments groups vs 33.5% (76/227) in
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placebo group. This led to an imbalance be-
tween groups. The reason for missing out-
come data was likely related to true out-
come
Incomplete outcome data for adverse ef-
fects
All outcomes
High risk Quote: “The safety population included all
patients who received at least one dose of
randomized study medication.” (p.275)
All 552 randomized participants were in-
cluded in the safety population. With-
drawals due to adverse events: 20.9%
(68/325) in combined tramadol treatment
groups vs 7.5% (17/227) in placebo group.
Withdrawals for reasons other than adverse
events (treatment failure, participant re-
quest, investigator initiated): 24.6% (80/
325) in the combined tramadol treatments
groups vs 33.5% (76/227) in placebo
group. This led to an imbalance between
groups. The reason for missing outcome
data was likely related to true outcome
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical
function, and stiffness) appeared to have
been reported in the results, but we did not
have access to the protocol for verification
Other biases Low risk No other sources of bias
Fleischmann 2001
Methods Multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group
clinical trial
Participants 129 participants ages 35-75 years, with symptomatic (painful) OA of knee for ≥ 1 year,
who had used NSAIDS ≥ 3 months before study entry and were otherwise in good
health. Participants were required to have at least moderate pain (PI ≥ 2 on a scale of
0 to 4, with 0 being the least and 4 being the greatest PI) in the target knee when their
current analgesic was discontinued
Number of participants: tramadol group: 63; control (placebo) group: 66
% women: active group: 65.1%; control group: 59.1%
Interventions 10-day analgesic washout period
Active group: tramadol in 50 mg increments every 2 days, titrated to a target 200 mg
after 7 days (1 capsule 4 times daily). Participants were permitted to increase their dose
up to 400 mg/day if needed for 84 days. 91-day treatment period
Control group: placebo identical in appearance for 91 days.
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Outcomes PI (5-point Likert scale)
Pain relief: measure of change in pain relative to the end of the washout phase (7-point
Likert Scale
Overall WOMAC score; subscores for pain, stiffness and physical function
Global Assessment of Efficacy
Number of participants in each group with who reported adverse events
Withdrawals due to adverse events
We reported on: WOMAC Pain and Physical Function subscales, adverse events and
withdrawals due to adverse events
Extracted pain outcome: PI score (5-point Likert scale) at 91 days, with lower values
indicating benefit
Extracted physical function outcome: WOMAC Disability score (0-10) at 91 days, with
lower values indicating benefit
Notes Funded by OrthoMcNeil Pharmaceutical, Raritan (NJ)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients (…) were randomly as-
signed in a 1:1 ratio to receive tramadol or
placebo. Study medications were randomly
assigned by a computer to a numerical list
for each site, and patients were enrolled se-
quentially using the list” (p.117)
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment
Blinding of personnel Unclear risk Authors did not explicitly report blinding
of personnel
Blinding of participants Low risk Quote: “tramadol 50-mg capsules were
identical in appearance to the placebo cap-
sules.” (p.117)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Since this was a participant-reported
outcome and participants were blinded,
the outcome assessment was considered
blinded
Incomplete outcome data for pain and
physical function
High risk Quote: “All analyses included all random-
ized patients who took ≥ 1 dose of study
medication and for whom an efficacy mea-
surement was available (the intent-to-treat
population).” (p.118)
Unknown how many of the 129 random-
ized participants were included in the anal-
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yses. Withdrawals due to adverse events:
22.2% with tramadol vs 15.2% with
placebo. Total withdrawals from study: 68.
3% with tramadol vs 74.2% with placebo.
The high withdrawal rate impacts the va-
lidity of the imputed data used for the ITT
analysis
Incomplete outcome data for adverse ef-
fects
All outcomes
High risk Quote: “All analyses included all random-
ized patients who took ≥ 1 dose of study
medication and for whom an efficacy mea-
surement was available (the intent-to-treat
population).” (p.118)
Unknown how many of the 129 random-
ized participants were included in the anal-
yses. Total withdrawals from study: 68.3%
with tramadol vs 74.2% with placebo. The
high withdrawal rate impacts the validity of
the imputed data used for the ITT analysis
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (PI, WOMAC
Osteoarthritis Index) appeared to have
been reported in the results, but we did not
have access to the protocol for verification
Other biases Low risk No other sources of bias
Fujii 2014
Methods Randomized, prospective, parallel group, active-controlled study. Participants random-
ized according to minimization method for 3 groups. Authors employed sex and age as
stratification factors
Setting: hospital
Participants 200 participants (148 female, 52 male) who attended authors’ hospital for knee or hip
pain, mean age 71.0 (SD 7.0) years who had had knee or hip pain originating from OA
for ≥ 1 month, were admitted into the study
Number of participants: tramadol/acetaminophen: 65; loxoprofene: 70; transdermal
fentanyl: 65
% women: tramadol/acetaminophen: 45%; loxoprofen: 56%; transdermal fentanyl: 47%
Interventions Participants were randomized 1:1:1 to tramadol/acetaminophen, loxoprofen or trans-
dermal fentanyl
Active group 1: tramadol/acetaminophen (tramadol 37.5 mg/acetaminophen 325 mg
combination pills) starting dose 2 pills/day. If this dose was not effective, it was increased
to 8 pills/day. Maximum dose 8 pills
Active group 2: loxoprofen sodium 60 mg 3 times/day, or a total of 180 mg/day
Active group 3: transdermal fentanyl starting dose 12.5 µg/hour. If this dose was not
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effective, it was increased sequentially to 25 µg/hour, 37.5 µg/hour and 50 µg/hour.
Maximum dose 50 µg/hour
Study medications administered for 12 weeks.
Other drugs and injections into the knee or hip joints were not allowed
Outcomes VAS evaluation of pain on movement before randomization, and after 1, 4 and 12 weeks
of randomized therapy
Extracted pain outcome: pain on VAS (0-10) at 12 weeks, with lower values indicating
benefit
No physical function outcome reported
Notes Authors’ hospital not specified in article, only academic affiliation: Department of Or-
thopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
Funding source not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Two hundred patients were se-
lected from 210 knee or hip pain patients
who matched the following criteria.” (p.
1380)
Quote: “The patients were randomized ac-
cording to the minimization method for
three groups.” (p.1380)
Minimization method used; author con-
firmed that 10/210 knee or hip participants
were excluded because they did not match
the observation of OA of the knee or hip
joint on examination of an anterior-poste-
rior X-ray image in the supine position
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Unclear risk Blinding not confirmed or described for
outcome of interest of this review (i.e. pain)
Blinding of participants Unclear risk Blinding not confirmed or described for
outcome of interest of this review (i.e. pain)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not confirmed or described for
outcome of interest of this review (i.e. pain)
Incomplete outcome data for pain and
physical function
Unclear risk Quote: “Thirty patients dropped out of this
study.” (p.1381)
Author confirmed that reasons for with-
drawal of 15% of randomized participants
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(15% with tramadol vs 13% with loxo-
profen vs 17% with transdermal fentanyl)
unknown; appeared that per-protocol ap-
proach to analysis was used (see Figure 1,
p.1381)
Note: physical function not reported on in
this study.
Incomplete outcome data for adverse ef-
fects
All outcomes
Unclear risk Adverse effects not reported on in this
study.
Selective reporting (reporting bias) Unclear risk Protocol not found online. All prespecified
outcomes (pain and X-ray examinations)
appeared to have been reported in the re-
sults, but we did not have access to the pro-
tocol for verification
Other biases Low risk No other sources of bias.
Gana 2006
Methods Multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group
clinical trial
*We also included data from another publication by Kosinski which was a secondary
analysis of the trial conducted by Gana and coworkers (Gana 2006).
Participants 1011 men/women ages 18-74 years with radiographically confirmed ACR Functional
Class I-III OA of the knee or hip
Number of participants: tramadol 100 mg: 202; tramadol 200 mg: 201; tramadol 300
mg: 201; tramadol 400 mg: 202; control group: 205
Participants were required to have baseline index joint pain of at least 40 mm on 100-
mm pain VAS (0 = no pain, 100 = extreme pain) after the washout period
% women: tramadol 100 mg: 62.4%; tramadol 200 mg: 63.7%; tramadol 300 mg: 59.
2%; tramadol 400 mg: 57.9%; placebo: 68.8%
Interventions Active group 1: tramadol 100 mg once daily
Active group 2: tramadol 200 mg once daily
Active group 3: tramadol 300 mg once daily
Active group 4: tramadol 400 mg once daily
Control group: placebo once daily
Treatment for 12 weeks.
Outcomes From the Gana publication:
PI: WOMAC Osteoarthritis Index for index and non-index joints in the past 48 hours
using 100-mm VAS (0 ’no pain’ to 100 ’extreme pain’), overall pain rated daily at
approximately 8:00 p.m. using a 100-mm VAS in response to the question “Overall,
how much pain have you experienced in your study joint today?”
Other: WOMAC Physical Function subscale (0-1700 mm), participant and physician
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global assessments of disease activity on a 100-mm VAS, participants responded to the
following sleep-related questions using a 100-mm VAS: (trouble falling asleep, need for
sleep medication, how often they were awakened by pain during the night and how often
they were awakened by pain in the morning). Participants assessed the overall quality
of sleep using a 100-mm VAS in response to the question, “Over the past week, how
would you rate the overall quality of your sleep?”; SF-36 Health Survey; adverse events
(either spontaneously or in response to non-directed questioning; results of physical
exams, vital signs, clinical laboratory tests and electrocardiograms at study visits); and 16-
item questionnaire to record the presence or absence of common symptoms of physical
dependence
Extracted physical function outcome: WOMAC Physical Function subscale (0-1700
mm) at 12 weeks, with lower values indicating benefit
From the Kosinski publication:
PI: arthritis PI during the past 48 hours in the index joint using a 100-mm VAS with
anchors of 0 (no pain) and 100 (extreme pain)
Other: CPSI, which consists of 5 questions about severity of sleep impairment during
previous week; adverse events, withdrawal symptoms, and physical dependence after
abrupt discontinuation of study
treatment.
Extracted pain outcome: Arthritis Pain Intensity scale (0-100 mm) at 12 weeks, with
lower value indicating less pain
Notes From the Gana publication:
Supported by Biovail Laboratories International SRL
From the Kosinski publication:
Supported by a grant from Ortho-McNeil Janssen Scientific Affairs, LLC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A randomization schedule was
generated with permuted blocks of 10 sub-
jects. Each site received study medication
kits that were marked with the randomiza-
tion numbers. Investigators used an inter-
active voice-response system to assign ran-
domization numbers to subjects.” (p.1392)
Allocation concealment (selection bias) Low risk Quote: “Each site received study medica-
tion kits that were marked with the ran-
domization numbers. Investigators used an
interactive voice-response system to assign
randomization numbers to subjects. Eligi-
ble subjects were randomly assigned to a 1:
1:1:1:1 ratio.” (p.1392)
Blinding of personnel Unclear risk Authors did not explicitly report blinding
of personnel.
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Blinding of participants Low risk Quote: “To preserve blinding, study med-
ication tablets were similar in appearance
and size.” (p.1392)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Since this was a participant-reported out-
come and participants were blinded, the
outcome assessment can be considered
blinded
Incomplete outcome data for pain and
physical function
High risk Quote: “Analyses were conducted on an in-
tent-to-treat (ITT) population, defined as
all randomized subjects who took at least
one dose of study medication, using the
last-observation-carried-forward approach
to replace missing post-baseline efficacy
data.” (p.1393)
558/1020 (55.2%) of participants com-
pleted 12 weeks of treatment. However,
1011/1020 participants were included in
the ITT population. Those omitted from
ITT did not receive treatment. With-
drawals due to adverse events: 22.7% with
tramadol vs 10.2% with placebo. With-
drawals for reasons other than adverse
events: 22.4% with tramadol vs 15.3%
with placebo. The imbalance in with-
drawals due reasons other than adverse
events was likely to also impact the out-
come data despite an ITT analysis
*Gana 2006 provided outcome data for
physical function while Kosinski 2007 pro-
vided outcome data for pain
Incomplete outcome data for adverse ef-
fects
All outcomes
High risk Quote: “Analyses were conducted on an in-
tent-to-treat (ITT) population, defined as
all randomized subjects who took at least
one dose of study medication, using the
last-observation-carried-forward approach
to replace missing post-baseline efficacy
data.” (p.1393)
558/1020 (55.2%) of participants com-
pleted 12 weeks of treatment. However,
1011/1020 participants were included in
the ITT population. Those omitted from
ITT did not receive treatment. With-
drawals due to adverse events: 22.7% with
tramadol vs 10.2% with placebo. With-
drawals for reasons other than adverse
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events: 22.4% with tramadol vs 15.3%
with placebo. The imbalance in with-
drawals due reasons other than adverse
events was likely to also impact the out-
come data despite an ITT analysis
*Gana 2006 provided outcome data for any
adverse events, withdrawals due to adverse
events and serious adverse events
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical
function and stiffness, and sleep quality)
appeared to have been reported in the re-
sults, but we did not have access to the pro-
tocol for verification
Other biases Low risk No other sources of bias.
Jensen 1994
Methods Parallel, multicenter double-blind RCT
Participants Participants with radiologically confirmed diagnosis of OA of hip or knee
Number of participants: tramadol group: 135; control group: 129
% women: active group: 76%; control group: 82%
Interventions 3-7-day washout period: participants received up to 4 mg of acetaminophen
2-week double-blind phase: participants with moderate to severe pain despite the ac-
etaminophen were randomly allocated to:
Active group 1: tramadol 100 mg 3 times/day
Active group 2: dextropropoxyphene 100 mg 3 times/day
Drugs were administered in capsules identical in appearance.
Outcomes Assessment of pain/pain relief: pain during walking/daily activities, and pain during sleep
(4-point Likert scale)
Assessment of functional impairment: climbing stairs, getting out of bed, or rising from
a chair (4-point Likert scale)
Overall assessment of therapy at the last visit
Adverse effects: signs and symptoms
Withdrawals due to adverse events
Extracted pain outcome: pain relief on VAS (0-100 mm) at 2 weeks, with lower values
indicating benefit
Extracted disability outcome: participant overall assessment (proxy for physical function)
Notes Funded by Grünenthal GmBH, Aachen, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “Patients were given a patient number
in the order that they were enrolled, and re-
ceived their allocated treatment according to
a computer-generated assignment schedule.”
(p.213)
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment
Blinding of personnel Unclear risk Authors did not explicitly report blinding of
personnel.
Blinding of participants Low risk Quote: “Both drugs were administered as
capsules, and were identical in appearance.”
(p.213)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “To quantify pain relief, patients
made daily recordings.” (p.213)
Quote: “At the last visit, the patient and the
investigator were asked to give an overall as-
sessment of the therapy.” (p.213)
Incomplete outcome data for pain and
physical function
Low risk Quote: “Patients who provided information
on different efficacy parameters, i.e. who at-
tended all visits, were evaluated for efficacy
(evaluable cohort, EVAL).” (p.213)
Quote: “The results in the EVAL cohort were
consistent with the ITT cohort.” (p.215)
For tramadol (135 ITT, 81 EVAL, 54 [40%]
not included in benefits assessment). For dex-
tropropoxyphene (129 ITT, 109 EVAL, 20
[16%] not included in benefits assessment).
Since only participants who attended all their
visits were included in the benefits assess-
ment, other participant data would have been
missed. Withdrawals due to adverse events:
35.6% with tramadol vs 10.9% with dextro-
propoxyphene. The reason for missing out-
come data was likely to be related to true out-
come
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “All patients randomized (intent-to-
treat cohort, ITT) were included in the anal-
ysis of safety.” (p.213)
Quote: “The results in the EVAL cohort were
consistent with the ITT cohort” (p.215)
Quote: “A significantly larger number of
withdrawals in the tramadol group occurred
as a result of adverse events.” (p.215)
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Data on safety analysis were presented in ta-
ble III for 135 tramadol participants and 129
dextropropoxyphene participants which was
the amount of people included in the ITT
cohort. However, withdrawals due to adverse
events were 35.6% with tramadol vs 10.9%
with dextropropoxyphene
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain status, physi-
cal impairment, adverse signs/symptoms) ap-
peared to have been reported in the results,
but we did not have access to the protocol for
verification
Other biases Low risk No other sources of bias.
Karlsson 2009
Methods Randomized, open-label, controlled, parallel-group non-inferiority study
Participants Participants ages > 18 years with clinical diagnosis of OA of the hip or knee (or both),
based on ACR and radiographic criteria
% women: active group: 59.4%; control group: 53.8%
Interventions Active group 1: tramadol pills (75, 100, 150 and 200 mg) titrated as needed to achieve
stable pain control over 12 weeks
Active group 2: 7-day buprenorphine patches (5, 10 and 20 µg/hour)
Outcomes PI: mean weekly BS-11 pain score, calculated from the scores recorded in the participant
diaries every evening. Global assessment of pain relief obtained by asking participants
and investigators to rate the study medication in terms of pain relief (very poor, poor,
fair, good or very good). Investigators assessed participants’ pain, stiffness and ability to
perform daily activities using WOMAC
Other: participant-recorded number of acetaminophen pills (rescue medication) taken
daily. Sleep disturbance and quality of sleep assessed by asking participants the following
questions: “How many nights have you woken due to pain in the past 7 nights?” and
“Please rate the quality of sleep over the past 7 nights” (response options: very poor,
poor, fair, good and very good). Participants’ quality of life using the EuroQol EQ-5D
Health Status Index and EQ-VAS. Adverse events reported. At visits 2 and 8, physical
exam performed, and systolic and diastolic blood pressure and heart rate measured
Extracted pain outcome: scores on 11-point box scale at 12 weeks, with lower values
indicating benefit
Physical function outcomes not reported
Notes Sponsored and designed by Mundipharma AB, Goteborg, Sweden
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a computer-generated randomiza-
tion schedule was used to allocate patients.
” (p.505)
Quote: “Patients were randomized in a 1:1
ratio.” (p.503)
Quote: “Eligible patients were randomized
to the lowest available patient number at
their site.” (p.506)
Allocation concealment (selection bias) Unclear risk Quote: “Sealed envelopes with the treat-
ment codes were forwarded to investigators
at each site.” (p.506)
Insufficient information about allocation
concealment.
Blinding of personnel High risk Quote: “When the study was designed, it
was felt that the potential benefits of an
open-label design outweighed those of a
blinded design.” (p.511)
Blinding of participants High risk Quote: “When the study was designed, it
was felt that the potential benefits of an
open-label design outweighed those of a
blinded design.” (p.511)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “When the study was designed, it
was felt that the potential benefits of an
open-label design outweighed those of a
blinded design.” (p.511)
Incomplete outcome data for pain and
physical function
High risk Quote: “The full analysis set (FAS) in-
cluded all patients who were randomized
and received at least 1 dose of study medica-
tion. The per-protocol analysis set (PPAS)
included patients who were in the FAS and
had no major protocol violations.” (p.507)
The FAS did not include all randomized
participants who completed the treatment.
20/69 (28.9%) participants in the patches
group were not included in FAS. 25/66
(37.8%) participants in the tramadol group
were not included in the FAS. Withdrawals
due to adverse events: 28.8% with tra-
madol vs 14.5% with patches. Total with-
drawals: 31.8% with tramadol vs 20.3%
with patches
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Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “The full analysis set (FAS) in-
cluded all patients who were randomized
and received at least 1 dose of study medica-
tion. The per-protocol analysis set (PPAS)
included patients who were in the FAS and
had no major protocol violations.” (p.507)
The per-protocol analysis set does not
include all randomized participants who
completed the treatment. 20/69 (28.9%)
participants in the patches group were not
included in FAS. 25/66 (37.8%) partici-
pants in the tramadol group were not in-
cluded in the FAS. Withdrawals due to ad-
verse events: 28.8% with tramadol vs 14.
5% with patches. Total withdrawals: 31.
8% with tramadol vs 20.3% with patches
Selective reporting (reporting bias) Low risk Quote: “There were changes from baseline
to study completion on all WOMAC Os-
teoarthritis Index subscale scores in both
treatment groups, with no significant dif-
ferences between treatment groups.” (p.
508)
WOMAC Osteoarthritis Index subscale
scores not reported but stated to have no
significant differences between treatments
Other biases Low risk No other sources of bias.
Kean 2009
Methods 2 parallel, multicenter, double-blind, double-dummy, placebo-controlled, phase III clin-
ical trials
Participants 685 women ages 40-75 years with moderate-to-severe pain associated with OA of the
knee. Conducted from January to August 2003 across 149 active centers in the US
included in analysis
Participants were required to have a WOMAC Pain subscale VAS score > 150 mm at
baseline
Interventions Active group 1: tramadol 100 mg for up to 12 weeks
Active group 2: tramadol 200 mg for up to 12 weeks
Active group 3: tramadol 300 mg for up to 12 weeks
Control group: placebo.
Washout period ≥ 2 days or a minimum of 5 half-lives. All participants who were
randomized to active treatment started by taking 100 mg/day. Over the next 6 days,
participants randomized to 200 mg/day and 300 mg/day treatment arms were titrated
in a double-blind manner by 100 mg/day increments every 2-3 days until they reached
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their randomized dosages
Randomized dosage or placebo maintained for a maximum of 12 weeks
Outcomes PI: WOMAC Pain and Physical Function subscale scores at baseline and at end of study,
participant global rating of pain relief was assessed using a Likert-type scale with the
possible responses of ’very effective,’ ’effective’ and ’ineffective.’ This evaluation was
completed at all study visits during the maintenance phase
Other: treatment compliance (number of dispensed pills taken relative to the number
of dispensed pills planned) and adverse events, physical examination, laboratory assess-
ments, and concomitant medications was used to assess safety
Extracted pain outcome: WOMAC Pain subscale (0-500 mm) at 12 weeks, with lower
values indicating benefit
Extracted physical function outcome: WOMAC Physical Function subscale (0-1700
mm) at 12 weeks, with lower values indicating benefit
Notes Funded by Labopharm Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomized to a pre-
determined fixed dose.” (p.1003)
Quote: “Once randomized, patients en-
tered the run-in phase.” (p.1003)
No mention as to how the randomization
process was carried out
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Low risk Quote: “Treatment assignments remained
blinded until the clinical trial database was
locked.” (p.1003)
Blinding of participants Low risk Quote: “double-blind, double-dummy” (p.
1003)
Quote: “Treatment assignments remained
blinded until the clinical trial database was
locked.” (p.1003)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Treatment assignments remained
blinded until the clinical trial database was
locked.” (p.1003)
Incomplete outcome data for pain and
physical function
High risk Quote: “The primary analysis population
for this post hoc efficacy analyses was the fe-
male full-analysis (FA) population, defined
as all randomized women who received at
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least one dose of the assigned study medi-
cation and had at least one post-baseline as-
sessment of any functional scale.” (p.1004)
Quote: “Sixteen women from both studies
who were randomized were not included
in the full-analysis population because they
did not have a post-baseline efficacy assess-
ment.” (p.1005)
Quote: “A total of 309 (45.1%) discontin-
ued the study prior to week 12 of the main-
tenance phase.” (p.1004)
685 women randomized. Withdrawals due
to adverse events: 25.2% (102/405) with
tramadol vs 5% (14/280) with placebo.
Withdrawals for reasons other than adverse
events (treatment failure, participant re-
quest, investigators initiated, administra-
tive, death): 24.9% (101/405) with tra-
madol vs 32.9% (92/280) with placebo.
Withdrawals between the groups were not
balanced and it was likely that missing out-
come data were related to true outcome
Incomplete outcome data for adverse ef-
fects
All outcomes
High risk Quote: “The safety population was com-
prised of all women from each study who
received at least one dose of the assigned
study medication within each of the treat-
ment arms used in the analysis.” (p.1004)
Quote: “A total of 685 women comprised
the safety population.” (p.1004)
Table 3 presented data regarding adverse
events for the total randomized population
of 685 women. Withdrawals due to adverse
events: 25.2% (102/405) with tramadol vs
5% (14/280) with placebo. Withdrawals
for reasons other than adverse events (treat-
ment failure, participant request, investi-
gators initiated, administrative, death): 24.
9% (101/405) with tramadol vs 32.9%
(92/280) with placebo. Withdrawals be-
tween the groups were not balanced and it
was likely that missing outcome data were
related to true outcome
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical
function, and stiffness) appeared to have
been reported in the results, but we did not
have access to the protocol for verification
80Tramadol for osteoarthritis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kean 2009 (Continued)
Other biases Low risk No other sources of bias.
Malonne 2004
Methods Parallel, multicenter, double-blind RCT
Participants 231 adults ages 45-80 years with OA of hip or knee diagnosis made with the European
League Against Rheumatism criteria. Participants were included if they had a pain score
≥ 35 mm on 100-mm Huskisson horizontal VAS scale (scale 0 = no pain to 100 = worst
pain) and a functional discomfort score ≥ 4 on the Lequesne Functional Discomfort
Index (total score 0 = absence of pain to 20 = most intense pain)
% women: active group: 72.1%; control group: 73.1%
Interventions 14-day treatment period.
Active group: tramadol LP SR 200 mg/day
Control group: placebo
Concomitant treatment with acetaminophen as a rescue medication
Outcomes PI evaluated with VAS Patient Global Assessment and use of rescue medication
Extracted pain outcome: Huskisson VAS for pain (0-100 mm) at 14 days, with lower
values indicating benefit
Physical function data not extractable for purposes of this review
Notes Funding source not mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Study drugs were allocated to pa-
tients based on a center randomization list.”
(p.1776)
No mention as to how the randomization
was carried out.
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Unclear risk Authors did not explicitly report blinding of
personnel
Blinding of participants Low risk Quote: “Capsules of identical appearance
containing either inactive ingredients or tra-
madol LP 200 mg were prepared and dis-
pensed in blister packs.” (p.1776)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Since this was a participant-reported out-
come and participants were blinded, the out-
come assessment was considered blinded
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Incomplete outcome data for pain and
physical function
Low risk Quote: “Two hundred thirty-one patients
were randomized to treatment, and 230 (…)
were evaluable for efficacy and safety.” (p.
1776)
Quote: “A separate analysis was conducted
in the patients who did not take rescue med-
ication.”
Quote: “92 patients were included in the as-
sessment of those who did not take rescue
medication.” (p.1776)
230/231 analyzable participants used in sa-
fety analysis but only 197 completed treat-
ment and were used in the benefits analy-
sis. The missing 33 participants were omitted
due to no VAS at day 14. Total withdrawals:
23.4% with tramadol vs 5.9% with placebo.
Withdrawals due to adverse events: 21.6%
with tramadol vs 1.7% with placebo
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “Two hundred thirty-one patients
were randomized to treatment, and 230 (…)
were evaluable for efficacy and safety.” (p.
1776)
Quote: “A separate analysis was conducted
in the patients who did not take rescue med-
ication.”
Quote: “92 patients were included in the as-
sessment of those who did not take rescue
medication.” (p.1776)
230/231 analyzable participants used in sa-
fety analysis but only 197 completed treat-
ment and were used in the benefits analy-
sis. The missing 33 participants were omitted
due to no VAS at day 14. Total withdrawals:
23.4% with tramadol vs 5.9% with placebo.
Withdrawals due to adverse events: 21.6%
with tramadol vs 1.7% with placebo
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (global pain score,
Lequesne Functional Discomfort Index, sa-
fety/adverse events) appeared to have been
reported in the results, but we did not have
access to the protocols for verification
Other biases Low risk No other sources of bias.
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Methods Randomized, multicenter, open comparative study in outpatients at 6 sites
Setting: outpatient clinic at 6 sites.
Participants Ages 40-75 years. 143 participants (women 121, men 22) enrolled, mean age 61.15 (SD
7.80). With symptomatic moderate knee OA pain (≥ 5 on NRS) for > 1 year despite
treatment with stable doses of NSAIDs (meloxicam 7.5 mg or 15 mg once daily or
aceclofenac 100 mg twice daily) for ≥ 4 weeks. Investigators used the 1986 ACR clinical
and radiographic criteria for classification of idiopathic knee OA and checked standing
anteroposterior view of knee joints. Participants with moderate knee joint pain (≥ 5 on
NRS) in last 48 hours of the screening/washout phase eligible to enter study
% women: active group: 84%; control group: 87%.
Interventions During the 14-day screening/washout phase, participants discontinued cyclobenzaprine,
antidepressant or anticonvulsant therapy and underwent clinical and radiologic exam.
During the 4-week tramadol/acetaminophen add-on period, participants maintained
their existing NSAID dose and tramadol/acetaminophen was titrated from 1 pill at
bedtime for 3 days, 1 pill twice/day for 4 days, 1 pill 3 times/day for 3 days, and thereafter
as needed from 3 to 8 pills per day. On day 29, participants with reduced pain (< 4 on
NRS) were randomized to continue with either tramadol/acetaminophen or NSAID for
a further 8 weeks
Outcomes Major benefits measure was the Korean version of the WOMAC Osteoarthritis Index
score; minor outcome measures included PI on NRS, pain relief score, and overall medi-
cation assessment by participants and investigators. Benefits evaluations were performed
on days 29 and 57 during monotherapy. Safety assessments comprised adverse event
monitoring, changes from baseline in vital signs, physical examination at every visit and
clinical laboratory tests at the end of study
Extracted pain outcome: PI on NRS (0-8) for 4 weeks, with lower values indicating
benefit
Extracted physical function outcome: WOMAC Physical Function subscale (0-1700
mm) for 4 weeks, with lower values indicating benefit
Notes Specific sites involved were not listed in the paper. All authors based in South Korea
Supported by a grant from Janssen Korea, Ltd, Seoul, Korea.
ClinicalTrials.gov identifier: NCT00635349.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study described as randomized, but ran-
domization procedure not described by au-
thors
Allocation concealment (selection bias) High risk No mention of allocation concealment.
Blinding of personnel High risk Quote: “This was a randomized, multicen-
ter, open comparative study in out-patients
at six sites.” (p.318)
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Study described as “open,” author con-
firmed that personnel were not blinded
Blinding of participants High risk Quote: “This was a randomized, multicen-
ter, open comparative study in out-patients
at six sites.” (p.318)
Study described as “open,” author con-
firmed that participants were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This was a randomized, multicen-
ter, open comparative study in out-patients
at six sites.” (p.318)
Study described as “open,” author con-
firmed that outcome assessors were not
blinded
Incomplete outcome data for pain and
physical function
High risk Quote: “Efficacy analyses were performed
on the intent-to-treat population, defined
as patients who took at least one dose of
study medication and had available efficacy
measurements.” (p.319)
Quote: “Ninety-one of the 97 random-
ized subjects were included in the ITT
population (44 in tramadol/APAP [ac-
etaminophen] group; 47 in NSAID group)
…” (p.319)
For ITT population, 3 excluded in each
group. Total discontinued: 19% (23% with
tramadol vs 14% with NSAID); reasons for
discontinuation differed between 2 groups
Incomplete outcome data for adverse ef-
fects
All outcomes
Unclear risk Quote: “The population evaluable for sa-
fety was used for above safety analyses…”
(p.319)
Safety population not specified.
Selective reporting (reporting bias) Unclear risk Outcome measures listed in ’Methods’ were
adequately reported, with 1 exception: sec-
ondary measure “overall medication assess-
ment by patients and investigators” (p.319)
. This measure was reported as follows:
“Although NSAID monotherapy tended to
be superior to tramadol/APAP with respect
to pain relief score and overall assessment
by participants and investigators, the dif-
ferences failed to reach statistical signifi-
cance” (p.320), with no data to support
this conclusion. ClinicalTrials.gov identi-
fier: NCT00635349
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Other biases Low risk No other sources of bias.
Pavelka 1998
Methods Cross-over, double-blind RCT
Participants 60 adults (8 men, 52 women) ages > 18 years with radiologically confirmed diagnosis
of OA of hip or knee and at least moderate pain on a one-off 4-point verbal rating scale
assessment (0 = none to 3 = severe)
Interventions Cross-over trial
Participants randomized to tramadol (50-100 mg up to 3 times/day on demand), then
diclofenac (25-50 mg up to 3 times/day on demand) for 28 days. 1-week washout period
before the first course of trial medication and again between the first and second courses
Outcomes Pain and physical function were evaluated with WOMAC Index Pain Intensity scores,
WOMAC Composite Index and global assessment were similar in both treatment phases
Extracted pain outcome: WOMAC Osteoarthritis Index Pain subscore (0-100 mm) at
28 days, with lower values indicating benefit
Extracted physical function outcome: WOMAC Total score
Notes Sponsored by Grünenthal GmbH, Aachen, Germany.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomized via a computer-gen-
erated code.” (p.423)
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Unclear risk Authors did not explicitly report blinding of personnel
Blinding of participants Low risk Quote: “The appearance of the tramadol and di-
clofenac medication (…) was identical (’capsule-in-a-
capsule’ technique).” (p.423)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Since this was a participant-reported outcome and par-
ticipants were blinded, the outcome assessment was
considered blinded
Incomplete outcome data for pain and
physical function
Low risk Quote: “Six patients terminated the study prematurely,
three from group one and three from group two, all
because of adverse events.” (p.425)
Quote: “sample size of 30 per group.” (p.423)
Quote: “Only patients with all measurements at all
visits were evaluated.” (p.423)
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Table I provided WOMAC questionnaire scores for
54/60 participants in total so there were missing data
for 6 participants who dropped out due to adverse
events. The 6 participants were not included in the
benefits analysis. However, there was only a 10% with-
drawal rate due to adverse events for the tramadol and
diclofenac groups, and there was an equal amount of
withdrawals in each group
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “Six patients terminated the study prematurely;
three from group one and three from group two, all
because of adverse events.” (p.425)
Quote: “sample size of 30 per group.” (p.423)
Quote: “Only patients with all measurements at all
visits were evaluated.” (p.423)
Those who terminated the study early would not have
had all measurements taken so they were not included
in the analyses. However, there was only a 10% with-
drawal rate due to adverse events for the tramadol and
diclofenac groups, and there was an equal amount of
withdrawals in each group
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical function and
stiffness, and sleep quality) appeared to have been re-
ported in the results, but we did not have access to the
protocol for verification
Other biases High risk Quote: “There was comparability between groups with
regard to age, weight, Broca index and vital parameters.
” (p.424)
There was no figure showing the distribution of partic-
ipants in each study group and the group demograph-
ics
Was use of a cross-over design appropriate? Yes, OA
was stable
Was it clear that the order of receiving treatments
was randomized? Yes, randomized “computer gener-
ated code.”
Can it be assumed that the trial was not biased from
carry-over effects? Yes, 1-week washout period; “there
were only slight period effects.”
Were unbiased data available? No, used Chi2 (inde-
pendent test).
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Methods Randomized, double-blind, placebo-controlled, 3-period cross-over study
Participants Participants ages ≥ 45 years with knee OA > 6 months based on clinical and radiographic
criteria and had an American Rheumatological Association functional class of I-III
Eligible participants had PI while standing ≤ 5 on a 0-10 NRS
% women (active and control group combined): 63.6%.
Interventions Cross-over trial
Comprised 3 × 3-day periods. Participants randomized to naproxen, tramadol/ac-
etaminophen and placebo for 3 days with a 4-7-day washout period between the 3 phases
of treatment
Tramadol/acetaminophen period: participants received total daily doses of tramadol 75
mg/acetaminophen 650 mg on day 1 and tramadol 112.5 mg/acetaminophen 975 mg
on day 2 and tramadol 75 mg/acetaminophen 650 mg administered as a single dose on
day 3
Naproxen period: participants received 1000 mg total daily dose of naproxen on days 1
and 2 and 500 mg on the morning of day 3
Outcomes Pain: change from baseline in TWA PI for both postdose self-pace walks on day 3,
with TWA reflective of pain across the entire walk. Key secondary endpoints included
TWA PI for all self-pace walks on day 1 and for each individual walk on days 1 and 3,
TTMP using a 4-point Likert scale (none, slight, moderate, severe), and if applicable,
TTSP. WOMAC questionnaire VAS 3.0 (100-mm VAS) collected at end of days 1 and
3 after the completion of the last timed walks, with participants reporting pain, physical
function and stiffness results for the preceding 24 hours
Other: the incidence of overall adverse events, serious adverse events, drug-related adverse
events and discontinuation due to adverse events collected to evaluate tolerability and
safety
No extractable pain or physical function outcomes as authors combined time periods
for this cross-over study
Notes ClinicalTrials.gov Identifiers: NCT00772967 and NCT00565084.
sponsored by Merck & Co., Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Allocation to balanced treatment
sequences was determined according to a
computer-generated schedule by the study
statistician.” (p.647)
Allocation concealment (selection bias) Low risk Quote: “Numbered containers were used
to implement allocation.” (p.647)
Blinding of personnel Low risk Quote: “All study personnel, including in-
vestigators, study site personnel, patients,
monitors, and central laboratory person-
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nel, were blinded to treatment allocation
throughout the study; the code was re-
vealed to the researchers once recruitment,
data collection, and laboratory analyses
were complete.” (p.647)
Blinding of participants Low risk Quote: “Study medication was adminis-
tered in double-dummy fashion with over-
encapsulated pills.” (p.647)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All those involved in study were blinded, as
noted above.
Incomplete outcome data for pain and
physical function
Low risk Quote: “Only observed data were analyzed;
no data were imputed.” (p.648)
Quote: “Nineteen patients (86.4%) com-
pleted the study, and all 19 were included
in both the primary efficacy analysis and
safety analysis. Two patients discontinued
due to protocol violations, and one patient
discontinued due to an adverse event (acute
gouty attack), which was not considered to
be drug-related.” (p.648)
Unknown what treatment (naproxen 500
mg twice daily, tramadol/acetaminophen
or placebo) the participant was receiving
when they withdrew. ClinicalTrials.gov in-
dicated that the 22 participants were ran-
domized to 6 groups corresponding to a
different order of treatment administra-
tion (e.g. placebo, naproxen, tramadol/ac-
etaminophen; or naproxen, tramadol/ac-
etaminophen, placebo, etc.). However, the
percentage of total withdrawals in both
groups combined was only 13.6% and rea-
sons for withdrawal were included. % of
withdrawals due to adverse events in both
groups combined was 4.5%
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “Only observed data were analyzed;
no data were imputed.” (p.648)
Quote: “Nineteen patients (86.4%) com-
pleted the study, and all 19 were included
in both the primary efficacy analysis and
safety analysis. Two patients discontinued
due to protocol violations, and one patient
discontinued due to an adverse event (acute
gouty attack), which was not considered to
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be drug-related.” (p.648)
Unknown what treatment (naproxen 500
mg twice daily, tramadol/acetaminophen
or placebo) the participant was receiving
when they withdrew. ClinicalTrials.gov in-
dicated that the 22 participants were ran-
domized to 6 groups corresponding to a
different order of treatment administra-
tion (e.g. placebo, naproxen, tramadol/ac-
etaminophen; or naproxen, tramadol/ac-
etaminophen, placebo, etc.). However, the
percentage of total withdrawals in both
groups combined was only 13.6% and rea-
sons for withdrawal were included. % of
withdrawals due to adverse events in both
groups combined was 4.5%
Selective reporting (reporting bias) Low risk Outcomes listed in earliest iteration of pro-
tocol were consistent with those reported
as results in the article (ClinicalTrials.gov
Identifier: NCT00772967)
Other biases Low risk No other sources of bias.
Was use of a cross-over design appropriate?
Yes, OA was stable
Was it clear that the order of receiving treat-
ments was randomized? Yes, randomized
“computer generated schedule.”
Can it be assumed that the trial was not
biased from carry-over effects? Yes, 4-7-day
washout period; “there were only slight pe-
riod effects.”
Were unbiased data available? Yes, analysis
of variance model for a 3-period cross-over
design
Schnitzer 1999
Methods Parallel, multicenter, double-blind RCT
Setting: clinic
Participants Participants ages ≥ 45 years with symptomatic OA of knee.
% women: naproxen responders tramadol group: 55.6%; naproxen responders placebo
group: 57.4%; naproxen non-responders tramadol group: 61.5%; naproxen non-respon-
ders placebo group: 70.6%
Interventions 2 phases, and we evaluated the 8-week double-blind phase. Participants whose pain did
not resolve with 500 mg of naproxen were randomized. Randomization was stratified
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based on response to naproxen 1000 mg (responders and non-responders)
Active group: tramadol plus naproxen for 54 days.
Control group: placebo plus naproxen for 54 days.
During the double-blind phase the naproxen dose was reduced to 250 mg every 2 weeks.
Dosage of tramadol (200 mg/day) or placebo remained constant during the double-blind
phase
Outcomes Primary aim to determine whether tramadol decreased naproxen requirements. No data
on PI during the double-blind phase. Number of participants who discontinued therapy
due to adverse events was reported
Pain data not reported for double-blind phase
Physical function data not reported for double-blind phase
Notes Supported by research grant from Ortho-McNeil Pharmaceutical, Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The randomization was stratified
based on the patient’s baseline VAS score”
(p.1371)
Unknown if the sequence was computer-
generated. No mention of sequence gener-
ation
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel High risk Quote: “During the 8-week double-blind
phase, the initial dosage of naproxen in the
double-blind phase was 750 mg/day. This
dosage was reduced by 250 mg every two
weeks. The naproxen dosage reduction was
accomplished in a single-blind manner (i.
e. the patients did not know what dosage of
naproxen they were receiving). The dosage
of tramadol or placebo remained constant
during the double-blind phase.” (p.1372)
Authors did not describe blinding of per-
sonnel, and the quote provided above sug-
gests that they may have known which par-
ticipants were taking naproxen once the
dosage started being reduced
Blinding of participants Low risk Quote: “patients were randomly assigned
to treatment with tramadol 200 mg/day or
matching placebo” (p.1372)
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Personnel interacting with participants
with regard to outcome assessment were
not explicitly reported to be blinded
Incomplete outcome data for pain and
physical function
Low risk Quote: “Four patients (3 taking tramadol,
1 taking placebo) were randomized but
were not included in the efficacy analysis
because they did not have an efficacy assess-
ment or they did not take the study medi-
cation. A total of 236 patients were evalu-
ated.” (p.1373)
236/240 randomized participants were an-
alyzed for benefits. % withdrawals due to
adverse events: 22% with tramadol vs 13%
with placebo. Total number of withdrawals
in each treatment group unknown
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “Twenty-two percent of tramadol
patients and 13% of placebo patients dis-
continued due to an adverse event during
the double-blind phase.” (p.1374)
Outcome data for withdrawals due to ad-
verse events were likely included in the
analysis since there were only 4 participants
in total not included in the benefits analysis
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain) appeared
to have been reported in the results, but
we did not have access to the protocol for
verification
Other biases Low risk No other sources of bias.
Silverfield 2002
Methods Parallel, multicenter, double-blind RCT
Participants Participants ages 35-75 years with symptomatic OA of hip or knee received stable doses
of NSAID or COX-2
Number of participants: tramadol/acetaminophen group: 197; control group: 111
% women: active group: 76.6%; control group: 63.1%
Interventions Active group: tramadol 37.5 mg/acetaminophen 325 mg 1 or 2 pills QID
Control group: placebo
Treatment for 10 days in addition to ongoing NSAID or COX-2-selective inhibitor
therapy
Number of pills/day increased up to 8. Participants continued receiving NSAID or COX-
2 at the same doses taken before study entry
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Outcomes PI and pain relief evaluated using a 4-point adjective scale (none, mild, moderate, severe)
% participants in each relief category
WOMAC Index score
Participants who received tramadol had less pain than participants who received placebo
(data not used in the pooling because of 4-point scale)
Extracted pain outcome: WOMAC Pain subscale (0-5) at 10 days, with lower values
indicating benefit
Extracted physical function outcome: WOMAC Physical Function subscale (0.5) at 10
days, with lower values indicating benefit
Notes We contacted 1 of the coauthors and obtained the requested information (percentage of
participants with moderate pain relief )
Funding source not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were assigned sequentially
according to a randomization schedule” (p.
286)
Quote: “A list of unique medication code
numbers was prepared using a computerized
random-number generator to ensure that any
given patient was assigned randomly to 1 of
3 initial treatment groups.” (p.286)
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Low risk Quote: “Treatment assignments were not re-
vealed to patients, investigators, clinical staff,
or monitors until all patients had completed
treatment and database was finalized.” (p.
286)
Blinding of participants Low risk Quote: “Study medication consisted of iden-
tical-appearing tablets containing tramadol/
acetaminophen or matching placebo.” (p.
286)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Treatment assignments were not re-
vealed to patients, investigators, clinical staff,
or monitors until all patients had completed
treatment and database was finalized.” (p.
286)
Incomplete outcome data for pain and
physical function
High risk Quote: “Efficacy summaries were based on
the intent-to-treat population, defined as all
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patients randomized to receive study medi-
cation who took at least 1 dose and had post
randomization efficacy data. Safety sum-
maries were based on all randomized patients
who took at least 1 dose of study medication.
” (p.287)
Quote: “If a patient dropped out within
the first 4 hours after taking the first dose,
the baseline-observation-carried forward ap-
proach was used to impute missing pain as-
sessments. All other missing assessments were
imputed using the last-observation-carried-
forward approach.” (p.287)
All randomized participants were included
in ITT analysis and were evaluable for sa-
fety. Withdrawals due to adverse events: 12.
7% (25/197) with tramadol vs 5.4% (6/
111) with placebo. Withdrawals for reasons
other than adverse events (discontinued pre-
maturely, lack of efficacy, protocol violations,
other): 7.6% (15/197) with tramadol vs 0%
with placebo. Last or baseline observations
carried forward are hardly adequate imputa-
tion techniques. In addition, there was differ-
ential dropout since the adverse events pre-
dominantly occurred in the tramadol group
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “Efficacy summaries were based on
the intent-to-treat population, defined as all
patients randomized to receive study medi-
cation who took at least 1 dose and had post
randomization efficacy data. Safety sum-
maries were based on all randomized patients
who took at least 1 dose of study medication.
” (p.287)
Quote: “If a patient dropped out within
the first 4 hours after taking the first dose,
the baseline-observation-carried forward ap-
proach was used to impute missing pain as-
sessments. All other missing assessments were
imputed using the last-observation-carried-
forward approach.” (p.287)
All randomized participants were included
in ITT analysis and were evaluable for sa-
fety. Withdrawals due to adverse events: 12.
7% (25/197) with tramadol vs 5.4% (6/
111) with placebo. Withdrawals for reasons
other than adverse events (discontinued pre-
maturely, lack of efficacy, protocol violations,
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other): 7.6% (15/197) with tramadol vs 0%
with placebo. Last or baseline observations
carried forward are hardly adequate imputa-
tion techniques. In addition, there was differ-
ential dropout since the adverse events pre-
dominantly occurred in the tramadol group
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical
function, and WOMAC Index score) ap-
peared to have been reported in the results,
but we did not have access to the protocol
for verification
Other biases Low risk No other sources of bias.
Thorne 2008
Methods Randomized, double-blind, cross-over RCT
Setting: clinic
Participants 100 participants (45 men and 55 non-pregnant, non-nursing women) ages ≥ 18 years,
diagnosed with OA and requiring the use of acetaminophen, anti-inflammatory agents
or combination opioid and non-opioid analgesics for ≥ 3 months
77/100 randomly assigned participants (36 men and 41 women with a mean age 59.4
(SD 9.6) years were evaluable for efficacy of the 8-week cross-over study
Interventions Active group: conventional release tramadol 150 mg/day
Control group: placebo
Treatment was titrated weekly to 200 mg, 300 mg or a maximum of 400 mg once daily
over 4 weeks, at which point participants were crossed over to the alternate treatment
for another 4 weeks. Analgesic washout for 2-4 days except acetaminophen before start
of randomly selected treatment
Outcomes Pain: PI in a diary, twice per day (08:00 and 20:00), using 5-point ordinal scale (0 =
none, 1 = mild, 2 = moderate, 3 = severe, 4 = excruciating) and 100-mm VAS bounded
by ’no pain’ and ’excruciating pain.’ PI over the previous 24 hours and over the previous
week was assessed using the 100-mm VAS and 5-point ordinal scales. WOMAC Pain,
Stiffness and Physical Function subscales
Other: pain-related disability using the PDI, which consists of 7 × 11-point ordinal
subscales. Impact of pain on sleep (since the last evaluation) assessed with 8-item Pain
and Sleep Questionnaire. SF-36 benefits of treatment assessed by participant and in-
vestigator using a 4-point categorical scale (not effective, slightly effective, moderately
effective, highly effective). Overall treatment phase preference assessed by participant
and investigator at end of study, without unblinding the treatment allocation, clinical
benefit and adverse events
No extractable pain or physical function outcomes as it appeared that authors combined
time periods for this cross-over study
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Notes Funding source not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized treatment phase.” (p.
95)
Quote: “All patients were randomly as-
signed to receive either active or placebo
CR tramadol.” (p.95)
No mention of how the randomization
process was carried out.
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Blinding of personnel Low risk Quote: “Both patients and investigators
rated CR tramadol in a blinded manner…”
(p.100)
Blinding of participants Low risk Quote: “Medications included oral CR tra-
madol 150 mg, 200 mg, 300 mg and 400
mg tablets and matching placebo tablets.”
(p.95)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Overall treatment phase prefer-
ence was assessed by the patient and the
investigator at the end of the study, with-
out unblinding the treatment allocation, by
answering the question: ’Which treatment
period did you prefer in the management
of your pain?’ (treatment period 1; treat-
ment period 2; no preference).” (p.95)
Incomplete outcome data for pain and
physical function
Low risk Quote: “The full analysis set (intent-to-
treat [ITT]) was used to confirm the re-
sults of the primary efficacy variables, the
WOMAC and overall treatment prefer-
ence.” (p.96)
Quote: “Seventy seven patients (36 men,
41 women) were evaluable for efficacy (Fig-
ure 1), with an average age of 59.4 ± 9.6
years and a mean weight and height of 91.0
± 21.4 kg and 167 ± 10.9 cm, respectively.
” (p.96)
Composite scores for pain and physical
function of the WOMAC Osteoarthritis
Index reported. 75/100 participants com-
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Thorne 2008 (Continued)
pleted full 8 weeks of treatment. In Phase
1, % withdrawals due to reasons other than
adverse events: 8% with tramadol vs 6%
with placebo
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “The full analysis set (intent-to-
treat [ITT]) was used to confirm the re-
sults of the primary efficacy variables, the
WOMAC and overall treatment prefer-
ence.” (p.96)
Quote: “Seventy seven patients (36 men,
41 women) were evaluable for efficacy (Fig-
ure 1), with an average age of 59.4 ± 9.6
years and a mean weight and height of 91.0
± 21.4 kg and 167 ± 10.9 cm, respectively.
” (p.96)
Composite scores for pain and physical
function of the WOMAC Osteoarthritis
Index reported. 75/100 participants com-
pleted full 8 weeks of treatment. In Phase
1, % withdrawals due to reasons other than
adverse events: 8% with tramadol vs 6%
with placebo
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, physical
function and stiffness, and sleep quality)
appeared to have been reported in the re-
sults, but we did not have access to the pro-
tocol for verification
Other biases Low risk No other sources of bias detected.
Was use of a cross-over design appropriate?
Yes, OA was stable
Was it clear that the order of receiving treat-
ments was randomized? Unclear, random-
ized but no details on randomization pro-
cedure
Can it be assumed that the trial was not
biased from carry-over effects? Yes, 2-7-day
washout (tramadol can take about a day
and a half for the drug to completely exit
the body)
Are unbiased data available? Yes, paired t-
test and tested for carry-over effect which
was not statistically significant
*We did not combine the data for pain or
physical function outcomes since the au-
thors combined time periods for this cross-
over study
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Wilder-Smith 2001
Methods Open-label, randomized, parallel-group study
Setting: Groote Schuur Hospital Rheumatology Department outpatient clinic
Participants Over 6 months, investigators recruited 95 participants with OA awaiting hip or knee
replacement surgery. 8 of these dropped out. Data from 29 participants with dihy-
drocodeine, 28 with tramadol and 30 with control with NSAIDs only were completely
evaluable. Ages 55-65 years
% women: dihydrocodeine group: 31%; tramadol group: 29%; NSAID-only group:
37%
Interventions Participants were hospitalized for dose titration for the first 4 days
Active group 1: tramadol 100 mg
Active group 2: dihydrocodeine 60 mg every 12 hours
Control group: NSAID control
The corresponding immediate-release drug solution (tramadol: 100 mg/mL and dihy-
drocodeine: 10 mg/mL) was used for dose titration and breakthrough pain. Adaptations
of study drug doses during the 1-month treatment period were performed as required
Outcomes PI at rest and with movement using a 4-point adjective scale
Extracted pain outcome: pain on movement (0-3 scale) for 28 days, with lower values
indicating benefit
Physical function outcomes not reported
Notes We contacted the author to determine the percentage of participants with minor and
major adverse events, but obtained no response
Supported by research funds from Gr nenthal AG, Switzerland and Gr nenthal GmbH,
Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “randomised using a computer-
generated code list kept by the hospital
pharmacy.” (p.24)
Quote: “Sixty successive patients (…) were
recruited for the opioid trial.” (p.24)
Quote: “Thirty additional successive pa-
tients from the same department with os-
teoarthritis and NSAID treatment, but
mean pain intensity below 3 in the VRS
[verbal rating scale] in the run-in period
were included for comparison (NSAID-
only control arm).” (p.24)
Only the treatment group was randomized.
Control group was specifically chosen for
their low disease activity to compare against
the treatment group
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Wilder-Smith 2001 (Continued)
Allocation concealment (selection bias) High risk No mention of allocation concealment.
Blinding of personnel High risk Quote: “Due to open label design investi-
gators were not blinded to treatment.” (p.
24)
Blinding of participants High risk Trial described as open.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Investigators interacting with participants
were not blinded, and participant blinding
was not described
Incomplete outcome data for pain and
physical function
Low risk Quote: “95 patients were recruited for this
study. There were eight drop-outs. The rea-
sons for drop-out were: ’too busy’ (n = 2)
, ’no transport to hospital’ (2), ’poor com-
pliance during dosing’ (2), and two were
lost to follow-up.” (pp.25-26)
Unknown if missing outcome data for
dropouts were imputed. Although the rea-
son for participants lost to follow-up was
not mentioned, only 2/95 (2.1%) partic-
ipants fell into this category so it is rea-
sonable to assume that their missing data
would not significantly alter the overall out-
come assessment
Incomplete outcome data for adverse ef-
fects
All outcomes
Low risk Quote: “95 patients were recruited for this
study. There was eight drop-outs. The rea-
sons for drop-out were: ’too busy’ (n = 2)
, ’no transport to hospital’ (2), ’poor com-
pliance during dosing’ (2), and two were
lost to follow-up.” (pp.25-26)
Unknown if missing outcome data for
dropouts were imputed. Although the rea-
son for participants lost to follow-up was
not mentioned, only 2/95 (2.1%) partic-
ipants fell into this category so it is rea-
sonable to assume that their missing data
would not significantly alter the overall out-
come assessment
Selective reporting (reporting bias) Unclear risk All prespecified outcomes (pain, sleep qual-
ity, physiologic tests, and sensory tests) ap-
peared to have been reported in the results,
but we did not have access to the protocol
for verification
Other biases Low risk No other sources of bias.
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ACR: American College of Rheumatology; ARCI: Addiction Research Center Inventory; COX: cyclo-oxygenase; CPSI: Chronic Pain
Sleep Inventory; CR: controlled release; EQ-VAS: EuroQol visual analog scale; ER: extended release; IL: interleukin; ITT: intention
to treat; n: number of participants; NRS: numerical rating scale; NSAID: non-steroidal anti-inflammatory drug; OA: osteoarthritis;
PDI: Pain and Disability Index; PDQ: Physical Dependence Questionnaire; PI: pain intensity; PI-NRS: Pain Intensity - Numerical
Rating Scale; RCT: randomized controlled trial; SF-36: 36-item Short Form; SR: sustained release; TTMP: time to develop moderate
pain; TTSP: time to develop severe pain; TWA: time-weighted average; VAS: visual analog scale; WOMAC: Western Ontario and
McMaster Universities Arthritis Index.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adams 2006 Data not presented separately for people with osteoarthritis
Argoff 2009 Narrative review
Avouac 2007 Meta-analysis
Choi 2007 Titration study
Di Lorenzo 2010 Non-randomized
Estrada 2006 Osteoarthritis not evaluated.
Estrada 2007 Osteoarthritis not evaluated.
Florete 2008 Post-hoc analyses of an included trial (Gana, 2006)
Grupo Empresarial Químico-Farmacéutico 2010 Not an RCT.
Mariconti 2008 Pain not evaluated.
McMahon 2008 Review of evidence, not single RCT
McMeniman 2010 Osteoarthritis not evaluated.
Olaya 2011 Osteoarthritis not evaluated.
Pascual 2007 Data not presented separately for people with osteoarthritis
Rauck 2006 RCT but evaluated osteoarthritis and other pain syndromes and results not re-
ported separately
Stitik 2006 Review of evidence, not single RCT
Turhano lu 2010 Tramadol iontophoresis
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(Continued)
Vorsanger 2007 Post-hoc analyses of an included trial (Gana, 2006)
RCT: randomized controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
EUCTR2014-004718-27-PL
Methods Title: a study comparing the effectiveness and safety of tramadol and micronized magnesium lactate as functional
excipient to tramadol alone for the treatment of moderate to severe pain due to osteoarthritis (OA)
Randomized, multicenter, single-blinded, parallel-group study that seeks to assess the efficacy, safety and tolerability
of the combination of IR tramadol with micronized magnesium lactate in managing chronic pain in people with OA
of the hip or knee, or both
Participants Adults with clinical diagnosis of OA of hip or knee (or both), based on ACR and radiographic criteria (presence of
knee or hip joint symptoms (pain, stiffness, disability) and signs (bony crepitus), and radiographic evidence of OA
(functional class I-III))
Inclusion criteria
1. Men (not less than 35% of all participants) and women aged 18-75 years (with negative pregnancy test at
baseline) of non-childbearing potential or if of childbearing potential, using a medically acceptable form of
contraception
2. Baseline numeric rating scale PI score NRS-11 = 4 (at day 1) before randomization to study treatments.
3. Suboptimal response to non-opioid treatment as judged by investigator
4. Willing to withhold any medicines that may interfere with tramadol metabolism for 2 weeks prior to start of
the study and continue to withhold them during treatment periods.
Interventions Non-inferiority study. Main objective is to evaluate efficacy, safety and tolerability of the new formulation composed
of tramadol 50 mg and micronized magnesium lactate 75 mg of magnesium ions in the application of daily dose
tramadol 150 mg/magnesium lactate 225 mg for the management of chronic pain. Secondary objective is to assess
acceptance during disease treatment and to collect data on quality of life and the impact on the economy (cost-
effectiveness analysis and cost utility analysis)
Outcomes Major outcome
1. PI: change between baseline (V1) to end of treatment (V4 or the day of discontinuation) of PI measured on
11-point PI-NRS that is achieved on the day of therapy discontinuation or at the end of the trial.
Minor outcome
1. Quality of life and impact on the economy on the day of therapy discontinuation or at the end of the trial.
Notes World Health Organization International Clinical Trials Registry Platform Main ID: EUCTR2014-004718-27-PL
URL: www.clinicaltrialsregister.eu/ctr-search/search?query=eudract number:2014-004718-27
Contact Information:
Department of Pharmacodynamics
Address: 1B Banacha Street, 02-097, Warsaw, Poland
Telephone: +4822116 61 26
Email: farmakodynamika@wum.edu.pl
Affiliation: Medical University of Warsaw
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Krebs 2017
Methods Title of publication: Design, recruitment outcomes, and sample characteristics of the Strategies for Prescribing
Analgesics Comparative Effectiveness (SPACE) trial
Pragmatic randomized comparative effectiveness trial conducted in multiple VA primary care clinics within 1 VA
healthcare system to compare benefits and harms of opioid therapy vs non-opioid medication therapy over 12 months
Participants Participants with moderate-to-severe chronic back pain or hip/knee OA pain despite analgesic therapy; participants
already receiving regular opioid therapy were excluded
Interventions Participants were randomized to receive opioid therapy or non-opioid medication therapy, for 12 months
Opioid therapy: participants first received morphine IR, hydrocodone/acetaminophen or oxycodone IR. Opioid
dosage was titrated, with adjustments made nearly every 4 weeks, to a maximum daily dosage of 100 ME mg. If
participants did not have a clear response at a daily dosage of 60 ME mg, rotation to a different opioid was considered
Non-opioid therapy: participants first received acetaminophen or an NSAID medication. Adjuvant oral therapies
were usually added to an initial regimen, but were given if first-line medications were not appropriate. Tramadol
was included in the third-line and considered only when participants did not respond to other medications or
combinations of medications. Diclofenac 1% gel was added in the last year of the trial as a first line agent or adjuvant
option when oral NSAIDs could not be used
In both groups, pain medication management was tailored to participant preferences
Outcomes evaluated by masked assessors at 3, 6, 9 and 12 months after enrollment
Outcomes Among the 265 enrolled participants, 25 withdrew before randomization. Of 240 randomized participants, 87.9%
were men, 84.1% were white and age range was 21-80 years
Major outcomes
1. Pain using the BPI interference scale, a 7-item measure of pain-related function. The main measure of PI is the
BPI severity scale.
2. Adverse events using a modified adverse symptom checklist that assessed number and severity of common
symptoms and participants’ beliefs about whether symptoms occurred due to treatment.
Minor outcomes
1. Hospitalizations
2. Emergency room visits
3. Falls
Notes Protocol outlined here: Krebs EE, Jensen AC, Nugent S, DeRonne B, Rutks I, Leverty D, Gravely A, Noorbaloochi
S, Bair MJ, Kroenke K. Design, recruitment outcomes, and sample characteristics of the Strategies for Prescribing
Analgesics Comparative Effectiveness (SPACE) trial. Contemporary Clinical Trials. 201;62:130-9
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NCT00426647
Methods Official title: a randomised double-blind multicentre equivalence study with active parallel comparator group to
evaluate the efficacy and safety of Norspan® patches versus tramadol in subjects with chronic, moderate to severe
osteoarthritis pain in the hip, knee &/or lumbar spine
Randomized, double-blind, multicenter equivalence study with active comparator, parallel group, to evaluate the
efficacy and safety of Norspan® patches vs tramadol in people with OA pain in hip, knee, lumbar spine, or a
combination of these, currently receiving suboptimal analgesic treatment (defined as BS-11 score > 4) when treated
with acetaminophen 4000 mg/day or another analgesic at least comparable to this
4 phases: run-in, washout, double-blind and follow-up
Participants Diagnosed with OA pain in hip, knee, lumbar spine, or a combination of these and aged ≥ 18 years
Interventions Tramadol
Buprenorphine
Outcomes Major outcome: efficacy of Norspan®
Minor outcome: safety and general satisfaction
Notes Study start date: February 2007
Primary completion date: July 2009
Study completion date: August 2009
Contact information:
Address: GP, Noerretorv 10, DK-7200 Grindsted, Denmark, Olavi, Airaksinen DM (principal investigator), Oma
Lääkäri Oy, Vuorikatu 20, FIN-70100 KUOPIO
Email: olavi.airaksinen@kuh.fi
Email: norpharma@norpharma.dk
ClinicalTrials.gov identifier: NCT00426647
NCT00736853
Methods Official title: a phase 3 study of JNS013 in patients with chronic pain
Multicenter, double-blind, placebo-controlled, parallel-group comparison study. Total duration will be 11 weeks and
consists of 4 periods; a preobservation period (4 weeks), open-label period (2 weeks), double-blind period (4 weeks)
and follow-up period (1 week). Participants will receive tramadol hydrochloride plus acetaminophen pills orally 4
times/day for 2 weeks at ≥ 4-hour intervals (up to 8 pills/day) during the open-label period and the dose will be fixed
for each participant in the latter 1 week. During the double-period participants will receive tramadol hydrochloride
plus acetaminophen pills or placebo at the same dose as used for the latter 1 week of the open-label period for up to
4 weeks. Efficacy will be primarily evaluated by number of participants with insufficient pain relief after the start of
double-blind period. Participant’s safety will be monitored throughout the study
Participants Participants with sustention of chronic pain associated with OA or LBP for ≥ 3 months and aged ≥ 20 years
Interventions Tramadol 37.5 mg and acetaminophen 325 mg 4 times/day or placebo, for 4 weeks
Outcomes Major outcome
1. Number of participants with insufficient pain relief after the start of double-blind period
Minor outcomes
1. Change in VAS24 at start of double-blind period from baseline value at the start of open-label period
2. Change in VAS24 from baseline at the final time point of the double-blind period
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NCT00736853 (Continued)
3. Mean PI score during open-label period
4. Mean PI score during double-blind period
5. Mean PID during open-label period
6. Mean PID during double-blind period
7. Mean pain relief score during open-label period
8. Mean pain relief score during double-blind period
9. PID and pain relief scores during open-label period
10. PID and pain relief scores during double-blind period
Notes Study start date: June 2008
Primary completion date: January 2009
Study completion date: January 2009
Contact information:
Address: Paranaque City, Metro Manila, Philippines, 1700
Email: info@janbe.jnj.com
Phone: +32 14 60 21 11
ClinicalTrials.gov identifier: NCT00736853
NCT00743587
Methods Official title: a randomized, double-blind, placebo and active controlled methodology study investigating the effects
of tramadol and naproxen on the pain thresholds of patients with severe pain due to osteoarthritis of the thumb
Methods not provided in detail
Allocation: randomized
Intervention model: cross-over assignment
Blinding: double (participant, investigator)
Participants Diagnosed with OA of the hand, ≥ 6 months’ duration and aged ≥ 18 years
Interventions Oxycodone 20 mg
Tramadol 50 mg
Naproxen 500 mg
Placebo
Outcomes Major outcome
1. Pressure pain threshold - area under the curve
Minor outcomes
1. Pressure pain threshold - at specific time points
2. Present pain intensities - at specific time points
Notes Study start date: September 2008
Primary completion date: March 2009
Study completion date: March 2009
Contact information:
Address: Pfizer Investigational Site, Brussels, Belgium, 1070
Email: www.pfizer.com/contact/email contact?inquiry=Clinical%20Research (to send an email)
Phone: 1-212-733-2323
ClinicalTrials.gov identifier: NCT00743587
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NCT00832416
Methods Study title: a four-arm study comparing the analgesic efficacy and safety of tramadol once a day 100, 200 and 300
mg versus placebo for the treatment of pain due to osteoarthritis of the knee
Methods not provided.
Participants Diagnosed with moderate to severe OA of the knee, consistent with the ACR clinical classification criteria for arthritis
of the knee, and aged 40-75 years
Interventions Tramadol 100 mg daily
Tramadol 200 mg daily
Tramadol 300 mg daily
Placebo
Outcomes Major outcomes
1. Patient global rating of pain for the study period (12 weeks)
2. Percentage difference between WOMAC Pain subscale score from baseline to end of study (week 12)
3. Percentage difference between WOMAC Physical Function subscale score from baseline to end of study (week
12)
Minor outcomes
1. Percentage difference in WOMAC Pain subscale score from baseline to intervening visits (visits 2-4)
2. Percentage difference in WOMAC Physical Function subscale score from baseline to intervening visits (visits
2-4)
3. Multiple dose effect using 24-hour VAS Pain Questionnaire
4. Investigator global rating of pain relief
5. Percentage of participants who dropped out from trial by dropout reason
Notes Study start date: January 2003
Primary completion date: August 2003
Contact information:
Address: 480 boulevard, Armand-Frappier, Laval, Québec, H7V 4B4
Email: info@labopharm.com
Phone: 450 680-2444
ClinicalTrials.gov identifier: NCT00832416
NCT01019265
Methods Official title: a randomised open label parallel group study comparing Norspan patch and oral tramadol
Primary objective of this non-inferiority study with active, parallel control group is to compare and assess efficacy
and safety of buprenorphine transdermal patch (Norspan® patch 5 mg, 10 mg and 20 mg) and tramadol (Tridol®
SR (slow release) pill 100 mg) in people with moderate to severe pain due to OA. During the period of treatment
for 8 weeks, titration and maintenance is kept up using 1:1 ratio randomization
Participants Diagnosed with OA of the hip or knee (or both) including fulfilling the ACR criteria L13 and aged ≥ 18 years
Interventions Buprenorphine 5 mg for 8 weeks
Buprenorphine 10 mg for 8 weeks
Buprenorphine 20 mg for 8 weeks
Tramadol 100 mg for 8 weeks
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NCT01019265 (Continued)
Outcomes Major outcome:
1. PI - Box Score-11 pain scale
Minor outcomes
1. WOMAC
2. Degree of sleep disturbance due to pain and improvement in quality of sleep
3. Incidence of early discontinuation due to lack of efficacy
Notes Study start date: March 2008
Primary completion date: March 2009
Study completion date: May 2009
Contact information: not provided
ClinicalTrials.gov identifier: NCT01019265
NCT01728246
Methods Official title: a randomized controlled trial on the efficacy, safety and quality of life effects of add-on tramadol/
acetaminophen combination in chronic osteoarthritis
Open-label, randomized controlled study to evaluate the efficacy, safety and effects on quality of life of tramadol/
acetaminophen as an add-on therapy in Filipino participants with chronic pain because of chronic OA. Participants
will be randomly assigned to 2 groups: tramadol/acetaminophen group and non-tramadol/acetaminophen group.
Participants in tramadol/acetaminophen group will receive celecoxib 200 mg and fixed-dose combination of tramadol
37.5 mg/acetaminophen 325 mg as add-on therapy, and participants in non-tramadol/acetaminophen group will
receive celecoxib 200 mg only. Total duration of study will be 4 weeks. Participants in both groups will be given
celecoxib 200 mg once daily for 4 weeks. In addition, participants in the tramadol/acetaminophen group will be
given add-on tramadol/acetaminophen doses 3 times/day for 4 weeks. Participants will be asked to return for follow-
up at weeks 2 and 4. Efficacy will be assessed using 100-mm VAS while quality of life will be assessed using the
Oswestry Disability Index. Participant safety will be monitored throughout the study
Participants Diagnosed with chronic OA of knee or hip for ≥ 1 year, and aged ≥ 18 years
Interventions Celecoxib 200 mg once daily and tramadol 37.5 mg and acetaminophen 325 mg, for 4 weeks
Celecoxib once daily and non-tramadol and acetaminophen, for 4 weeks
Outcomes Major outcomes:
1. Change from baseline in VAS for Pain score at week 2
2. Change from baseline in VAS for Pain score at week 4
3. Change from baseline in Oswestry Disability Index score at week 2
4. Change from baseline in Oswestry Disability Index score at week 4
5. Percentage of participants who discontinued because of rescue medication
6. Time to discontinuation because of rescue medication
Notes Study start date: October 2007
Primary completion date: May 2008
Study completion date: May 2008
Contact information:
Address: Paranaque City, Metro Manila, Philippines, 1700
Email: info@janbe.jnj.com
Phone: +32 14 60 21 11
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NCT01728246 (Continued)
ClinicalTrials.gov identifier: NCT01728246
ACR: American College of Rheumatology; BPI: Brief Pain Inventory; BS-11: Box Score-11; IR: immediate release; LBP: low back
pain; ME: morphine-equivalent; NRS: numerical rating scale; NSAID: non-steroidal anti-inflammatory drug; OA: osteoarthritis;
PI: pain intensity; PI-NRS: pain intensity numerical rating scale; PID: pain intensity difference; VA: Veteran Affairs; VAS24: visual
analog scale for the last 24 hours; WOMAC: Western Ontario and McMaster Universities Arthritis Index.
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D A T A A N D A N A L Y S E S
Comparison 1. Tramadol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 10 Std. Mean Difference (Fixed, 95% CI) -0.25 [-0.32, -0.19]
1.1 Tramadol alone 8 Std. Mean Difference (Fixed, 95% CI) -0.25 [-0.32, -0.18]
1.2 Tramadol in combination
with acetaminophen
2 Std. Mean Difference (Fixed, 95% CI) -0.28 [-0.45, -0.12]
2 Physical function 7 Std. Mean Difference (Fixed, 95% CI) -0.22 [-0.30, -0.14]
2.1 Tramadol alone 5 Std. Mean Difference (Fixed, 95% CI) -0.20 [-0.29, -0.12]
2.2 Tramadol in combination
with acetaminophen
2 Std. Mean Difference (Fixed, 95% CI) -0.27 [-0.43, -0.11]
3 Number of participants
experiencing any adverse events
5 2347 Risk Ratio (IV, Fixed, 95% CI) 1.36 [1.26, 1.48]
3.1 Tramadol alone 4 2039 Risk Ratio (IV, Fixed, 95% CI) 1.34 [1.24, 1.46]
3.2 Tramadol in combination
with acetaminophen
1 308 Risk Ratio (IV, Fixed, 95% CI) 1.91 [1.32, 2.76]
4 Number of participants who
withdrew due to adverse events
11 5147 Risk Ratio (IV, Fixed, 95% CI) 2.65 [2.20, 3.19]
4.1 Tramadol alone 9 4533 Risk Ratio (IV, Fixed, 95% CI) 2.64 [2.17, 3.20]
4.2 Tramadol in combination
with acetaminophen
2 614 Risk Ratio (IV, Fixed, 95% CI) 2.78 [1.50, 5.16]
5 Number of participants
experiencing any serious
adverse events
8 3627 Risk Ratio (IV, Fixed, 95% CI) 1.78 [1.11, 2.84]
5.1 Tramadol alone 7 3612 Risk Ratio (IV, Fixed, 95% CI) 1.78 [1.11, 2.84]
5.2 Tramadol in combination
with acetaminophen
1 15 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Tramadol versus active treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 10 Std. Mean Difference (Fixed, 95% CI) 0.12 [0.01, 0.22]
1.1 Tramadol alone vs
acetaminophen
1 Std. Mean Difference (Fixed, 95% CI) 0.13 [-0.80, 1.06]
1.2 Tramadol alone vs
NSAIDs
3 Std. Mean Difference (Fixed, 95% CI) 0.21 [0.07, 0.36]
1.3 Tramadol alone vs other
opioids
4 Std. Mean Difference (Fixed, 95% CI) -0.11 [-0.33, 0.12]
1.4 Tramadol in combination
with acetaminophen vs
NSAIDs
2 Std. Mean Difference (Fixed, 95% CI) 0.12 [-0.16, 0.39]
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1.5 Tramadol in combination
with acetaminophen vs other
opioids
1 Std. Mean Difference (Fixed, 95% CI) 0.06 [-0.31, 0.43]
2 Physical function 4 Std. Mean Difference (Fixed, 95% CI) 0.23 [0.09, 0.36]
2.1 Tramadol alone vs
NSAIDs
3 Std. Mean Difference (Fixed, 95% CI) 0.23 [0.09, 0.37]
2.2 Tramadol in combination
with acetaminophen vs
NSAIDs
1 Std. Mean Difference (Fixed, 95% CI) 0.2 [-0.21, 0.61]
3 Function: overall assessment 1 190 Risk Ratio (IV, Fixed, 95% CI) 1.32 [1.04, 1.68]
3.1 Tramadol alone vs other
opioids
1 190 Risk Ratio (IV, Fixed, 95% CI) 1.32 [1.04, 1.68]
4 Number of participants
experiencing any adverse even
5 663 Risk Ratio (IV, Fixed, 95% CI) 1.07 [0.96, 1.19]
4.1 Tramadol alone vs
NSAIDs
1 128 Risk Ratio (IV, Fixed, 95% CI) 1.31 [1.03, 1.67]
4.2 Tramadol alone vs other
opioids
3 438 Risk Ratio (IV, Fixed, 95% CI) 0.99 [0.87, 1.13]
4.3 Tramadol in combination
with acetaminophen vs
NSAIDs
1 97 Risk Ratio (IV, Fixed, 95% CI) 1.17 [0.87, 1.57]
5 Number of participants who
withdrew due to adverse events
6 1387 Risk Ratio (IV, Fixed, 95% CI) 2.07 [1.57, 2.73]
5.1 Tramadol alone vs
acetaminophen
1 20 Risk Ratio (IV, Fixed, 95% CI) 5.0 [0.27, 92.62]
5.2 Tramadol alone vs
NSAIDs
2 929 Risk Ratio (IV, Fixed, 95% CI) 1.88 [1.27, 2.76]
5.3 Tramadol alone vs other
opioids
3 438 Risk Ratio (IV, Fixed, 95% CI) 2.26 [1.52, 3.37]
6 Number of participants
experiencing any serious
adverse events
7 698 Risk Ratio (IV, Fixed, 95% CI) 1.31 [0.16, 10.79]
6.1 Tramadol alone vs NSAID 2 188 Risk Ratio (IV, Fixed, 95% CI) 0.21 [0.01, 4.34]
6.2 Tramadol alone vs other
opioids
4 495 Risk Ratio (IV, Fixed, 95% CI) 7.42 [0.39, 141.00]
6.3 Tramadol in combination
with acetaminophen vs
NSAIDs
1 15 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Symptoms of opioid dependence:
propensity for abuse
1 97 Risk Ratio (IV, Fixed, 95% CI) 1.03 [0.62, 1.74]
7.1 Tramadol alone vs
NSAIDs
1 97 Risk Ratio (IV, Fixed, 95% CI) 1.03 [0.62, 1.74]
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Analysis 1.1. Comparison 1 Tramadol versus placebo, Outcome 1 Pain.
Review: Tramadol for osteoarthritis
Comparison: 1 Tramadol versus placebo
Outcome: 1 Pain
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone
Babul 2004 -0.4183 (0.1289) 6.3 % -0.42 [ -0.67, -0.17 ]
Burch 2007 -0.2417 (0.0877) 13.5 % -0.24 [ -0.41, -0.07 ]
DeLemos 2011 -0.1986 (0.0818) 15.6 % -0.20 [ -0.36, -0.04 ]
Fishman 2007 -0.1873 (0.0876) 13.6 % -0.19 [ -0.36, -0.02 ]
Fleischmann 2001 -0.3451 (0.1774) 3.3 % -0.35 [ -0.69, 0.00 ]
Gana 2006 -0.2634 (0.0784) 17.0 % -0.26 [ -0.42, -0.11 ]
Kean 2009 -0.199 (0.1034) 9.7 % -0.20 [ -0.40, 0.00 ]
Malonne 2004 -0.3471 (0.1329) 5.9 % -0.35 [ -0.61, -0.09 ]
Subtotal (95% CI) 84.9 % -0.25 [ -0.32, -0.18 ]
Heterogeneity: Chi2 = 3.71, df = 7 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 7.10 (P < 0.00001)
2 Tramadol in combination with acetaminophen
Emkey 2004 -0.2585 (0.1148) 7.9 % -0.26 [ -0.48, -0.03 ]
Silverfield 2002 -0.3135 (0.1203) 7.2 % -0.31 [ -0.55, -0.08 ]
Subtotal (95% CI) 15.1 % -0.28 [ -0.45, -0.12 ]
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.43 (P = 0.00061)
Total (95% CI) 100.0 % -0.25 [ -0.32, -0.19 ]
Heterogeneity: Chi2 = 3.98, df = 9 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 7.88 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 1.2. Comparison 1 Tramadol versus placebo, Outcome 2 Physical function.
Review: Tramadol for osteoarthritis
Comparison: 1 Tramadol versus placebo
Outcome: 2 Physical function
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone
Babul 2004 -0.4183 (0.1289) 9.4 % -0.42 [ -0.67, -0.17 ]
DeLemos 2011 -0.0242 (0.0814) 23.6 % -0.02 [ -0.18, 0.14 ]
Fleischmann 2001 -0.3336 (0.1774) 5.0 % -0.33 [ -0.68, 0.01 ]
Gana 2006 -0.2542 (0.0784) 25.4 % -0.25 [ -0.41, -0.10 ]
Kean 2009 -0.2304 (0.1054) 14.1 % -0.23 [ -0.44, -0.02 ]
Subtotal (95% CI) 77.4 % -0.20 [ -0.29, -0.12 ]
Heterogeneity: Chi2 = 8.65, df = 4 (P = 0.07); I2 =54%
Test for overall effect: Z = 4.56 (P < 0.00001)
2 Tramadol in combination with acetaminophen
Emkey 2004 -0.3235 (0.1151) 11.8 % -0.32 [ -0.55, -0.10 ]
Silverfield 2002 -0.2159 (0.1199) 10.9 % -0.22 [ -0.45, 0.02 ]
Subtotal (95% CI) 22.6 % -0.27 [ -0.43, -0.11 ]
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.27 (P = 0.0011)
Total (95% CI) 100.0 % -0.22 [ -0.30, -0.14 ]
Heterogeneity: Chi2 = 9.57, df = 6 (P = 0.14); I2 =37%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.50, df = 1 (P = 0.48), I2 =0.0%
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Analysis 1.3. Comparison 1 Tramadol versus placebo, Outcome 3 Number of participants experiencing any
adverse events.
Review: Tramadol for osteoarthritis
Comparison: 1 Tramadol versus placebo
Outcome: 3 Number of participants experiencing any adverse events
Study or subgroup Tramadol Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone
Babul 2004 98/124 78/122 24.4 % 1.24 [ 1.05, 1.45 ]
Fishman 2007 217/325 116/227 28.8 % 1.31 [ 1.13, 1.52 ]
Gana 2006 614/806 114/205 38.6 % 1.37 [ 1.20, 1.56 ]
Malonne 2004 50/111 23/119 3.6 % 2.33 [ 1.53, 3.55 ]
Subtotal (95% CI) 1366 673 95.4 % 1.34 [ 1.24, 1.46 ]
Total events: 979 (Tramadol), 331 (Placebo)
Heterogeneity: Chi2 = 7.83, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 7.07 (P < 0.00001)
2 Tramadol in combination with acetaminophen
Silverfield 2002 88/197 26/111 4.6 % 1.91 [ 1.32, 2.76 ]
Subtotal (95% CI) 197 111 4.6 % 1.91 [ 1.32, 2.76 ]
Total events: 88 (Tramadol), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.41 (P = 0.00064)
Total (95% CI) 1563 784 100.0 % 1.36 [ 1.26, 1.48 ]
Total events: 1067 (Tramadol), 357 (Placebo)
Heterogeneity: Chi2 = 11.13, df = 4 (P = 0.03); I2 =64%
Test for overall effect: Z = 7.64 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.30, df = 1 (P = 0.07), I2 =70%
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Analysis 1.4. Comparison 1 Tramadol versus placebo, Outcome 4 Number of participants who withdrew
due to adverse events.
Review: Tramadol for osteoarthritis
Comparison: 1 Tramadol versus placebo
Outcome: 4 Number of participants who withdrew due to adverse events
Study or subgroup Tramadol Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone
Babul 2004 33/124 9/122 7.1 % 3.61 [ 1.80, 7.22 ]
Burch 2007 44/431 11/214 8.4 % 1.99 [ 1.05, 3.77 ]
DeLemos 2011 132/599 15/200 13.2 % 2.94 [ 1.77, 4.89 ]
Fishman 2007 68/325 17/227 13.5 % 2.79 [ 1.69, 4.62 ]
Fleischmann 2001 14/63 10/66 6.4 % 1.47 [ 0.70, 3.06 ]
Gana 2006 183/806 21/205 19.0 % 2.22 [ 1.45, 3.39 ]
Kean 2009 102/405 14/280 11.9 % 5.04 [ 2.94, 8.62 ]
Malonne 2004 24/111 1/119 0.9 % 25.73 [ 3.54, 187.02 ]
Schnitzer 1999 25/114 16/122 10.5 % 1.67 [ 0.94, 2.97 ]
Subtotal (95% CI) 2978 1555 91.0 % 2.64 [ 2.17, 3.20 ]
Total events: 625 (Tramadol), 114 (Placebo)
Heterogeneity: Chi2 = 17.92, df = 8 (P = 0.02); I2 =55%
Test for overall effect: Z = 9.77 (P < 0.00001)
2 Tramadol in combination with acetaminophen
Emkey 2004 20/153 6/153 4.4 % 3.33 [ 1.38, 8.07 ]
Silverfield 2002 25/197 6/111 4.6 % 2.35 [ 0.99, 5.55 ]
Subtotal (95% CI) 350 264 9.0 % 2.78 [ 1.50, 5.16 ]
Total events: 45 (Tramadol), 12 (Placebo)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0011)
Total (95% CI) 3328 1819 100.0 % 2.65 [ 2.20, 3.19 ]
Total events: 670 (Tramadol), 126 (Placebo)
Heterogeneity: Chi2 = 18.26, df = 10 (P = 0.05); I2 =45%
Test for overall effect: Z = 10.30 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 1.5. Comparison 1 Tramadol versus placebo, Outcome 5 Number of participants experiencing any
serious adverse events.
Review: Tramadol for osteoarthritis
Comparison: 1 Tramadol versus placebo
Outcome: 5 Number of participants experiencing any serious adverse events
Study or subgroup Tramadol Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone
Babul 2004 0/124 0/122 Not estimable
Burch 2007 9/431 1/214 5.2 % 4.47 [ 0.57, 35.04 ]
DeLemos 2011 83/599 14/200 74.3 % 1.98 [ 1.15, 3.41 ]
Fishman 2007 2/325 2/227 5.7 % 0.70 [ 0.10, 4.92 ]
Fleischmann 2001 0/63 2/66 2.4 % 0.21 [ 0.01, 4.28 ]
Gana 2006 16/806 2/205 10.3 % 2.03 [ 0.47, 8.78 ]
Malonne 2004 0/111 1/119 2.2 % 0.36 [ 0.01, 8.68 ]
Subtotal (95% CI) 2459 1153 100.0 % 1.78 [ 1.11, 2.84 ]
Total events: 110 (Tramadol), 22 (Placebo)
Heterogeneity: Chi2 = 4.74, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
2 Tramadol in combination with acetaminophen
Peeva 2010 0/8 0/7 Not estimable
Subtotal (95% CI) 8 7 Not estimable
Total events: 0 (Tramadol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2467 1160 100.0 % 1.78 [ 1.11, 2.84 ]
Total events: 110 (Tramadol), 22 (Placebo)
Heterogeneity: Chi2 = 4.74, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Tramadol versus active treatment, Outcome 1 Pain.
Review: Tramadol for osteoarthritis
Comparison: 2 Tramadol versus active treatment
Outcome: 1 Pain
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone vs acetaminophen
Bianchi 2003 0.1295 (0.4748) 1.3 % 0.13 [ -0.80, 1.06 ]
Subtotal (95% CI) 1.3 % 0.13 [ -0.80, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
2 Tramadol alone vs NSAIDs
Beaulieu 2008 0.0386 (0.2036) 7.0 % 0.04 [ -0.36, 0.44 ]
DeLemos 2011 0.2695 (0.0816) 43.4 % 0.27 [ 0.11, 0.43 ]
Pavelka 1998 -0.1081 (0.2724) 3.9 % -0.11 [ -0.64, 0.43 ]
Subtotal (95% CI) 54.3 % 0.21 [ 0.07, 0.36 ]
Heterogeneity: Chi2 = 2.60, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 2.92 (P = 0.0036)
3 Tramadol alone vs other opioids
Bird 1995 0 (0.2582) 4.3 % 0.0 [ -0.51, 0.51 ]
Jensen 1994 -0.4263 (0.2807) 3.7 % -0.43 [ -0.98, 0.12 ]
Karlsson 2009 -0.0799 (0.1729) 9.7 % -0.08 [ -0.42, 0.26 ]
Wilder-Smith 2001 0 (0.2649) 4.1 % 0.0 [ -0.52, 0.52 ]
Subtotal (95% CI) 21.8 % -0.11 [ -0.33, 0.12 ]
Heterogeneity: Chi2 = 1.65, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
4 Tramadol in combination with acetaminophen vs NSAIDs
Fujii 2014 -0.04 (0.19) 8.0 % -0.04 [ -0.41, 0.33 ]
Park 2012 0.31 (0.21) 6.6 % 0.31 [ -0.10, 0.72 ]
Subtotal (95% CI) 14.6 % 0.12 [ -0.16, 0.39 ]
Heterogeneity: Chi2 = 1.53, df = 1 (P = 0.22); I2 =35%
Test for overall effect: Z = 0.83 (P = 0.40)
5 Tramadol in combination with acetaminophen vs other opioids
Fujii 2014 0.06 (0.19) 8.0 % 0.06 [ -0.31, 0.43 ]
Subtotal (95% CI) 8.0 % 0.06 [ -0.31, 0.43 ]
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 100.0 % 0.12 [ 0.01, 0.22 ]
Heterogeneity: Chi2 = 11.38, df = 10 (P = 0.33); I2 =12%
Test for overall effect: Z = 2.15 (P = 0.031)
Test for subgroup differences: Chi2 = 5.60, df = 4 (P = 0.23), I2 =29%
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Analysis 2.2. Comparison 2 Tramadol versus active treatment, Outcome 2 Physical function.
Review: Tramadol for osteoarthritis
Comparison: 2 Tramadol versus active treatment
Outcome: 2 Physical function
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone vs NSAIDs
Beaulieu 2008 0.061778 (0.2036483) 11.5 % 0.06 [ -0.34, 0.46 ]
DeLemos 2011 0.310646 (0.081732) 71.4 % 0.31 [ 0.15, 0.47 ]
Pavelka 1998 -0.381456 (0.274629) 6.3 % -0.38 [ -0.92, 0.16 ]
Subtotal (95% CI) 89.2 % 0.23 [ 0.09, 0.37 ]
Heterogeneity: Chi2 = 6.61, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 3.14 (P = 0.0017)
2 Tramadol in combination with acetaminophen vs NSAIDs
Park 2012 0.2 (0.21) 10.8 % 0.20 [ -0.21, 0.61 ]
Subtotal (95% CI) 10.8 % 0.20 [ -0.21, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Total (95% CI) 100.0 % 0.23 [ 0.09, 0.36 ]
Heterogeneity: Chi2 = 6.63, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 2.3. Comparison 2 Tramadol versus active treatment, Outcome 3 Function: overall assessment.
Review: Tramadol for osteoarthritis
Comparison: 2 Tramadol versus active treatment
Outcome: 3 Function: overall assessment
Study or subgroup Tramadol Active control Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone vs other opioids
Jensen 1994 54/81 55/109 100.0 % 1.32 [ 1.04, 1.68 ]
Total (95% CI) 81 109 100.0 % 1.32 [ 1.04, 1.68 ]
Total events: 54 (Tramadol), 55 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Tramadol versus active treatment, Outcome 4 Number of participants
experiencing any adverse even.
Review: Tramadol for osteoarthritis
Comparison: 2 Tramadol versus active treatment
Outcome: 4 Number of participants experiencing any adverse even
Study or subgroup Tramadol Active control Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone vs NSAIDs
Beaulieu 2008 48/62 39/66 19.8 % 1.31 [ 1.03, 1.67 ]
Subtotal (95% CI) 62 66 19.8 % 1.31 [ 1.03, 1.67 ]
Total events: 48 (Tramadol), 39 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
2 Tramadol alone vs other opioids
Bird 1995 9/20 16/20 4.1 % 0.56 [ 0.33, 0.96 ]
Jensen 1994 75/135 41/129 13.4 % 1.75 [ 1.30, 2.35 ]
Karlsson 2009 51/65 61/69 49.2 % 0.89 [ 0.76, 1.03 ]
Subtotal (95% CI) 220 218 66.7 % 0.99 [ 0.87, 1.13 ]
Total events: 135 (Tramadol), 118 (Active control)
Heterogeneity: Chi2 = 20.61, df = 2 (P = 0.00003); I2 =90%
Test for overall effect: Z = 0.17 (P = 0.86)
3 Tramadol in combination with acetaminophen vs NSAIDs
Park 2012 33/47 30/50 13.5 % 1.17 [ 0.87, 1.57 ]
Subtotal (95% CI) 47 50 13.5 % 1.17 [ 0.87, 1.57 ]
Total events: 33 (Tramadol), 30 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI) 329 334 100.0 % 1.07 [ 0.96, 1.19 ]
Total events: 216 (Tramadol), 187 (Active control)
Heterogeneity: Chi2 = 25.06, df = 4 (P = 0.00005); I2 =84%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Chi2 = 4.44, df = 2 (P = 0.11), I2 =55%
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Analysis 2.5. Comparison 2 Tramadol versus active treatment, Outcome 5 Number of participants who
withdrew due to adverse events.
Review: Tramadol for osteoarthritis
Comparison: 2 Tramadol versus active treatment
Outcome: 5 Number of participants who withdrew due to adverse events
Study or subgroup Tramadol Active control Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone vs acetaminophen
Bianchi 2003 2/10 0/10 0.9 % 5.00 [ 0.27, 92.62 ]
Subtotal (95% CI) 10 10 0.9 % 5.00 [ 0.27, 92.62 ]
Total events: 2 (Tramadol), 0 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Tramadol alone vs NSAIDs
Beaulieu 2008 10/62 10/66 11.8 % 1.06 [ 0.48, 2.38 ]
DeLemos 2011 132/599 20/202 39.0 % 2.23 [ 1.43, 3.46 ]
Subtotal (95% CI) 661 268 50.8 % 1.88 [ 1.27, 2.76 ]
Total events: 142 (Tramadol), 30 (Active control)
Heterogeneity: Chi2 = 2.48, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 3.18 (P = 0.0015)
3 Tramadol alone vs other opioids
Bird 1995 4/20 6/20 6.3 % 0.67 [ 0.22, 2.01 ]
Jensen 1994 48/135 14/129 25.8 % 3.28 [ 1.90, 5.65 ]
Karlsson 2009 19/65 10/69 16.2 % 2.02 [ 1.01, 4.01 ]
Subtotal (95% CI) 220 218 48.3 % 2.26 [ 1.52, 3.37 ]
Total events: 71 (Tramadol), 30 (Active control)
Heterogeneity: Chi2 = 6.60, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 4.02 (P = 0.000057)
Total (95% CI) 891 496 100.0 % 2.07 [ 1.57, 2.73 ]
Total events: 215 (Tramadol), 60 (Active control)
Heterogeneity: Chi2 = 9.87, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 5.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.79, df = 2 (P = 0.67), I2 =0.0%
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Analysis 2.6. Comparison 2 Tramadol versus active treatment, Outcome 6 Number of participants
experiencing any serious adverse events.
Review: Tramadol for osteoarthritis
Comparison: 2 Tramadol versus active treatment
Outcome: 6 Number of participants experiencing any serious adverse events
Study or subgroup Tramadol Active control Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone vs NSAID
Beaulieu 2008 0/62 2/66 48.8 % 0.21 [ 0.01, 4.34 ]
Pavelka 1998 0/30 0/30 Not estimable
Subtotal (95% CI) 92 96 48.8 % 0.21 [ 0.01, 4.34 ]
Total events: 0 (Tramadol), 2 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
2 Tramadol alone vs other opioids
Bird 1995 0/20 0/20 Not estimable
Jensen 1994 0/135 0/129 Not estimable
Karlsson 2009 3/65 0/69 51.2 % 7.42 [ 0.39, 141.00 ]
Wilder-Smith 2001 0/28 0/29 Not estimable
Subtotal (95% CI) 248 247 51.2 % 7.42 [ 0.39, 141.00 ]
Total events: 3 (Tramadol), 0 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
3 Tramadol in combination with acetaminophen vs NSAIDs
Peeva 2010 0/8 0/7 Not estimable
Subtotal (95% CI) 8 7 Not estimable
Total events: 0 (Tramadol), 0 (Active control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 348 350 100.0 % 1.31 [ 0.16, 10.79 ]
Total events: 3 (Tramadol), 2 (Active control)
Heterogeneity: Chi2 = 2.73, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 2.73, df = 1 (P = 0.10), I2 =63%
0.01 0.1 1 10 100
Favors tramadol Favors active control
119Tramadol for osteoarthritis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.7. Comparison 2 Tramadol versus active treatment, Outcome 7 Symptoms of opioid
dependence: propensity for abuse.
Review: Tramadol for osteoarthritis
Comparison: 2 Tramadol versus active treatment
Outcome: 7 Symptoms of opioid dependence: propensity for abuse
Study or subgroup Tramadol Active control Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tramadol alone vs NSAIDs
Beaulieu 2008 17/45 19/52 100.0 % 1.03 [ 0.62, 1.74 ]
Total (95% CI) 45 52 100.0 % 1.03 [ 0.62, 1.74 ]
Total events: 17 (Tramadol), 19 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp osteoarthritis/
2. osteoarthr$.tw.
3. degenerative arthritis.tw.
4. tramadol.tw or tramadol.sh
5. ultracet.tw or ultracet.nm
6. or/1-5
7. randomized controlled trial.pt.
8. controlled clinical trial.pt.
9. randomized controlled trials.sh.
10. random allocation.sh.
11. double blind method.sh.
12. single-blind method.sh.
13. clinical trial.pt.
14. clinical trials.sh.
15. clinical trial.tw.
16. ((singl$ or doubl$ or trebl$ or tripl$) and (mask$ or blind$)).tw.
17. placebos.sh.
18. placebo$.tw.
19. random$.tw.
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20. Research Design/
21. comparative study.sh.
22. evaluation studies.sh.
23. follow-up studies.sh.
24. prospective studies.sh.
25. control$.tw.
26. prospectiv$.tw.
27. volunteer$.tw.
28. or/7-27
29. (animal not human).mp.
30. 28 not 29
31. and/6-30
Appendix 2. Table of protocols awaiting classification
Study name Author Registry Identifier
Norspan® patches versus tra-
madol in subjects with chronic,
moderate to severe osteoarthri-
tis pain in the hip knee and/or
lumbar spine
Dorthe Tvinnemose Clinicaltrials.gov NCT00426647
A study comparing Norspan
patch and oral tramadol
M Karlsson (principal investi-
gator)
Clinicaltrials.gov NCT01019265
A comparative study of tra-
madol hydrochloride plus ac-
etaminophen tablets mainte-
nance versus non-steroidal anti-
inflammatory drugs (NSAIDs)
maintenance in participants
with knee osteoarthritis
Janssen Korea (study director) Clinicaltrials.gov NCT00635349
An efficacy, safety and effects
on quality of life of tramadol/
paracetamol [acetaminophen]
as add-on therapy in chronic os-
teoarthritis
Janssen Pharmaceutica (study
director)
Clinicaltrials.gov NCT01728246
An efficacy and safety study of
acetaminophen plus tramadol
hydrochloride (JNS013) in par-
ticipants with chronic pain
Janssen Pharmaceutica (study
director)
Clinicaltrials.gov NCT00736853
A four-arm study comparing
the analgesic efficacy and safety
of tramadol once a day 100, 200
and 300 mg versus placebo for
Not provided Clinicaltrials.gov NCT00832416
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(Continued)
the treatment of pain due to os-
teoarthritis of the knee
A study to assess the abil-
ity of tramadol, naproxen and
oxycodone to affect the pain
thresholds of patients with os-
teoarthritis of the thumb
Pfizer CT.gov Call Center
(study director)
Clinicaltrials.gov NCT00743587
A study of
the tolerability of titrated dose
tramadol/acetaminophen com-
bination tablet in Korean pa-
tients with osteoarthritis
James WEI (principal investiga-
tor)
Clinicaltrials.gov NCT01063842
W H A T ’ S N E W
Date Event Description
1 February 2018 New citation required but conclusions have not changed Updated search with 11 new studies. New author team.
Conclusions similar to those of the previous review pub-
lished in 2006
1 February 2018 New search has been performed Updated search - 11 new studies added.
H I S T O R Y
Protocol first published: Issue 4, 2005
Review first published: Issue 3, 2006
Date Event Description
10 November 2008 Amended Converted to new review format.
CMSG ID: C092-R
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
This is an update of a previous review published in 2008. This updated review has a new author team and there are some differences
from the previous review.
1. We used the Cochrane ’Risk of bias’ tool.
2. Our latest search did not include the LILACS database.
3. We created ’Summary of findings’ tables according to the latest guidance in the Cochrane Handbook for Systematic Reviews of
Interventions. We also added the percentage of people who reach the minimally clinically important difference in the ’Summary of
findings’ tables.
4. Our outcomes differed as we based our outcomes on the latest recommendations from the Cochrane Musculoskeletal Group.
5. We presented our results in terms of standardized mean difference instead of mean difference and used fixed-effect models. We
also used random-effects models to verify if the two models gave consistent results.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acetaminophen [therapeutic use]; Analgesics, Non-Narcotic [∗therapeutic use]; Osteoarthritis [∗drug therapy]; Randomized Controlled
Trials as Topic; Tramadol [∗therapeutic use]
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